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II. Summary
Background. Opisthorchiasis, schistosomiasis and soil-transmitted helminthiasis (STH) 
caused by Opisthorchis viverrini, Schistosoma mekongi and hookworm are neglected 
diseases in Southeast Asia. An estimated 40 million people are infected with 
opisthorchiasis, 207 million with schistosomiasis and more than 740 million individuals 
are infected with hookworm worldwide. There is growing recognition of substantial 
morbidity and mortality induced by these parasites. Nevertheless, the burdens of 
trematodes and hookworm are difficult to gauge due to their long subclinical disease 
and often insidious morbidity. While Cholangiocarcinoma (CCA) has been attributed to 
chronic O. viverrini, S. mekongi is the main cause of portal hypertension, liver cirrhosis 
and oesophageal varices. Hookworm infections are responsible for iron-deficiency 
anemia, physical and cognitive retardation, premature newborns, and low birth weights 
in at-risk populations (i.e., pre- and school-aged children; pregnant women). While O. 
viverrini and S. mekongi are mainly endemic in the central and southern Lao PDR, STH 
are ubiquitous, especially infections with hookworm, which is the most common STH 
species in Lao PDR. Health education on changing human eating behaviour, access to 
clean water as well as hygiene and sanitation remain challenging.  
No evidence for the appropriate interval between community-wide praziquantel 
treatments against O. viverrini, S. mekongi and mixed infections are available. Although 
regular deworming programmes have been emphasized as a pillar of helminth control 
in Lao PDR for a few decades already, the importance of quality drugs is still neglected. 
There is an urgent need for safe and efficacious drugs against helminth infections. 
Aim and Objectives. This Ph.D. had the aim to deepen our understanding on the 
importance of helminthic parasitic infections in Lao PDR and challenges of their 
treatments by documenting severe morbidity due to parasitic infections in Lao PDR and 
assessing the effects of available and new treatments on infection and morbidity status 
of common helminth infections and pursued three main objectives. First, to document 
severe morbidity of parasitic infection in Lao PDR: Capillaria philippinensis and S. 
mekongi. Second, to assess the burden of parasitic infections due to S. mekongi, O. 
viverrini and co-morbidity of S. mekongi and O. viverrini and resolution of morbidity 
after treatment. Third, to assess efficacy of present anthelmintic drugs and potentially 
new drug candidates. 
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Methods. All data of this Ph.D were obtained from two major epidemiological settings: 
community and hospital-based studies. The case series reports were identified from 
community and hospital-based studies. Three cases of Capillaria philippinensis were 
identified from 2005 to 2007 in three referral hospitals (provincial hospital, 
Savannakhet and Mahosot and Sethathirath hospitals, Vientiane capital, Lao PDR). 
Severe S. mekongi cases were obtained from community helminth survey on Khong 
district from 2006-2010. Detailed clinical, micro-biological and imaging technique 
examinations, including ultrasound (US) and intestinal aspiration or biopsy through 
endoscope (C. philippinensis) were performed at baseline and during yearly follow-up 
(S. mekongi).  
The cross-sectional study on morbidity due to S. mekongi and co-infections with 
O. viverrini was conducted in three villages, Khong district, Champasak province from 
March 2006 to March 2008. The participants were individuals who were infected with S. 
mekongi over the age of 6 months. Infection status and infection intensity were 
determined by 3 Kato-Katz thick smears (3 stool samples examined with single Kato-
Katz each). The individuals were given a single dose of 40 mg/kg praziquantel (PZQ) 
and/or Albendazole (ABZ) at the baseline. At midpoint (at 11 months since the last 
praziquantel) and endpoint (at 23 months post treatment) of the morbidity assessment, 
patients were evaluated by stool and ultrasound examination. Those individuals who 
completed at least 2 Kato-Katz and the US examinations at each follow-up were 
included at the final evaluation. Futhermore, the morbidity induced by O. viverrini was 
addressed with two sub-studies: the community- and hospital-based studies carried out 
in 2011. a community-based, cross-sectional study in a high prevalence area for 
O. viverrini in which adult community members with parasitologically confonfirmed O. 
viverrini infection was screened for hepatobiliary morbidity, including suspected 
lesions of CCA using ultrasonography. Additional data on risk factors etc. were obtained 
from each study participant. The second hospital-based study was carried out in six 
referral hospitals across country (Laungprabang, Vientiane capital, Savannakhet, 
Champasack). All medical records of patients admitted from 2006 to 2010 in Lao PDR 
included in the hospital-based, retrospective study in which suspected cases of CCA 
were identified in patient records of all referral hospital in Lao PDR.  
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A randomized open-label two-arm trial was assessed the efficacy of single 
albendazole and mebendazole in Bachieng, Champasack province, southern Laos.  In 
total, 200 schoolchildren infected with hookworm (determined by quadruplicate Kato-
Katz thick smears derived from two stool samples) were randomly assigned to 
albendazole (n=100) and mebendazole (n=100) in Bachieng district, Champasak 
province in 2006. The second study was a randomized, exploratory open-label trial 
assessing the efficacy and safety mefloquine (25 mg/kg), artesunate (10 mg/kg as 3 
split doses within 12 h), mefloquine-artesunate (100 mg artesunate plus 250 mg 
mefloquine once daily for 3 consecutive days), and tribendimidine (200 or 400 mg 
single dose) compared to praziquantel (75 mg/kg in 2 divided doses) in schoolchildren, 
in Attapeu, O. viverrini-endemic areas, southern Laos. Primary outcomes of both clinical 
trials studies were cure rates and egg reduction rates at 21-23 days posttreatment.  
Adverse events were assessed at 3h, 48h, and 120h after treatment.  
Principle findings/results. Our case series report on C. philippinensis was conducted at 
the referral hospital in Savannakhet and Vientiane. The three patients were unrelated 
previously healthy young men (24-27 years of age). Chronic diarrhea, abdominal pain, 
edema, and severe weight loss were the symptoms reported. Two of them acquired the 
infection in Thailand; one patient had acquired it indigenously in Lao PDR. Co-infections 
with trematode and nematodes were found. All patients recovered with albendazole 
treatment (400 mg/day for a month). The study on severe S. mekongi cases indentified 
nine patients. Male was the predominant sex, the mean age was 36 years. All patients 
had dwelled in Khong Island since birth and had previously been treated with several 
praziquantel rounds. Most of the patients developed hepato-splenic diseases. At the 
final follow-up, three patients improved, two adult patients remained unchanged or 
reversal after treatment. Two patients died due to rupture of oesophageal varices. Two 
were lost to follow-up. Liver regression improved after treatment in particular in young 
patients. 
The study on morbidity due to S. mekongi and co-infections with O. viverrini showed 
that there were significant changes after therapy such as reversals of periportal fibrosis 
among mild and moderate cases (p<0.001), as well as decreased size of the left liver 
lobe, the spleen and splenic veins (p<0.01). However, re-infection was common at 11 
months after therapy. The community- and hospital-based studies indicated a high 
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prevalence of hepatobiliary diseases attributable to O. viverrini infection. Of 431 
individuals with parasitologically confirmed O. viverrini infections screened during the 
community-based ultrasound study, five cases demonstrated lesion suggestive of CCA. 
Other hepatobiliary lesions were detected (gall bladder and kidney anormalities fatty 
liver, cirrhosis and so on). In the hospital-based study in O. viverrini endemic areas of 
Laos, lesions suggestive of CCA were found by means of US and CT scan in 274 patients 
admitted. Males and people aged 50 years and above were more commonly diagnosed 
with suspected CCA. Of 274 suspected CCA cases, 267 (97.4%) had dilated bile duct, 240 
(74.1%) had gallstone(s) or intrahepatic stone(s), but only 33 (12%) were 
parasitologically confirmed O. viverrini cases. Histopathology is not available in Laos 
and consequently, we could not have the final diagnosis of CCA. 
Compared to a recent meta-analysis, single dose of ABZ and MBZ resulted in 
disappointing efficacy against hookworms in terms of cure rates in our study (36.0% 
and 17.6% respectively). But single-dose of ABZ cleared significantly more hookworm 
infections than mebendazole with ERR of 86.7% and 76.3%, respectively. In addition, 
both ABZ and MBZ showed effects against O. viverrini with high egg reduction rates. In 
the second clinical trial, single dose of tribendimidine at the recommended dosage for 
the treatment of STH infections achieved higher cure and egg reduction rates compared 
to PZQ (CRs=70.4%, 56.0% and ERRs= 99.3%, 98.4%, respectively) in schoolchildren 
infected with O. viverrini. No or only very moderate effects were observed with 
mefloquine, artesunate and mefloquine-artesunate against O. viverrini. All children 
experienced drug-induced adverse events. The most frequent adverse events were 
among those patients treated with mefloquine and mefloquine-artesunate. Only mild 
and transient adverse events were observed in the tribendimidine group. 
Conclusion/significance. The case reports raises awareness of the re-emergence of 
S. mekongi and potential risk of outbreak of C. philippinensis in Lao PDR. Hence, These 
parasites require more attention. Substantial S. mekoni-, O. viverrini- and coinfection-
induced morbidity were present and caused various hepato-biliary and -splenic lesions, 
including lesion suggestive of CCA, liver cirrhosis and oesophageal varices. Monitoring 
on efficacy of current drugs used for mass drug administration campaigns (ABZ, MBZ 
and Praziquantel) is needed. Tribendimidine could be a potential drug of choice for liver 
fluke treatment as well as other parasitic infections.  
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III.  Zusammenfassung 
Hintergrund. Opisthorchiasis, Schistosomiasis und durch Bodenkontakt übertragene 
Helminthiasis (STH, Wurmerkrankungen) werden durch Opisthorchis viverrini, 
Schistosoma mekongi und Hakenwürmer und anderen verursacht und gehören zu den 
vernachlässigten Krankheiten. Geschätzte 40 Millionen Menschen sind weltweit mit 
Opisthorchis infiziert, 207 Millionen mit Schistosoma und mehr als 740 Millionen mit 
Hakenwürmern. Zunehmend wird die beachtliche Morbidität und Mortalität, die durch 
diese Parasiten verursacht wird, anerkannt. Nichtsdestotrotz ist die durch Trematoden 
und Hakenwürmer verursachte Krankheitslast aufgrund der langen subklinischen 
Erkrankung und unterschwelligen Morbidität schwierig abzuschätzen. Während 
Cholangiokarzinoma (CCA) chronischen Infektionen mit O. viverrini zugeschrieben wird, 
ist S. mekongi ein wichtigster Kausalfaktor für Pfortaderhochdruck, Leberzirrhosen und 
Ösophagus-Varizen. 
Hakenwurminfektionen sind für Eisenmangelanämie, physische und kognitive 
Entwicklungsverzögerung, Frühgeburten und geringe Geburtsgewichte in gefährdeten 
Bevölkerungsschichten (Kinder im Vorschul- und Schulalter, schwangere Frauen) 
verantwortlich. Während O. viverrini und S. mekongi mehrheitlich in Zentral- und Süd-
Laos endemisch sind, sind STH allgegenwärtig, insbesondere Infektionen mit dem 
Hakenwurm, der häufigsten STH-Art in Laos. Gesundheitskampagnen zur Änderung der 
Essgewohnheiten, Zugang zu sauberem Wasser sowie Hygiene bleiben 
Herausforderungen. 
Regelmässige Behandlungen mit Praziquantel ist die wichtigste Bekämpfung-
massnahme gegen S. mekongi und O. viverrini. Jedoch bis heute gibt es keine Angaben 
für das am Besten geeignete Intervall zwischen Praziquantel-Behandlungen. Obwohl 
regelmässige Entwurmungsprogramme seit mehreren Jahrzehnten als eine Stütze der 
Helminthen-Kontrolle in durchgeführt werden, wird die Überwachen der Effizienz 
Medikamenten vernachlässigt. Sichere und wirksame Medikamente gegen Helminthen-
Infektionen werden dringend benötigt. 
Ziele. Diese Doktorarbeit hatte das Ziel, unser Verständnis der Bedeutung von 
Parasiteninfektionen in Laos und Schwierigkeiten in ihrer Behandlung zu verbessern, in 
dem sie die schwere Morbidität aufgrund der Parasiteninfektionen dokumentiert und 
die Wirkung von bisher verfügbaren und neuen Behandlungen auf Infektion und 
Morbidität untersucht. Sie verfolgte deshalb drei Ziele. Erstens, die schwere Morbidität 
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aufgrund von Parasiteninfektionen, nämlich Capillaria philippinensis und S. mekongi in 
Laos zu dokumentieren. Zweitens, die Krankheitslast der Parasiteninfektionen aufgrund 
von S. mekongi, O. viverrini und Mischinfektionen der beiden Parasiten zu 
dokumentieren sowie die Besserung der Morbidität nach der Behandlung zu messen. 
Drittens, die Wirksamkeit aktuell erhältlicher Medikamente und neuer Medikamenten-
Kandidaten zu untersuchen. 
Methoden. Alle Daten für diese Doktorarbeit wurden in zwei epidemiologischen Milieus 
gesammelt: Studien in der Bevölkerung und in Krankenhäusern. Drei Fälle von 
Capillaria philippinensis wurden zwischen 2005 und 2007 in drei 
Referenzkrankenhäusern identifiziert (Provinzkrankenhäuser, sowie die 
Krankenhäuser Savannakhet, Mahosot und Sethathirath, in Vientiane). Schwere Fälle 
von S. mekongi wurden zwischen 2006 und 2010 währen einer Querschnittsstudie im 
Distrikt Khong gefunden. Detaillierte klinische, mikrobiologische und Ultraschall-
Untersuchung (Endoskop-Biopsie für C. philippinensis) wurden zu Beginn und bei der 
jährlichen Kontrolle durchgeführt (S. mekongi).  
Die Querschnittsstudie gefolgt von einer Kohort Studie zur Morbidität von S. 
mekongi und O. viverrini Infektionen wurde in drei Dörfern im Khong Distrikt, Provinz 
Champasak, zwischen März 2006 und März 2008 durchgeführt. Die Studienteilnehmer 
waren mit S. mekongi infiziert und über 6 Monate alt. Die Infektion und ihre Intensität 
wurden mit 3 Kato-Katz-Ausstrichen (3 Stuhlproben mit jeweils einmaligem Kato-Katz) 
bestimmt. Die Studienteilnehmer erhielten zu Beginn der Studie eine Einzeldosis von 
40mg/kg Praziquantel (PZQ) und/oder Albendazole (ABZ). Zur Halbzeit (11 Monate 
nach der Behandlung mit PZQ) und am Ende der Studie (23 Monate nach der 
Behandlung) wurden die Patienten mit einer Stuhlprobe und einer 
Ultraschalluntersuchung evaluiert. Diejenigen Teilnehmer, von denen zu jedem 
Untersuchungszeitpunkt mindestens 2 Kato-Katz-Ausstriche und die 
Ultraschalluntersuchung vorlagen, wurden in die Schlussanalyse einbezogen. Zudem 
wurde die durch O. viverrini verursachte Morbidität in zwei Teilstudien angegangen: 
den Studien in der Bevölkerung und in den Krankenhäusern, die 2011 durchgeführt 
wurden. In einer Querschnittstudie in der Saravan Provinz, in einem Gebiet mit hoher O. 
viverrini Prävalenz wurden alle erwachsenen Mitglieder der Dorfgemeinschaft mit 
parasitologisch bestätigter O. viverrini-Infektion auf Leber- Morbidität untersucht, im 
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speziellen auf mögliche CCA-Läsionen. Zusätzliche Daten über Risikofaktoren wurden 
von jedem Studienteilnehmer erhoben. Eine zweite Krankenhaus-basierte Studie wurde 
in 6 Referenzkrankenhäusern im ganzen Land (Luangprabang, Vientiane, Savannakhet, 
Champasack) durchgeführt. Vermutete CCA-Fälle wurden im Rahmen einer 
retrospektiven Studie in allen Patientenakten von Patienten, die von 2006 bis 2010 in 
diesen Referenzkrankenhäusern hospitalisiert worden waren, identifiziert. 
Eine randomisierte Studie mit zwei Behandlungsgruppen ohne Verblindung 
untersuchte 2006 die Wirksamkeit einer Einzeldosis von Albendzole (ABZ) und 
Mebendazole (MBZ) in Bachieng, Provinz Champasack, Süd-Laos. Insgesamt 200 
Hakenwurm-infizierte Schulkinder (durch vierfachen Kato-Katz-Ausstrich basierend auf 
zwei Stuhlproben bestimmt) wurden zufällig ABZ (n=100) oder MBZ (n=100) 
zugeordnet. Eine zweite Studie war eine randomisierte, explorative Studie, welche die 
Wirksamkeit und Sicherheit von Mefloquine (25mg/kg), Artesunat (10mg/kg in 3 
getrennten Dosen innerhalb 12 Std), Mefloquine-Artesunat (100mg Artesunat und 
250mg Mefloquine einmal täglich während drei aufeinanderfolgenden Tagen) und 
Tribendimidine (200mg oder 400mg als Einzeldosis) im Vergleich zu Praziquantel 
(75mg/kg in 2 Dosen) in Schulkindern, in Attapeu, Süd-Laos, untersuchte. 
Primärergebnisse beider klinischen Studien waren die Heilungsrate und die Eizahl-
Reduktionsrate 21-23 Tage nach der Behandlung. Nebenwirkungen wurden 3 Std., 48 
Std. und 120 Std. nach der Behandlung untersucht. 
Wichtigste Ergebnisse. Unsere Fallreihe von C. philippinensis wurde in den 
Referenzkrankenhäusern von Savannakhet und Vientiane durchgeführt. Die drei 
Patienten waren nicht verwandte, vormals gesunde junge Männer (24-27 Jahre alt). Die 
genannten Symptome waren chronischer Durchfall, Bauchschmerzen, Ödema und 
starker Gewichtsverlust. Zwei von ihnen hatten die Infektion in Thailand aufgelesen; ein 
Patient hatte sie in Laos angesteckt. Es wurden Koinfektionen mit Trematoden und 
Nematoden gefunden. Alle Patienten erholten sich unter ABZ-Behandlung (400mg/Tag 
während 30 Tagen).  
In der Reihe von schweren Schistosoma-Fällen wurden neun Patienten gefunden. Das 
vorherrschende Geschlecht war männlich, das durchschnittliche Alter 36 Jahre. Alle 
Patienten hatten seit ihrer Geburt auf der Khong Insel gelebt und waren bereits zuvor 
mehrmals mit PZQ behandelt worden. Die meisten Patienten zeigten schwere Leber-
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Milz-Pathologien. Bei der letzten Kontrolle waren drei Patienten in besserem Zustand, 
zwei erwachsene Patienten zeigten unveränderten Zustand oder Rückfall nach 
Behandlung. Zwei Patienten starben im Verlaufe der Untersuchung aufgrund geplatzter 
Ösophagus-Varizen. Zwei Patienten konnten nicht mehr gefunden werden. Die 
Leberpathologien verbesserten sich nach der Behandlung insbesondere in jungen 
Patienten. 
Die Studie der Morbidität aufgrund von S. mekongi und Koinfektion mit O. viverrini 
zeigte signifikante Unterschiede nach der Behandlung, wie Heilung periportaler 
Fibrosen bei leichten und mittelschweren Befall (p<0.001) sowie verkleinerte linke 
Leberlappen, Milz und Kolateralevenen (p<0.01). Allerdings wurden Neuinfektionen 11 
Monaten nach der Behandlung beobachtet. Die Studien in der Saravabne Bevölkerung 
und in den Krankenhäusern deuteten auf eine hohe Prävalenz von Leberpathologien 
hin, welche O. viverrini zugeschrieben werden können. Von 431 Patienten mit 
parasitologisch bestätigter O. viverrini Infektion, die in der Ultraschall-Studie in der 
Bevölkerung untersucht wurden, wiesen fünf Fälle Läsionen auf, die auf CCA deuteten. 
Weitere Läsionen wurden ebenfalls entdeckt (Gallblasen- und Nieren-Anomalitäten, 
überfettige Leber, Zirrhose usw.). In der Krankenhaus-basierten Studie in Gebieten in 
Süd-Laos, in denen O. viverrini endemisch ist, wurden mithilfe von Ultraschall und 
Computertomographie bei 274 Patienten Läsionen gefunden, die auf CCA deuten. 
Männer und Patienten im Alter von 50 Jahren und mehr wurden gehäuft mit 
vermutlichem CCA diagnostiziert. Von 274 vermuteten CCA-Fällen hatten 267 (97.4%) 
einen erweiterten Gallengang, und 240 (74.1%) hatten Gallensteine, aber nur 33 (12%) 
waren parasitologisch bestätigte O. viverrini-Fälle. Histopathologie ist in Laos nicht 
verfügbar und folglich konnten wir keine definitive Diagnose von vermuteten CCA-
Fällen erstellen. 
Verglichen mit einer kürzlichen Meta-Analyse, führten Einzeldosen von ABZ und 
MBZ in unserer Studie zu enttäuschend niedriger Wirksamkeit gegen Hakenwürmer 
(Heilungsrate 36.0% respektive 17.6%). Aber die Einzeldosis ABZ heilte signifikant 
mehr Hakenwurm-Infektionen als MBZ mit einer Eier-Reduktionsrate von 86.7% 
respektive 76.3%. Zusätzlich zeigten ABZ und MBZ Wirkung gegen O. viverrini mit 
hohen Eizahl-Reduktionsraten. In der zweiten klinischen Studie, bewirkte eine 
Einzeldosis Tribendimidine in der für die Behandlung von STH empfohlenen Dosierung 
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verglichen mit Praziquantel hohe Heilungs- und Eier-Reduktionsraten (HR=70.4% bzw. 
56.0% und ERR=99.3% bzw. 98.4%) in Schulkindern, die mit O. viverrini infiziert waren. 
Keine oder nur sehr mittelmässige Wirkung wurden mit Mefloquin, Artesunat und 
Mefloquin-Artesunat gegen O. viverrini erreicht. Alle Kinder litten unter negativen 
Nebenwirkungen. Die häufigsten negativen Nebenwirkungen traten in den Patienten 
auf, die mit Mefloquin und Mefloquin-Artesunat behandelt wurden. Nur leichte und 
vorübergehende Nebenwirkungen wurden in der Tribendimidine-Behandlungsgruppe 
beobachtet. 
Schlussfolgerung. Die Fallserien erhöhen das Bewusstsein für das Widerauftreten 
von S. mekongi und das potenzielle Risiko eines Ausbruchs von C. philippinensis in Laos. 
Deshalb benötigen Capillariasis und Schistosomiasis mehr Aufmerksamkeit. 
Substanzielle Morbidität aufgrund von S. mekongi und O. viverrini war vorhanden und 
verursachte verschiedene Leber-Gallen- und Leber-Milz-Läsionen, einschliesslich 
Läsionen, die auf CCA hindeuten. Ein Monitoring der Wirksamkeit der gebräuchlichen 
Medikamente, die für Massenbehandlungs-kampagnen verwendet werden (ABZ, MBZ 
und PZQ) ist nötig. Tribendimidine könnte ein potenzielles Medikament der Wahl für 
die Behandlung von Leberegel und anderen Parasiteninfektionen werden. 
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 IV. Lao Summary  
¯½¹ ñ¸ñññ©£¸¾´À¯ñ−´¾:ñññ  ²½¨¾©Ã®Ä É´Ã−ªñ®, ²½¨¾©Ã®Ä É´©ø©Àìõº©, Áì½ ²½¨¾© ¡¾±¾¡ ê†ªò© 
¥¾¡ÎÉ¾©ò− §‡¤Á È´−¦¾¨À¹©À−ˆº¤´¾¥¾¡¡¾−ªò©À§œº²½¨¾©§½−ò© Opisthorchis viverrini, 
Schistosoma mekongi, Áì½ Á È´êÉº¤¯¾¡¢ð À¯ñ−²½¨¾©ê†¥ñ©µøÈÃ−¥¿²¸¡ê† ®ÒÄ©É»ñ® ¡¾− Àºö¾ 
Ã¥Ã¦ÈµøÈÃ−²¾¡²œ−º¾§óª¾À¸ñ−ºº¡¦¼¤ÃªÉ. Ã−ê‰¸Âì¡ ¯½´¾− 40 ìÉ¾−£ö− ªò©À§œº 
²½¨¾©Ã®Ä É´Ã−ªñ®, 207 ìÉ¾−£ö− ªò©À§œº²½¨¾©Ã®Ä É´©ø©Àìõº©, Áì½ ¹ì¾¨¡ È¸¾ 740 ìÉ¾− 
£ö−ªò©À§œºÁ È´êÉº¤¯¾¡¢ð. …¨¤À¯ñ−ê†»ñ®»øÉ¡ñ−¹ì¾¨¢›− È¸¾²½¨¾©Á È´¡¾±¾¡©„¤¡È¾¸ Á È´−À¯ñ−¦¾¨ 
À¹©ªí−ªð¦¿ìñ®¡¾−À¥ñ®À ñ¯− Áì½ ¡¾−ª¾¨. ÁªÈÀ«ò¤µÈ¾¤Ã©¡ðÒª¾´²½¨¾© Ã®Ä É´ Áì½ 
Á È´êÉº¤¯¾¡¢ð¡ð¨ñ¤À ñ¯−Àìœº¤¨¾¡ê†¥½¯½À ó´−£¸¾´»÷−Á»¤¢º¤²½¨¾© ©„¤¡È¾¸ Ä©ÉµÈ¾¤§ñ©À¥− 
À−ˆº¤¥¾¡ È¸¾ ñ´−À¯ñ−²½¨¾©ê†À»ñ©Ã¹É»È¾¤¡¾¨§÷©Â§´¨¾¸−¾−Áì½¦È¸−¹ù¾¨À¯ñ−¡¾−À¥ñ®À¯ñ−Á
®® ò´©¤¼®ÍõÀ§ˆº¤§Éº−º¾¡¾−.Ã−¢½−½©¼¸¡ñ−−˜−«É¾ ó´¡¾−ªò©À§õœº²½¨¾©Ã®Ä É´Ã−ªñ®Á®®§Õ
À»œºÁ È´− ó´Âº¡¾©ê†¥½À¯ñ−´½À»ñ¤êÒ¦‰¤−Õ®ó,Áì½À§„−©¼¸¡ñ−¡ñ®²½¨¾©Ã®Ä É´©ø© Àìõº© ¥½À ñ¯− 
¦¾¨À¹©ªí−ªð²¾Ã¹ÉÀ¡ó© ó´£¸¾´©ñ− Àìõº©µøÈÃ−À¦˜−Àìõº©©¿Ã−ªñ® (Portal vein), ªñ®Á¢¤, 
Áì½À¦˜−Àìõº©¢º©ê¾¤êÒÀ©ó−º¾¹¾−.¡¾−ªò©À§œºÁ È´êÉº¤¯¾¡¢ðÁ È´−¥½¡ÒÃ¹ÉÀ¡ó©À¯ñ− ²½¨¾© 
Àìõº©¥¾¤ É¨º−¢¾©ê¾©À¹ìñ¡, ¡¾−¢¾¨¹¨¾¨ªö¸ê¾¤»È¾¤¡¾¨Áì½ ñ´−¦½Ïº¤§ñ¡§É¾, À©ñ¡À¡ó© 
¡Èº−¡¿−ö© Áì½ ó´−ÕÎñ¡¹ì÷© µøÈÃ−¡÷È´¯½§¾¡º−ê† ó´£¸¾´¦È¼¤ (À§„− À©ñ¡¡Èº−Ä¸»¼− 
Áì½Ã−Ä¸»¼−§˜−¯½«ö´Áì½Á È´ ò¨¤«õ²¾).²½¨¾©Ã®Ä É´Ã−ªñ®Áì½²½¨¾©Ã®Ä É´©ø©Àìõº©¦È¸− 
¹ì¾¨Á È´−ì½®¾©µøÈ²¾¡¡¾¤Áì½²¾¡ÃªÉ¦È¸−²½¨¾©¡¾±¾¡ê†ªò©´¾¥¾¡ÎÉ¾©ò− Â©¨¦½À²¾½ 
Á È´êÉº¤¯¾¡¢ðÁ È´−²ö®À¹ñ−µøÈê÷¡®Èº−Ã−¢º®À¢©ê‰¸¯½Àê©.¡¾−¦÷¢½¦ô¡¦¾À²ˆº¯È¼−Á¯¤²ô©ªò 
¡¿¡¾−¡ò−, ¡¾−À¢í¾À«ò¤−Õ¦½º¾© À§„−©¼¸¡ñ−¡ñ® ¡¾−º½−¾Ä´ Áì½ ¦÷¢½º½−¾Ä´ 
ñ¨¤À¯ñ−¦…¤ê†êÉ¾ê¾¨. ¯½¥÷®ñ− ñ¨¤®Òêñ− ó´¢Ó ø´ø−ê†À¯ñ−¹ìñ¡«¾−²ò¦ø©¡È¼¸¡ñ®¡¾− …¯− ö¯¸ê‰¸¯¸¤§ö− 
ê†«õ¡ªÉº¤ÀÏ¾½¦ö´§‡¤−¿Ã§Éµ¾¯ì¾§ó¡ñ¤Áª−¯…− ö¯¸²½¨¾©Ã®Ä É´Ã−ªñ®, ²½¨¾©Ã®Ä É´©ø©Àìõº© 
Áì½ ¡¾−ªò©À§œºÁ®®¯½¦ö´êñ¤¦º¤§½−ò©.  
À«ò¤Á È´− È¸¾ µøÈ ¦¯¯ ì¾¸ ¡¾−µ¾¨µ¾ …¯− ö¯¸²½¨¾©Á È´¡¾±¾¡ê‰¸¯¸¤§ö−Ä©É«õ¡ ô¨©«õÀ¯ñ− 
¡ò©¥½¡¿ªí−ªðÃ−¡¾−£¸®£÷´²½¨¾©¡¾±¾¡µøÈÃ−¯½Àê©´¾Ä©É¹ì¾¨êö©¦½¸ñ© ÁìÉ¸ ¡Òª¾´ 
ÁªÈ£¸¾´¦¿£ñ−©É¾−£÷−−½²¾®¢º¤µ¾ ñ¨¤®Òêñ−Ä©É»ñ®¡¾−Àºö¾Ã¥Ã¦È. ¦½−˜− ¥‡¤ À¹ñ−¸È¾ ó´£¸¾´ 
¥¿À¯ñ−ºñ−»ó®©È¸−ê†¥½ªÉº¤¯½À ó´−£¸¾´¯º©Ä² Áì½ £÷−−½²¾®¢º¤µ¾ ê†Ã§ÉÃ−¡¾− …¯− ö¯¸ 
²½¨¾©Á È´¡¾±¾¡.  
¸ñ©«÷¯½¦ö¤:ñ ÷ öñ ÷ öñ ÷ ö  Ã−®ö©£¸¾´ê†¡È¾¸´¾¢É¾¤Àêò¤−š, ®ö©−ò²ö−¯½ëò−¨¾Àº¡¦½®ñ®−š Ä©É ó´ ¦¾´¥÷© 
¯½¦ö¤¹ìñ¡£õ: 1.) À²ˆº®ñ−êô¡£¸¾´»÷−Á»¤¢º¤²½¨¾©Á È´¡¾±¾¡ À§„− ²½¨¾© ¡¾±¾¡ §½−ò© 
Capillaria philippinensis, and Schistosoma mekongi; 2.)  ¯½À ó´− £¸¾´Îñ¡ÎÈ¸¤¢º¤²½ ¨¾© 
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Á ú´¡¾±¾¡ê†À−ˆº¤´¾¥¾¡¡¾−ªò©À§œº¡¾±¾¡§½−ò© O. viverrini,  S. mekongi, Áì½ 
¡¾−ªò©À§œº¡¾±¾¡Á®®¯½¦ö´êñ¤¦º¤§½−ò© Áì½ À²ˆºªò© ª¾´£¸¾´°ò© ö¯¡¡½ªò²¾¨¹ìñ¤ 
¡¾− …¯−¯ö¸, Áì½ 3.) À²ˆº¯½À ó´−¯½¦ò©êò°ö−¢º¤µ¾ …¯− ö¯¸ ²½¨¾©Á È´¡¾±¾¡Ã−¯½¥÷®ñ− ¡ñ® 
ªö¸µ¾ÃÏÈ.   
¸òêó¸òê½¨¾¡¾−£í−£ É¸¾:ò ó ò í Éò ó ò í Éò ó ò í É ¢Ó ø´−êñ¤Ïö©ê†µøÈÃ−®ö©−ò²ö−¦½®ñ®−šÁ È´−Ä©É´¾¥¾¡Á¹ìÈ¤¢Ó ø´−©É¾− ì½ 
®¾©¸òê½¨¾¦º¤Á¹ìÈ¤ªí−ªð À§„− ¡¾−¦ô¡¦¾Ã−§÷´§ö− Áì½ Â»¤Ïð §‡¤¡¸´Àºö¾®ö©ì¾¨¤¾− 
¡È¼¸¡ñ®¡¾−À¡ó©²½¨¾©¢º¤²½¨¾©Ã®Ä É´Ã−ªñ®, ²½¨¾© Ã®Ä É´©ø©Àìõº© Áì½ ¡¾−ªò©À§œº 
Á®®¯½¦ö´êñ¤¦º¤§½−ò©, Áì½ ¡¾−¯½À ó´−¯½¦ò© êò°ö−¢º¤µ¾ …¯− ö¯¸²½¨¾© Á È´¡¾ ±¾¡ ¯¾¡ 
¢ðÃ−¯½¥÷®ñ− Áì½ ªö¸µ¾ÃÏÈÀ²ˆºÃ§ÉÀ¢í¾ Ã−¡¾− …¯− ö¯¸²½¨¾©Ã®Ä É´Ã−ªñ® Áì½ ²½¨¾© 
Á È´¡¾±¾¡ê‰¸Ä¯.  
®ö©ì¾¨¤¾−¡ðì½−ó¦ô¡¦¾Á È´−Ä©É´¾¥¾¡§÷´§ö− Áì½ Â»¤Ïð. ¡¾−¦ô¡¦¾Ã−¦¾´ ¡ðì½−ó 
ê†ªò©À§œºÁ È´¡¾±¾¡§½−ò© Capillaria philippinensis  ê†²ö®À¹ñ−µøÈÃ−Â»¤ ÏðÁ¢¸¤ £õ Á¢¸¤ 
¦½¹¸ñ−−½À¢© Áì½ Â»¤Ïð¦ø−¡¾¤ À§„− Â»¤Ïð´½Â¹¦ö©, Áì½ À¦©«¾ êòì¾© −½£º−¹ì¸¤ 
¸¼¤¥ñ− Ã−ì½¹ È¸¾¤¯ó 2005Œ2007. ¡¾−¦ô¡¦¾¡È¼¸¡ñ®²½¨¾© Ã®Ä É´©ø©Àìõº©ê†ªò©À§œº»÷−Á»¤ 
Á È´−Ä©É´¾¥¾¡¡¾−¦¿¹ì¸©µøÈÃ−§÷´§ö− §‡¤Ä©É¥ñ©ª˜¤ ¯½ªò®ñ©Ã− ó¯ 2006Œ2010. ì¾¨ì½º¼© 
¢º¤¡¾−¦ô¡¦¾©É¾−º¾¡¾−¦¾©, ¡¾−¡¸©¥÷ìò−§ó ¸òê½¨¾ (Microbiology examination), 
¡¾−¡¸©ìñ¤¦ó¸òê½¨¾§‡¤ì¸´ ó´¡¾−¡¸©ìñ¤¦óÂ©¨ Ã§É£œ−¦¼¤, Áì½ ¡¾−©ø©Àºö¾§™−¦È¸− º½ 
Ä¸¨½¸½Ä¯ ò¸Ä¥ (endoscope), Áì½ ¡¾− …¯− ö¯¸ ²½¨¾©¡¾±¾¡§½−ò© Capillariasis 
Philippinenses, §‡¤êñ¤Ïö©À¹ì‰¾−šÁ È´−Ä©ÉÀ¡ñ®¢Ó ø´− À®œº¤ªí− (Baseline survey) Áì½ ªò©ª¾´ 
£ö−À¥ñ®ê†À¯ñ−²½¨¾©Ã®Ä É´©ø©Àìõº©Ã−ÁªÈì½ ó¯ (yearly follow-up of schistosomiasis cases).  
¡¾−¦ô¡¦¾Á®®ªñ©¢¸¾¤ ¡È¼¸¡ñ®¡¾−À¥ñ®À¯ñ−ê†À−ˆº¤´¾¥¾¡¡¾−ªò©À§œº S. mekongi Áì½ 
¡¾−ªò©À§œº¯½¦ö´¡ñ® O. viverrini  §‡¤Ä©É©¿À−ó−µøÈÃ−¦¾´®É¾−¢º¤ ©º−Âì¤, À õ´º¤Â¢¤, Á¢¸¤ 
¥¿¯½¦ñ¡ ÁªÈÀ©õº− ó´−¾ 2006 À«ò¤ ó´−¾ 2008.  °øÉ-ê†-À¢í¾-»È¸ -´Ã−-¡¾−-¦ô¡¦¾-Á È´−-°øÉ-ê†-ªò©-À§œº ²½ 
¨¾©-Ã®-Ä É´-©ø©-Àìõº©-§‡¤- ó´-º¾¨÷-ªÔ-¡¸È¾ 06 À©õº−, ¦½²¾®Íõ £¸¾ -´»÷−-Á»¤-¢º¤¡¾−-ªò©-À§œº-Á È´−-
Ä©É-´¾¥¾¡-¡¾−¡¸©-º¾¥ö´ -Â©¨-Ã§É-Àªñ¡−ò¡-¡¾-Âª-¡¾¦ (¦¾ -´Á°È−¡¾-Âª-¡¾¦-ªÒªö¸µÈ¾¤º¾¥ö´ 01 
ºñ−). ®÷¡£ö−-ê†-ªò©-À§œº²½¨¾©-Ã®-Ä É´-Ã−-ªñ®-Á È´−-Ä©É-»ñ®-¡¾−- …¯− ö¯¸-©É¸¨-µ¾-¯ì¾-§ó-¡ñ¤-Áª− 40´¡ 
ªÒÈ¡ò-Âì-−ÕÎñ¡-»È¾¤¡¾¨ -Áì½ µ¾-º¾−-Á®ñ−©¾-Â§− 400´¡ Î‡¤-À ñ´© µøÈ-Ã−-§È¸¤-¢º¤-¡¾−-¦¿-¹ì¸©-
À®œº¤ªí−.   
¡¾−-¦¿-¹ì¸©-Äì¨½-ê† 2-Ä©É-©¿-À−ó−-²¾¨¹ìñ¤-ê†-Ä©û-¡ò−-µ¾-À¯ñ−-À¸ì¾ 11 À©õº−, -Áì½ ¡¾−-¦¿-¹ì¸©-
£˜¤¦÷©-êÉ¾¨-Ä©É-©¿-À−ó−-²¾¨¹ìñ¤-Ä©É-¡ò−-µ¾-À¯ñ−-À¸ì¾ 23 À©õº−. ¡¾−--¯½-À ó´−-ºñ©ª¾-¡¾−À¥ñ®-À¯ñ− 
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Á È´−-Ä©É¡¸©-º¾¥ö -´-À²ˆº-§º¡-¹¾-²½¨¾©-Ã®-Ä É´-Ã−-ªñ® -Áì½ -¡¸©-©É¸¨-£œ−¦¼¤. ¦¿ìñ®®÷¡£ö−-ê†-«õ-
¸È¾¦¿-Àìñ©-¦ö´®ø−-Ã−-¡¾−-¦¿-¹ì¸©-ÁªÈì½£˜¤-Á È´−µÈ¾¤-ÎÉº¨ªÉº¤-Ä©É-¡¸©-º¾¥ö´ 
¦º¤--¦½-Äì Áì½- »ñ®-¡¾−¡¸©-À£ˆº¤§Èº¤-Ä³³É¾-ê†-Ã§É-£œ−¦¼¤.  −º¡-¥¾¡−˜− Ä©É-©¿-À−ó−¡¾−-¦ô¡¦¾µøÈ-
¢˜−-§÷ -´§ö− Áì½ -Â»-¤²½¨¾®¾−- -Ã−- ó¯ 2011 À²ˆº-§º¡-¹¾-ºñ©ª¾-¡¾−-À¥ñ®-À¯ñ−-ê†-À¡ó©-¥¾¡-²½¨¾©-Ã®-
Ä É´-Ã−-ªñ®. ¡¾−-¦ô¡¦¾-§÷ -´§ö−-Á È´−-¡¾−-¦ô¡¦¾-Á®®-ªñ©-¢¸¾¤- À²ˆº-§º¡-¹¾-ºñ©ª¾-¡¾−-§÷¡-§÷ -´¢º¤-
¡¾−-À¯ñ−-²½¨¾©-µøÈ-À¢©-ê†- ó´-¡¾−-ªò©-À§œº¢º¤-²½¨¾©-Ã®-Ä É´-Ã−-ªñ®-¦ø¤ §‡¤-Ã−-−˜−®ñ−©¾-®÷¡£ö−-ê†-À¢í¾-
»È¸ -´¡¾−-¦ô¡¦¾-Á È´−-À¯ñ−-°øÉ-ê†-ªò©-À§œº²½¨¾©-Ã®-Ä É´-Ã−-ªñ®- Áì½-Ä©É-©¿-À−ó−-¡¾−¡¸©-À²ˆº-§º¡-¹¾-
ºñ©ª¾-¡¾−-À¥ñ®-À¯ñ−-Ã−-êÒ-−Õ®ó ©É¸ -¨¡¾−¡¸©-§Èº¤-Ä³³É¾-£œ−¦¼¤. −º¡¥¾¡-−˜− ñ¨¤-Ä©É-ì¸®-ì¸´¢Ó-
ø´−-©É¾−- ñ¯©-Ã¥-¦È¼¤-ªÈ¾¤Å ¢º¤-¡¾−-−¿-Ä -¯¦øÈ-¡¾−-ªò©-À§œº-Â© -¨Ã§É-Á®®-¦º®-«¾ -´°øÉ-ê†-ªò©-À§œº²½¨¾©-
©„¤¡È¾¸-−˜−. ¡¾−-¦ôõ-¡¦¾-µøÈ-Â»¤²½¨¾®¾−-Ä©É-©¿-À−ó−-µøÈ 06 Á¹È¤ -Ã−-ê‰¸-¯½-Àê© £õ −½£º−¹ì¸¤-¸¼¤-
¥ñ−, ¹ì¸¤-²½-®¾¤, ¦²¹¸ñ−−½-À¢©, -Áì½ ¥¿-¯½-¦ñ¡. §‡¤-Ã−-−˜−-Ä©É-À¡ñ®-¢Ó- ø´−-¨Éº−-¹ìñ¤-¢º¤°øÉ-¯È¸ -¨
ê†-¦ö¤--Ä¦-¸È¾-À¯ñ−-´½-À»ñ¤-êÒ-¦‰¤-−Õ®óê†-À¢í¾-−º−- …¯− ö¯¸-µøÈ-Â»¤Ïð-©„¤¡È¾¸ ì½¹¸È¾¤ ó¯ 2006Œ2010 µøÈ 
¦¯¯ ì¾¸.  
¡¾−-êö©-ìº¤-©û¸ -¨¡¾−-§÷È -´Àìõº¡-Á®®-À¯ó©-À°ó-¨ (randomized open label) Ã−-¡÷È -´êö©-ìº¤-¦º¤-¡÷È´ -
À²ˆ-º¯½-À ò´ó−¯½¦ò©-ê½-²¾®-¢º¤-¡¾−-−¿-Ã§É-µ¾ º¾−-Á®ñ−©¾-Â§− Áì½ -À -´Á®ñ−©¾-Â§− µøÈ-À õ´º¤-®¾-
¥¼¤ -Á¢¸¤ ¥¿-¯½-¦ñ¡ -Ã−- ó¯ 2009. Ã−À©ñ¡-−ñ¡»¼− ¥¿−¸− 200 £ö− ê†-ªò©-À§œº²½¨¾©-¯¾¡-¢ð §‡¤-
¡¸©²ö®-Â© -¨Ã§É-Àªñ¡−ò¡¡¾−¡¸©-º¾¥ö -´Á®®-¡¾-Âª-¡¾¦ Ä©É-§÷È -´Ã¹É-µ¾-º¾−-Á®ñ−©¾-Â§−  100 £ö− -
Áì½ --À -´Á®ñ−©¾-Â§− 100 £ö−.   
¡¾−-¦ô¡¦¾-ê†-¦º¤-Á È´−-¡¾−-¦ô¡¦¾-Â© -¨−¿-Ã§É-¸òêó-¡¾−-¦÷È -´êö©-ìº¤-Á®®-À¯ó©-À°ó¨ ¦¿ìñ®-¡¾−-¯½-À ó´−-
¯½¦ò©êò²¾® -Áì½ £¸¾ -´¯º©-Ä²-¢º¤-µ¾ Mefloquine (25mg/kg), artesunate (10mg/kg Ã¹û¦¾ -´
£˜¤²¾¨-Ã− 12 §´), µ¾-¯½¦ö´ Mefloquine Áì½ artesunate (artesunate 10mg ¡ñ® Mefloquine 
250mg 1 £˜¤ ªÒ- œ´ Ã−-¦¾´ œ´ªò©-ªÒ-¡ñ− À²ˆº-¦ö -´ê¼®-¡ñ®-µ¾ ¯ì¾-§ó-¡ñ¤-Áªñ− (75´¡ ªÒ-¡ò-Âì-−ÕÎñ¡-
»È¾¤¡¾¨ -Á®È¤-À¯ñ− ¦º¤-£¾®) Ã−-À©ñ¡-−ñ¡»¼−- ñ´©ê½ ö¨ -´ê†-Á¢¸¤-ºñ©-ª½¯õ, ¦¯¯ ì¾¸. À¹ñ−- È¸¾-À¢©-
©„¤¡È¾¸-Á È´−- ó´-¡¾−-ªò©-À§œº¦ø¤. °ö−-¡¾−-¸ò-Ä¥-¢º¤-êñ¤-¦º¤-Á®®-êö©-ìº¤-Ä©É-¡¿−ö©-Àºö¾-ºñ© ª¾-¡¾−-
¹¾¨-¢¾©-¥¾¡-¡¾−-ªò©-À§œº -Áì½ ¥¿−¸−-Ä¢É-¹ì÷©-ìö¤²¾¨¹ìñ¤-¡¾−-¯…− ö¯¸-Ã−- œ´ê† 21 Áì½ 23. 
º¾¡¾−-¦ö−-¢º¤-µ¾--Á È´−-¯½-À ó´−-µøÈ-Ã− 3 §´, 48, -Áì½ 120 §´ ¹ìñ¤-¥¾¡-Ä©É-»ñ®-µ¾-¯…− ö¯¸.  
°ö−-¡¾−-¦ô¡¦¾: ¡ðì½-−ó¡¾−-¦ô¡¦¾-²½¨¾© C. philippinensis -Á È´−-Ä©É--¦ô¡¦¾-µøÈ-Â»¤Ïð-Á¢¸¤-
¦½¹¸ñ−−½-À¢© -Áì½-Â»¤Ïð-¦ø−-¡¾¤-ê†-−½£º−¹ì¸¤-¸¼¤-¥ñ−, §‡¤- ó´-êñ¤-Ïö©-¦¾ -´¡ðì½−ó Áì½ -°øÉ-¯È¸ -¨®Ò-
À£ó¨- ó´-®ñ−¹¾-©É¾−-¦÷¢½²¾®´¾-¡Éº− êñ¤-Ïö©-Á È´−-À¯ñ−-§¾¨-Î÷È´ º¾¨÷-ì½¹¸È¾¤ 24Œ27 ¯ó º¾¡¾−-ê†-
¯½-¡ö©-ºº¡-Á È´− ó´-¡¾−-«º¡êÉº¤-Á®®-ªÒ-À−ˆº¤, -À¥ñ®êÉº¤, ®¸´ -Áì½ ó´-¡¾−-À¦¨-−ÕÎñ¡-Á®®-»÷−-
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Á»¤. £ö−-À¥ñ®-¦º¤-£ö−-Á È´−-£¾©- È¸¾-º¾-ªò©-À§œº²½¨¾©-−š¥¾¡-¯½-Àê©-Äê Áì½- ºó¡-−‡¤-¡ðì½-−ó £¾©- È¸¾-
º¾©-ªò©-À§œºµøÈ ¦¯¯ ì¾¸. Ã−-−˜−²ö®- È¸¾ ó´-¡¾-−ªò©-À§œº-Á È´-¡¾-±¾¡-ºˆ−-¦ö´êö®-£õ ²½¨¾©-Ã®-Ä É´-Ã−-ªñ® 
-Áì½ ¡¾−-±¾¡-Âª-¡ö -´ºÈ¼−. Ã−-¡¾−-¦ô¡¦¾-¡ðì½−ó-²½¨¾©-¡¾-±¾¡-Ã®-Ä É´-©ø©-Àìõº© µøÈ-ê†- À õ´º¤-Â¢¤ -
Á¢¤-¥¿-¯½-¦ñ¡ ¥¿−¸− 9 ¡ðì½−ó-²ö®- È¸¾ ¦È¸−-¹ì¾¨ -À¯ñ−-À²©-§¾¨ ê†- ó´-º¾¨÷-¦½-ÀìÈ¨ ¯½´¾− 36 ¯ó . 
êñ¤-Ïö©-Á È´−-º¾-Ä¦-µøÈ©º−-Â¢¤ª˜¤-ÁªÈ-¡¿-À−ó-© -Áì½-°È¾−-´¾-¡ð-Ä©É-»ñ®-¡¾−- …¯− ö¯¸-©É¸¨-µ¾ ¯ì¾-§ó-¡ñ¤-
Áª−. Ã−-Äì¨½-ªò©ª¾ -´£˜¤¦÷©-êÉ¾¨-²ö®¸È¾ ó´-¦¾ -´¡ðì½−ó-¦ô¡¦¾ ó´-º¾¡¾−-©ó-¢›− ¦º¤-¡ðì½−ó-¨ñ¤- ó´-
º¾¡¾−²½¨¾©-£õ-À¡‰¾²¾¨¹ìñ¤-ê†-Ä©É-»ñ®-µ¾-¯…− ö¯¸, ¦º¤-¡ðì½−ó-Á È´−-À¦ -¨§ó ò¸©-¨Éº−-Àìõº©-Ä¹ì-À−ˆº¤-
¥¾¡-À¦˜−-Àìõº©-©¿-ª¾ -´êÒ-¡½-À²¾½º¾¹¾−-¥ó¡¢¾©, -Áì½ ó´¦º¤-¡ðì½−óÄ©Éºº¡-¥¾¡-¡¾−-¦ô¡¦¾. 
¦¿ìñ®º¾¡¾−-¢º¤-ªñ®-ê†-ªò©-À§œºÀ¹ñ−¸È¾-©ó-¢›−²¾¨¹ìñ¤-ê†-Ä©É-»ñ®-µ¾.  
¡¾−-¦õ-¡¦¾-¡È¼¸-¡ñ®-¡¾−-À¯ñ−-²½¨¾©-¢º¤-²½¨¾©-Ã®-Ä É´-©ø©-Àìõº© -Áì½- ¡¾−-ªò©-À§œº»È¸ -´¡ñ®-Á È´-
±¾¡-²½¨¾©-Ã®-Ä É´-Ã−-ªñ®²ö®-¸È¾- ó´-¡¾−-¯È¼−-Á¯¤-Ã−-ê¾¤-ê†-©ó-¢›−²¾¨¹ìñ¤-¡¾−-¡ò−-µ¾ -À¯ñ−ªí− ¡¾−-
¹¾¨-©ó-Ã−-À−œºªñ®-¦¿ìñ®-°øÉ-ê†-ªò©-À§œºì½©ñ®-À®ö¾®¾¤ -Áì½ ¯¾−¡¾¤ (P<0.001), ì¸´êñ¤-¢½ Î¾©-
ªñ®¢É¾¤-§É¾¨, É¯¾¤, -Áì½ -À¦˜−-Àìõº©-ê†-Ä¯-¹ìÒìÉ¼¤-¯É¾¤--Á È´−-¹ì÷©-ìö¤ (P<0.01). ÁªÈ-¡¾−-ªò©-À§œº-Á È´-
¡¾-±¾¡£õ−-ÃÏÈ Ã−-À©õº−-ê† 11 ²¾¨¹ìñ¤-¡¾−-¯…−¯ö -¸Á È´−-¨ñ¤²ö®-À¹ñ−Ã−¥¿−¸−-¹ì¾¨. ¡¾−-¦ô¡¦¾-
Ã−-§÷ -´§ö− Áì½ -Â»¤²½¨¾®¾− ²ö®- È¸¾ ²½¨¾©-Ã®-Ä É´-Ã−-ªñ®-Á È´−-À¯ñ−-¦¾ -¨À¹©-ê†--À»ñ©Ã¹É- ó´-¡¾−-À¥ñ®-
À¯ñ−-Ã−-ªñ® -Áì½ -êÒ-−Õ®ó. Ã−-¥¿−¸−-£ö−-À¥ñ® 431 £ö− ê†-ªò©-À§œº²½¨¾©-Ã®-Ä É´-Ã−-ªñ®-²ö®- È¸¾ ó´-
¥¿−¸− 5 £ö− Á È´−--¦ö¤-Ä¦-¸È¾À¯ñ−-²½¨¾©-´½-À»ñ¤-êÒ-¦‰¤-−Õ-®ó, ²¾¨¹ìñ¤-¡¾−¡¸©-©É¸ -¨À£ˆº¤§Èº¤-
Ä³³É¾-ê†-Ã§É-£œ−¦¼¤ -Ä©É-²ö®-£¸¾ -´°ò©- ö¯¡¡½ªò-¢º¤-ªñ® -Áì½ «ö¤-®ó À§„−-¡ñ− (£¸¾ -´°ò©-¯ö¡¡½ªò-¢º¤-«ö¤-
®ó Áì½ -Ä¢È¹ìñ¤, ªñ®-§õ´−Õ ñ´−, ªñ®-Á¢¤, -Áì½- ºˆ−Å). Ã−-¡¾−-¦ô¡¦¾-µøúÂ»¤²½¨¾®¾−-Ã−-À¢©-ê†- ó´-
ºñ©ª¾¡¾−-§÷¡-§÷ -´¢º¤-²½¨¾©-Ã®-Ä É´-Ã−-ªñ® µøÈ ¦¯¯ ì¾¸ ²ö®-¸È¾ ó´-¥¿−¸− 274 £ö− ê†- ó´-¡¾−-¦ö¤-Ä¦--
Ä©ÉÀ¢í¾-−º−-Â»¤Ïð ¨Éº−-²½¨¾©-´½-À»ñ¤-êÒ-¦‰¤-−Õ-®ó . °øÉ-§¾¨ -Áì½ º¾¨÷ 50 ¯ó Íõ º¾ ÷¨-¹ì¾¨-¡ È¸¾ 50 
ó¯ Á È´−-²ö®-À¹ñ−-À¯ñ−-¥¿−¸−-¹ì¸¤¹ì¾ -¨ê†-¦ö¤-Ä¦-¸È¾-À ñ¯−-´½-À»ñ¤-êÒ-¦‰¤-−Õ-®ó. Ã−-¥¿−¸− 274 £ö−-ê†µøÈ-
Ã−-¡ðì½−ó-¦ö¤-Ä¦ -Á È´− 267 £ö− - ó´-êÒ-−Õ®ó-ª‡¤-,  -274 £ö− Á È´−- ó´Îš¸«ö¤-®ó Íõ -Îš¸êÒ-ê¾¤-À©ó−-ªñ® -ÁªÈ-¸È¾-
ó´-²¼¤-ÁªÈ-¥¿−¸− 33 £ö− Ä©É-«õ¡-®‰¤´½ªò-¸È¾-À¯ñ−-²½¨¾©-Ã®-Ä É´-Ã−-ªñ®. ¡¾−-®‰¤´½ªò-Â© -¨¡¾−-
ªñ©¦™−¦È¸−-º½-Ä¸¨½-¸½-Á È´− ñ¨¤-®Ò- ó´-Ã−-¯½-Àê©-ì¾¸ -Áì½ ©É¸¨-À¹©°ö−-©„¤¡È¾¸ ²½¨¾©´½-À»ñ¤-êÒ-¦‰¤-
−Õ®ó-¥‡¤-®Ò-Ä©É-«õ¡-®‰¤´½ªò.  
«É¾-¦ö´ê¼®¡ñ®-¡¾−-¦ô¡¦¾Á®® meta-analysis ê†-°È¾−-´¾ ¡¾−-¯…− ö¯¸-©É¸ -¨µ¾-º¾-Á®ñ− ©¾-Â§− 
Áì½ --À -´Á®ñ−©¾-Â§− À¹ñ−-¸È¾ -¯½¦ò©êò²¾®-Ã−-¡¾−- …¯− ö¯¸-Á È´-êÉº¤-¯¾¡-¢ð ñ¨¤-À ñ¯−-ê†-®Ò-À²…¤-²ð-Ã¥. ÁªÈ-
¦¿ìñ®-¡¾−- …¯− ö¯¸-©É¸ -¨µ¾-º¾−-Á®ñ−-©¾-Â§-− Á È´−-À¹ñ−-¸È¾ -ºñ©ª¾-Ä¢È¢º¤-²½¨¾©-Á -´úêÉº¤¯¾¡-¢ð -¹ì÷-
©ìö¤-µÈ¾¤- ó´-£¸¾ -´¦¿£ñ−-ê¾¤-¦½«òªò ¦ö -´ê¼®-Ã¦È-µ¾º¾−-Á®ñ−©¾-Â§− (86,7% -Áì½ 76,3% ª¾ -´
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ì¿©ñ®). −º¡-−˜− ñ¨¤²ö®-¸È¾ µ¾-º¾−-Á®ñ−©¾-Â§− Áì½ -À -´Á®ñ−©¾-Â§− ¨ñ¤- ó´-¯½¦ò©êò-°ö−-Ã−-¡¾−-¢É¾-
À§œº²½-¨¾©-¡¾-±¾¡-Ã®-Ä É´-Ã−-ªñ® -Â© -¨À»ñ©-Ã¹É-¥¿−¸−-Ä¢È-¹ì÷©-ìö¤-µÈ¾¤-¹ì¸¤¹ì¾¨,  -Ã−-¡¾−-¦ô¡¦¾-
ê†-¦º¤ -Á®®-êö©-ìº¤-ê¾¤-©É¾−-£ìó-−ò¡ -Â© -¨−¿-Ã§É-µ¾ Tribendimidine §‡¤-Ã§É-Ã−-¢½Î¾©-£¸¾ -´Á»¤-
¢º¤-µ¾-Ã§É- …¯− ö¯¸-²½¨¾©-Á È´-¡¾-±¾¡-ê†-ªò©-´¾-¥¾¡-ÎÉ¾©ò−. À¹ñ−-¸È¾¡¾−-¦ô¡¦¾-¯½¦ö®-°ö−¦¿-Àìñ©--Ã−-
©É¾−-ºñ©ª¾-¡¾−-¯…− ö¯¸-Áì½-ºñ©ª¾-¡¾−-¹ì÷©-ìö¤-¢º¤-Ä¢È-Á È´-²½¨¾© «É¾-¦ö -´ê¼®--µ¾-ê†-Ä©É-´¾©«¾−-
…¯− ö¯¸-²½¨¾©-Ã®-Ä É´-Ã−-ªñ® ¯ì¾-§ó-¡ñ¤-Áª− (CR 70%, 56% -Áì½ ERRs 99.3%, 98.4%). Ã−-
¡¾−-¯…−¯ö -¸µøÈ-Ã−-¡÷È -´À©ñ¡-−ñ¡»¼− ñ´©ê½¨ö -´ªí− Áì½ ¯¾¨ ê†- ó´-¡¾−-ªò©-À§œº²½¨¾©-Ã®-Ä É´-Ã−-ªñ®. 
¡¾−-¯…−¯ö¸²½¨¾©-Ã®-Ä É´-Ã−-ªñ® -©É¸ -¨¡¾−-−¿-Ã§Éµ¾ artesunate, mefloquine-artesunate Á È´−®Ò-Ä©É-
»ñ®-°ö−. ²¾¨¹ìñ¤-¡ò−-µ¾À©ñ¡-−ñ¡»¼−êñ¤-Ïö©-Á È´−- ó´-º¾¡¾−-¦ö−, -Â©¨¦½-À²¾½-Á È´−-¡÷È -´À©ñ¡-−ñ¡»¼−-
ê†-Ä©É-»ñ®-¡¾−-¡ò−µ¾ - mefloquine, mefloquine-artesunate Á È´−- ó´-º¾¡¾−-¦ö−-¹ì¾¨ -Áì½ -»÷−-Á»¤. 
¦¿ìñ®-¡÷È -´ê†-Ä©É-»ñ®-¡¾−- …¯−¯ö¸-©É¸ -¨µ¾ Tribendimidine  Á È´-®Ò- ó´-º¾¡¾−-¦ö−-¹ì¾¨ -Áì½ ®Ò-»÷−-Á»¤.  
¦½¹ì÷®÷÷÷ -- --°ö−ööö -- --¡¾−-- --¦ô¡¦/£¸¾´ôôô -- --¦¿£ñ−:ñññ   ¡¾−-ì¾¨-¤¾−-¡ðì½−ó-¡¾−-¦ô¡¦¾-Á È´−-ª½Îñ¡-Ä©É-À«ò¤-¡¾−-¡ñ®-
£õ−-¢º¤-²½¨¾©-Ã®-Ä É´-©ø©-Àìõº©-ê†-À õ´º¤-Â¢¤-Á¢¸¤-¥¿-¯½-¦ñ¡ -Áì½ -£¸¾ -´¦È¼¤-ê†-º¾©-À¡ó©-ì½®¾©-
¢º¤-²½¨¾© C philippinensis  µøÈ ¦¯¯ ì¾¸. ©„¤−˜− ¥‡¤-Ã¹É-£¸¾ -´¦¿£ñ−-²½¨¾©-©„¤¡È¾¸¹ì¾ -¨¢›−. 
ºñ©ª¾-¡¾−-§÷¡-§÷ -´ê†-À¡ó©-¥¾¡-²½¨¾©-Ã®-Ä É´-©ø©-Àìõº©, ²½¨¾©-Ã®-Ä É´-Ã−-ªñ® -Áì½ ¡¾−-ªò©-À§œºêñ¤-
¦º¤-§½−ò©-©„¤¡È¾¸-Á È´-¡Ò-Ã¹É-À¡ó©ºñ©ª¾-¡¾−-À¥ñ®-À¯ñ−-²½¨¾©-ªñ®,«ö¤-®ó Áì½ É¯¾¤ §‡¤-ì¸´êñ¤-¡ðì½-
−ó¦ö¤-Ä¦-²½¨¾©-´½-À»ñ¤-êÒ-−Õ®ó, ²½¨¾©-¡½©ñ−-ªñ® -Áì½ Íº©-Àìõº©-§Èº¤-²½-À²¾½-º¾¹¾−-ª‡¤. ¡¾−-
ªò©ª¾´¯½¦ò©êò²¾®-¢º¤¡¾−-−¿-Ã§É-µ¾- …¯− ö¯¸-²½¨¾©-Á È´-¡¾-±¾¡-Ã−-¯½¥÷-®ñ−-ê†-Ã§É-À¢í¾-Ã−-¡¾−-
…¯− ö¯¸-ê‰¸-¯¸¤-§ö−-Á È´−- ó´-£¸¾ -´»¼¡»Éº¤-ªÉº¤¡¾−-µÈ¾¤-»ó®-©È¸− Tribendimidine Á È´−-º¾©-À¯ñ−-ªö -¸
µ¾-ê¾¤-Àìõº¡ -Ã§É-À¢í¾-Ã−-¡¾−- …¯− ö¯¸-²½¨¾©-Ã®-Ä É´-Ã−-ªñ®-Áì½-À§„−-©¼¸-¡ñ−-¡ñ®-²½¨¾©-Á È´-¡¾-±¾¡-
ºˆ−Å-Ã−-ªÒÎÉ¾.  
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1. Introduction
1.1 Overview of present PhD thesis 
The purpose of this Ph.D thesis is to determine morbidity and treatments pertaining to 
the most common helminth infections in Lao People’s Democratic Republic (Lao PDR, 
Laos), namely food-borne trematode Opisthorchis viverrini, water-borne trematode 
Schistosoma mekongi and the soil-transmitted hookworm. Beside the routine stool 
examination and clinical exam, ultrasound visualization was employed in order to 
investigate helminthic morbidity. Emphasis is placed on detailed biology, life cycle, 
mode of transmission; epidemiology and disease burden estimates; clinical 
manifestations and consequences; diagnosis; and current strategies to control of O. 
viverrini, S. mekongi and hookworm infections, while less common parasitic infection, 
i.e., Capillaria philippinensis and other soil-transmitted helminths (i.e., Ascaris 
lumbricoides and Trichuris trichiura) are mentioned. 
1.2 Biology, life cycle and mode of transmission of O. viverrini, S. mekongi, 
hookworm and C. philippinensis 
Food and waterborne trematodiasis and soil-transmitted helminthiasis are the most 
prevalent human parasitic diseases in the developing world (Bethony et al., 2006; 
Gryseels et al., 2006; Keiser and Utzinger, 2005). Fish, snail, water and soil play an 
essential role for the transmission of O. viverrini, S. mekongi and human nematode 
including hookworm and C. philippinensis (Brooker et al., 2004; Gryseels et al., 2006; 
Odermatt et al., 2010; Sripa et al., 2010a). Fresh water fish is a main staple and daily 
consumed by people in East and Southeast Asia (SEA), particularly people dwelling 
along the main tributary and creeks. The behavior of eating raw or uncooked fish is 
traditionally deep-rooted, which is a prerequisite for the transmission of O. viverrini 
(Sripa, 2003; Sripa et al., 2010a). In areas where the raw or uncooked dishes are a 
dietary staple, notably in Laos, Northeastern Thailand, and also in Cambodia and 
Vietnam, the prevalence of food-borne trematodes is rampant (Sayasone et al., 2007; 
Sithithaworn et al., 2011; Sripa et al., 2010b). The most well-known Lao dishes are 
cooked with uncooked fish, including Koi pa, Lap pa, Pa dek, Som pa (Figure 1.1). 
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1.2.1 Opisthorchis viverrini (O. viverrini) 
O. viverrini, a hepatobiliary fluke, is a member of the family Opisthorchiidae. Four major 
flukes are known to parasitize humans, namely Fasciola gigantica, F.  hepatica, 
Opisthochis viverrini, O. felineus and Clonorchis sinensis (Keiser and Utzinger, 2005; 
Keiser and Utzinger, 2009; Marcos et al.,2008). The life cycle of O. viverrini is complex. It 
can not replicate in a single host and it needs at least three main hosts. The adult worm 
lives in the biliary duct of the human liver. Adult worms and their constantly produced 
eggs impact on host liver tissues (Keiser and Utzinger, 2009). Eggs of the parasite are 
excreted with faeces and infect two intermediate hosts to complete its life cycle (Sripa, 
2003). A fresh water snail of the genus Bithynia serves as a first intermediate host, 
although the infection rate of O. viverrini is relatively low in the snail population 
(Kaewkes, 2003; Kaewpitoon et al., 2008a). Within the snail, the eggs develop in to 
rediae, sporocysts and cercariae. Once cercariae release from snail, they penetrate the 
skin of fish and hatch inside the second intermediate host, Cryprinoid ssp, especially, 
young ones are the most susceptible to infective cercariae (Sripa, 2003). An estimated 
18 fish species of the family Cyprinidae harbour infective cysts called metacercariae 
hatching in their muscle and scales with the prevalence of O. viverrini infection higher 
rather than that in the snail population (Kaewkes, 2003; Lun et al., 2005; Muller R. & 
Wakelin D, 2002). Recent investigation showed trematode metacercariae infects various 
fish species in Laos (Rim et al., 2003).  Humans and acting as the definitive host are of a 
considerable importance for the transmission (Sripa, 2003). O. viverrini adult worms 
settle successfully in various mammal hosts, including pets such as cats, dogs and wild 
animals, hence opisthorchiasis may be considered a zoonosis (Conlan et al., 2011; Enes 
et al., 2010). The infection is acquired by ingesting raw or uncooked fish containing 
infective metacercariae. The flukes migrate to the liver through the ampullar of Vater 
and common bile duct and habitat in the bile ducts (biliary phase). Adult flukes can 
persist for 25 years in the biliary tract of human hosts and cause inflammatory lesions 
and tissue damage, which can lead to fatal complications (Lim et al., 2008; Sripa and 
Pairojkul, 2008). 
1.2.3 Schistosoma mekongi (S. mekongi) 
Schistosoma mekongi is the causative agent of schistosomiasis mekongi and closely 
related to S. japonicum (McManus et al., 2009; Zhou et al., 2010). It has been first dis- 
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covered in the late 1960ties by VicDupont and colleagues in a Lao migrant admitted at 
the hospital in Paris, France (VIC, 1957). Foci of S. mekongi tend to be geographically 
restricted in communities along the lower Mekong Basin and its tributaries, namely the 
northern provinces of Kratié and Stung Treng in Cambodia and Khong Island, 
Mounlapamok Districts and Champasack province, Lao PDR (Muth et al., 2010). 
However, the distribution of this disease may stretch to some areas in East of Thailand 
(Harinasuta and Harinasuta, 1984). The life cycle of the schistosomes includes stages in 
humans or mammalians and in snails as the intermediate host (Gryseels et al., 2006). 
The snail species Neotricula apata plays an important role acting as the only 
intermediate host for S. mekongi (Attwood, 2001; Attwood et al., 2008).  The infections 
in humans start when they have direct contact with infested fresh water. In addition, the 
adult worm of Schistosoma spp is hermaphroditic; hence, the interruption of the life 
cycle tends to be challenging (Gryseels et al., 2006). 
 
1.2.4 Hookworm 
Hookworm, Ascaris lumbricoides, and Trichuris trichiura are soil-transmitted helminths. 
Hookworm (Necator americanus and Ankylostoma duodenale) is considered the most 
widespread species worldwide and causes the most important public health threat 
Figure 1.1 Raw and pickle fish dishes 
(A) Pa dek -fermented fish sauce, (B) Som pa-uncooked pickle fish,  
(C) Koy Pa -citrus marinated raw fish, (D) Lap Pa -minced raw fish salad 
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worldwide (Bethony et al., 2006; de Silva et al., 2003). The terms “soil” and “intestine” 
were commonly used to refer to these parasites, because its mode of transmission and 
infection are related to the soil and intestinal tract of human (Brooker et al., 2004). 
Hookworms have a direct life cycle (Hoagland and Schad 1987). They are infecting 
transcutaneously the human host by active penetration through the skin by larvae (L3). 
After a migration through heart and lung they reach the intestinal tract. Hookworm 
attach and then invade intestinal mucosa of humans, where they develop to adult 
worms (small intestine), and feed on blood and reproduce (Bethony et al., 2006; Hotez 
et al., 2004; Jex et al., 2011). 
 
1.2.5 Capillaria philippinensis (C. philippinensis) 
Capillaria philippinensis is a rare food-borne nematode causing intestinal disease. It 
belongs to the family Trichinelloidae which is similar to Trichinella spp. There are three 
species, Capillaria hepatica, C. aerophila and C. philippinensis (Saichua et al., 2008). 
C. philippinensis is the most severe species parasitizing human in the genre of Capillaria 
(Chichino et al., 1992). Historically, it was first discovered in a schoolteacher living in 
Luzon, the Philippines in 1962 (Chitwood et al., 1968). An outbreak occurred during the 
1970s. More than 1000 cases and 77 deaths were documented at that time. 
Subsequently an outbreak appeared in Thailand (Chichino et al., 1992; Chitwood et al., 
1968). 
 
1.3 Epidemiology and disease burden estimates 
C. philippinensis exhibits a complex life cycle (Figure 1.2), composed of the intermediate 
host fish, namely Cyprinus carpio (Pa Nai), Puntius gonionotus (Pa Nin) or Rasbora 
boraperensis (Pa Sew) and human as definitive host (Cross and Basaca-Sevilla 1989; 
Saichua et al., 2008). Notably, natural reservoir is fish-eating water-birds. In addition, 
Capillaria spp. do not replicate within their mammalian hosts. The direct life cycle or the 
so-called autoinfection was observed in Gerbil. Autoinfection is when the offspring 
produced by adults can re-infect the same host, allowing the infestation to multiply 
within a single host animal. 
Since C. philippinensis can multiply in human hosts, intensity of infestation can become 
very high and may lead to death if left untreated (Cross, 1992). Humans get infected by 
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eating raw fish with infective larvae in their muscle. Consumption of raw fish is the 
main source of infection (Cross and Basaca-Sevilla 1989; Cross, 1992) (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Opisthorchiasis, schistosomiasis and hookworm belong to the neglected tropical 
diseases, and cause an extensive socio-economic and public health impact in humans 
and animals in poor countries (Hotez et al., 2007; Keiser and Utzinger, 2009). The 
impact of these pathogens occurs in many ways and exact extend of burden is difficult 
to assess due to various co-infections (e.g. species of Schistosoma and/or opisthorchis 
trematodes and/or soil-transmitted hlyelminths) (Raso et a., 2004; Steinmann et al., 
2008a; Steinmann et al., 2010). 
Lao PDR is a tropical, land-locked country in Southeast Asia, which lies along the middle 
part of the Mekong River and is bordered by China, Myanmar, Thailand, Vietnam and 
Cambodia. The country has an area of 236,800 square kilometres and more than 6.23 
million inhabitants (ADB, 2010). 72.5% were adult literacy, 33.9% of population were 
living on less than 1.25 dollars a day and the rest on less than 1 dollar per day in the 
year 2008.  ~60% of the national population having access to improved drinking water 
and less than half of the population having access to improved sanitation facilities 
Figure 1.2 (A) Life cycle for intestinal capillariais (adapted from CDC); (B) egg 
and Chacot-Layden crystal of Capillaria philippinensis; (C) Fish (Rasbora 
boraperensis), intermediate host  
A 
B 
C 
C 
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(World Bank, 2008). An estimated per capita gross national income was US$ 740 with a 
7.3% economic growth. Culture and ecological factors combined with culinary habits 
including raw food consumptions and hygiene, intensive agricultural activities and high 
levels of environmental exposure to human-animal and parasite contact result in the 
parasitic tropism development and more complex. In these contextual determinants, 
foodborne trematodiasis (O. viverrini, fasciolasis) and nematodiasis (Paragonemus spp, 
trichinellosis, Capillariasis) , waterborne trematode (S. mekongi), and the soil-borne 
hookworm are common in Lao PDR  (Barennes et al., 2008; Odermatt et al., 2009; 
Sayasone et al., 2009a; Sayasone et al., 2009b). 
 
1.3.1 Opisthorchis viverrini (O. viverrini) 
Food-borne liver fluke infection are emerging, neglected and underestimated disease 
worldwide with an estimated 700 million people are at risk of opisthorchiasis. 
Opisthorchiasis is caused by O. viverrini and C. sinensis (Keiser and Utzinger, 2005). It 
remains of high medical and economic importance in Southeast Asia (Figure 1.3) 
(Andrews et al., 2008; Sripa, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 the prevalence of O. viverrini and C. sinensis in Asian countries; endemicity level is 
defined based on prevalence infections following low (0-5%), medium (5.1-15%), high 
(>15%) (Sithithaworn et al., 2011). 
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Although, O. viverrini is confined to Northeast Thailand, Lao PDR, Central Vietnam, 
Cambodia. Currently, an estimated 8 million people are infected in Thailand and 2 
million people are infected in Lao PDR (Sithithaworn et al., 2011; Sripa et al., 2010a). 
Patients positive for eggs of C. sinensis have been confirmed recently in Attapeu 
(Personal communication; PD Dr. Peter Odermatt). 
In Lao PDR prevalence of O. viverrini is geographically heterogeneous (Rim et al., 2003; 
Sayasone et al., 2011). In all the provinces infections with O. viverrini are present with 
the highest infection rates in the central and southern parts exceeding 80% in adults 
(Figure 1.4) and 50% in children (Chai et al., 2007; Rim et al., 2003; Sayasone et al., 
2007; Forrer et al., 2011). Rim and colleagues reported on a nationwide stool survey 
among primary schoolchildren with the prevalence of O. viverrini infection about 10.9% 
(Rim et al., 2003). These numbers underestimate the true infection rates in the 
population as they have been conducted on a single stool examination which has only a 
low sensitivity. A recent epidemiological survey on helminths in three districts on 
Khong Island and Mounlapamok districts revealed the prevalence of O. viverrini 
infection ranging from 64.0-92.0%, respectively (Sayasone et al., 2011). In addition, the 
infection intensity was found to increase with age and decease in high land areas. 
Hence, it emphasizes that the parasitic infections are accumulating over time by 
repeated infection and geographical areas. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Predicted prevalence of O. viverrini in Champasack province, Southern 
Lao PDR (Forrer et al., 2011). 
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1.3.2 Schistosoma mekongi (S. mekongi) 
Schistosomes are the blood-dwelling flukes embedding in urinary bladder and intestinal 
venules of humans (Gryseels et al., 2006). There are five main species affecting humans, 
of which the most common are Schistosoma mansoni (Africa, South America and the 
Arabic peninsula), S. haematobium (Africa and the Middle East), S. japonicum (China, the 
Philippines, and Indonesia), S. intercalatum (west and central Africa) and S. mekongi 
(the Mekong Basin in Lao PDR and Cambodia) (Gryseels et al., 2006; Muth et al., 2010). 
In addition, S. intercalatum and S. haematobium primarily infect the urinary tract and 
may cause lesions in the reproductive system, whereas S. mansoni, S. mekongi and S. 
japonicum provoke the intestinal, hepatic schistosomiasis (Gryseels et al., 2006). 
An estimated 779 million people are at risk of schistosomiasis. An estimated 207 million 
in 76 countries are infected with this parsite, 120 million are symptomatic, 20 million 
suffer severe illness and 280,000 death per year (Chitsulo et al., 2000; Steinmann et al., 
2006; WHO, 2008). Schistosomiasis is the most important human helminth infection in 
terms of morbidity and mortality with a global burden of disease of about 1.7- 4.5 
million DALYs (Utzinger and Keiser, 2004; Utzinger et al., 2009; WHO, 2008) (Figure 
1.5). However, the global burden of schistosomiasis has been seriously underestimated 
(Bergquist et al., 2008; Doenhoff et al., 2008; King et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.5 Global burden of schistosomiasis (Utzinger et al., 2009) 
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S. mekongi is restricted to the lower Mekong Basin and mainly endemic in Lao PDR and 
Cambodia with approximately 140,000 individuals at risk of infection, of which 60,000 
in Lao PDR (Muth et al., 2010). Recent helminth surveys on Don Long, Khong Island 
showed prevalence of S. mekongi among school aged children were 87.8% (Lovis, pers. 
comm.) and adult accounted for 68 % (Sayasone et al., 2011). 
 
1.3.3 Hookworm 
STHs constitute a major public health problem worldwide. However, the bulk of the 
burden due to hookworms is concentrated in rural areas and deprived urban settings of 
low-income countries where clean water and good sanitation are lacking and access to 
health services and treatment is inadequate (Utzinger and Keiser, 2004). It is currently 
estimated that globally more than 2 billion individuals are infected with at least one 
species of STH and more than 135,000 die annually (de Silva et al., 2003). Thus, the 
burden of disease is comparable, in disability-adjusted life years (DALY), to malaria and 
tuberculosis.  
It is estimated that globally more than half a billion individuals are infected with 
hookworms (Ancylostoma duodenale and Necator americanus), the majority of whom 
are children with prevalence ranging from 9.3-11.4 % globally (de Silva et al., 2003; 
Bethony et al., 2006). As many as 65,000 individuals might die each year due to the 
long-term complications of chronic hookworm disease, the majority of whom is school-
aged children (Bethony et al., 2006; de Silva et al., 2003; Hotez et al., 2004).  
The global burden of disease study has attributed 3,000 deaths due to hookworm 
(Brooker et al., 2004; WHO, 2002a). Scale-up administration programme resulted 
dramatically in overt reduction of hookworm prevalence in SEA (Figure 1.6) (Loukas et 
al., 2006). In Lao PDR, STHs are of a major public health importance, in particularly 
school-aged children, with an estimated overall prevalence of hookworm infection 
above 50 % and 19.1% (3.0-45.1% by provinces) in schoolchildren, respectively (Figure 
1.6) (Rim et al., 2003). High hookworm prevalence rates have been reported from rural 
parts of Lao PDR. However, the highest prevalences were found in the Northern 
provinces due to limited access to the health facilities, poor hygiene and infrastructures 
and high exposure to animal faeces (Rim et al., 2003; Sayasone et al., 2007).  
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1.3.4 Capillaria philippinensis (C. philippinensis) 
Approximately 2,000 cases with almost 200 deaths have been documented worldwide, 
mostly from Southeast Asia. Subsequently sporadic cases have been reported from 
Europe and Africa (Odermatt et al., 2010). Outbreak of Capillariasis was mainly found in 
the Philippines and Thailand (Cross, 1992; Saichua et al., 2008).  
 
1.4 Clinical manifestations and consequences  
1.4.1 Opisthorchis viverrini (O. viverrini) 
Opisthorchiasis is considered as one of the neglected tropical disease (Hotez et al., 
2007; Keiser and Utzinger, 2009) and poses a public health threat particularly in 
Southeast Asia (Sripa, 2008; Sripa et al., 2010b). O. viverrini is the most important of the 
foodborne trematodes due to its link to advanced pathogen-specific disease or 
hepatobiliary disease including cholangiocarcinoma (Honjo et al., 2005; Sripa et al., 
2007; Sripa et al., 2003). Clinical manifestations show transient or unspecific signs and 
symptoms of abdominal disease except for heavy infection. The unspecific signs may 
include upper right quadrant pain or intestinal irritations, to severe manifestation 
(Mairiang and Mairiang, 2003). The insidious consequences of opisthorchiasis remain 
unnoticed by infected individuals for a long period and the most dangerous parasite in 
terms of mortality (Bouvard et al., 2009; Shin et al 2010). In addition, jaundice is caused 
Figure 1.6 (A) Prevalence of hookworm infection by region overtime (Loukas et al., 
2006; Rim et al., 2003)  
 
A 
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by mechanical obstruction due to a large number of flukes in the bile duct obstruction 
caused by cholangitis or cholangiocarcinoma as a late complication of long-term chronic 
infection (Mairiang and Mairiang, 2003; Sithithaworn et al., 2009). CCA is a common 
cancer in Southeast Asia, with the world highest prevalence in Northeast Thailand with 
the respective aged-standardized incidence rate of 33.4 and 12.3 per 100, 000 in men 
and women (Sripa and Pairojkul, 2008). Most importantly, studies revealed that the 
incidence of CCA is strongly associated with the prevalence of O. viverrini infection. It is 
well established that O. viverrini infection is triggering the CCA development. It is 
estimated that 60% of the CCA cases is due to O. viverrini infection (Haswell-Elkins et al., 
1992; Honjo et al., 2005; Mairiang et al 2006; Mairiang et al., 1992; Parkin et al., 1991; 
Sithithaworn et al., 1994; Sriamphorn et al., 2004; Sripa et al., 2007).  
Cholangiocarcinoma (CCA) is defined as an adenocarcinoma arising from epithelial of 
the intra and extra hepatic bile ducts. CCA is classified into intra and extra hepatic CCA. 
The respective intra hepatic (IH-CAA) and extra hepatic cholangiocarcinoma (EH-CAA) 
account for 40 % and 60% of all cases CCA (Uttaravichien et al., 1999). IH-CAA 
originates in the cholangiole or small peripheral bile duct. EH-CAA is tumours which are 
located at the large bile ducts, at the portal hepatic, common hepatic duct, cystic duct, 
common bile duct and peri-ampullary region (Uttaravichien et al., 1999).  However, 
most of the CCA cases are IH-CCA in Thailand (Sripa et al., 2008). The disease does not 
cause specific symptoms until very late (Sithithaworn et al., 2009). It is usually 
diagnosed at advanced stages, when effective treatment for cure or prolongation of life 
no longer exists. Primary and secondary prevention are therefore the primary strategies 
to reduce disease burden and CCA mortality (Kaewpitoon et al., 2008; Sripa et al., 2007; 
Sripa and Pairojkul, 2008). 
A number of definite precancerous conditions (risk factors) are strongly associated with 
increased CCA risk, including primary sclerosing cholangitis (PSC), hepatolithiasis, 
biliary malformations (choledochal cyst, Caroli’s disease), ulcerative colitis, thorotrast, 
liver fluke infection (O. viverrini) and secondary sclerosing cholangitis (SSC) related to 
mechanical obstruction. Other risk factors are possibly associated CCA factors namely, 
abestose, isniazid, methyldopa, oral contraception and polychlorinated biphenyls (Ben-
Menachem, 2007; Shin et al., 2010; Yeo et al., 1990).  Additional hypothesized CCA risk 
factors lending themselves as potential targets for prevention include dietary intake of 
nitrate and nitrosamines, aflatoxin B1, smoking, excessive alcohol consumption, obesity, 
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chronic hepatitis C (HCV) and hepatitis B (HBV) infection, cirrhosis, toxins (dioxin, 
polyvinyl chloride), alcohol and biliary-enteric drainage procedures (Ben-Menachem, 
2007; Honjo et al., 2005; Shin et al., 2010). To date, the association of these 
precancerous conditions with chronic O. viverrini infections is unknown. The evidence 
for the etiological role of these additional factors as well as for their interaction with 
chronic O. viverrini infections is still limited and inconsistent (Sripa et al., 2010; Sripa 
and Pairojkul, 2008). 
There is a paucity of data on the incidence rate of cholangiocarcinoma (CCA) in Lao PDR 
due to the absence of diagnostic and treatment possibilities in health services, a 
population-based cancer registry as well as population-based surveys on CCA. Most 
suspected cases admitted at the hospitals, in particularly from provincial hospitals are 
referred for further investigations at the central hospitals in Vientiane – for instance 
specific tumor-marker test, CT scan and recently ERCP has been available only at central 
hospitals in Vientiane, Lao PDR. At present, suspected CCA case numbers presented at 
the admission are accompanied by advanced signs and symptoms, including jaundice 
and right upper quadrant pain. Some of them were seen by annually check-up at the 
hospital. All suspected cases had been firstly examined by target abdominal ultrasound, 
then CT or ERCP. Therefore, today the incidence of CCA is unknown. Nonetheless, the 
incidence of CCA must be very high and similar to Thailand, given the comparable 
endemicity level of Opisthorchis infection in northeast Thailand, which has the highest 
incidence of CCA worldwide (Sripa and Pairojkul, 2008; Vatanasapt et al., 1990). 
 
1.4.2 Schistosoma mekongi (S. mekongi) 
Katayama fever or acute schistosomiasis is the most common acute symptoms 
occurring in Schistosoma japonicum and in S mansoni infections and rarely with S. 
haematobium (Ross et al., 2002). Most of infected individual with S. mekongi remain 
asymptomatic. There is no evidence that S. mekongi cause any acute symptoms 
previously (Gryseels et al., 2006). The onset of symptoms starts 4 to 8 weeks after the 
first exposure to infested water may result in anaemia, fatigue, abdominal pain, and 
intermittent diarrhoea or dysentery in the early evaluation of infection. S. mekongi egg 
deposit in the peri-intestinal tract and liver and release the antigens, evoking the 
inflammatory or granulomatous reactions at the site of intestine and liver, especially 
periportal vein. Ectopic organs can be found but rare (Carmody et al., 2008; Houston et 
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al., 2004). S. mekongi secretion causes microulceration in the intestinal tract, resulting 
in diarrhoea and also bloody stool. Later complication occurs several years after 
exposure and is associated with sustained heavy infection and several exposures to 
infected water bodies (Gryseels et al., 2006). Chronic disease are characterized by 
hepatomegaly, splenomegaly, liver fibrosis, and eventually lead to the progressive 
obstruction of blood flow, portal hypertension and ultimately varices or rupture of 
oesophageal varices, which is the most important cause of death due to this blood  fluke 
(Biays et al., 1999; Gryseels et al., 2006). 
 
1.4.3 Hookworm 
Acute infection can occur in areas where the transmission is high. Hookworm inactive 
phase (L3) infect human through skin penetration. It is characterized by a cutaneous 
syndrome or ground itch or the so-called puritic erythematous papulovesicular rash 
appearing most frequently on the feet and hands, where the larval (L3) migration are 
entered to body (Brooker et al., 2004). Parasites migrate to the lungs and penetrate the 
alveolar walls, ascend through the trachea and ultimately are swollen down into the 
small intestine (Haddad et al., 2008) Visceral larval migration to the lung may cause 
pathologically in form of transient pneumonitis (Loeffler’s like syndrome; Sarinas and 
Chitkara,  1997) or eosinophilic pleural effusion (Yassin et al., 2007). 
The major cause of hookworm infections is intestinal blood loss and hemaetophagy 
contributing to iron deficiency anaemia (Bethony et al., 2006). Anaemia is a major 
public health concern particularly in at-risk population notably, children, women child-
bearing age and pregnant women living in the least developed countries (Hotez et al., 
2004; Hotez et al., 2007). Chronic infection causes impaired physical and mental 
growth, reduced school performance, educational attainment in pre and school aged 
children and reduced productivity in adulthood. Anemia attributable to hookworm 
infections can lead to low birth weight, premature birth in pregnant women and women 
with child bearing age. Moreover, death may occur in individuals concurrently infected 
with hookworm and immuno-competent human, for in stance diabetes, HIV/AID 
tuberculosis (Bethony et al., 2006; Hotez et al., 2007; Lammie et al., 2006).  
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1.4.4 Capillaria philippinensis (C. philippinensis) 
Clinical findings of C. philippinensis include acute-on-chronic diarrhea with 
malabsorption. Capillariasis patients suffer with gastrointestinal symptoms, for instance 
abdominal pain, borborygmus, anorexia, nausea and episodic vomiting. Other 
symptoms, such as oedema, pitting oedema of the lower limbs, muscle wasting, severe 
weight loss were reported (Odermatt et al., 2010; Saichua et al., 2008). Patient may lead 
to fluid loss and electrolyte depletion (hypokalaemia), which may cause death due to 
heart failure and hypovolemic shock (Cross et al., 1992). Capillaria eggs has received 
little attention and may be frequently overlooked or confused with T. trichuria infection 
(Figure 1.2) in chronic diarrhoea and immunosuppressant disease such as Crohn 
disease and HIV/AIDS (Odermatt et al., 2010).  
 
1.5 Diagnosis 
The diverse diagnostic methods, namely direct parasitological examination, 
immunological- and molecular diagnostic tests, and imaging are essential for the 
diagnosis helminth infection and assess helminth-related morbidity (Keiser et al., 2010). 
Diagnostic capability is crucial to determine distribution, prevalence and severity of 
helminth diseases, which allow estimating the burden of disease (Bergquist et al., 2009; 
Johansen et al., 2010). Infection intensity is a crucial determinant to assess indirectly 
helminthiases related-morbidity (WHO, 2002b). Nonetheless, the true burden can not 
be determined without clinical examination and imaging techniques (Bergquist et al., 
2009; Keiser et al., 2010; Lun et al., 2005). 
 
1.5.1 Parasitological diagnosis 
A single diagnosis test does not enable to identify all species helminthic eggs because 
the helminthic diseases necessitate various diagnostic tools (Keiser et al., 2010). Kato-
Katz thick stool smear is widely used for parasitological diagnostic approach due to 
relatively simple and inexpensive tool, except for S. stercoralis. However, use of a single 
Kato-Katz thick stool smear lacks of sensitivity in detecting specific parasite of 
trematode eggs compared to ether-based concentration techniques (Keiser et al., 2010; 
Sayasone et al., 2009b). Multiple Kato-Katz slides and multiple stool sample analysis 
increase the sensitivity for helminth infection (Lovis et al., 2009). Other parasitological 
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techniques including immunological assays (i.e., ELISA or the enzyme-linked 
immunosorbent assay or specific parasitic antibodies), molecular assays (i.e., 
polymerase chain reaction [PCR]) and metabolic profiling (biological samples i.e., blood, 
stool and urine) and the recently developed FLOTAC apparatus possess higher 
sensitivity in detecting helminth eggs than the routine stool examination than Kato-Katz 
and also ether-based concentration techniques (Keiser et al., 2010; Knopp et al., 2009; 
Utzinger et al., 2008). However, these techniques have properties which make them 
challenging for field applications: more sophisticated technique, requiring equipments 
and well-and extensive-trained laboratory personnel (e.g. Speich et al., 2010). 
 
1.5.2 Ultrasound (US) examination 
Abdominal US is usually used as an initial imaging diagnostic tool for assessing 
trematodiasis related morbidity. It is non-invasive, relatively simple to perform and 
well-accepted by patients in hospital settings and in the communities (Hatz et al., 1992; 
Mairiang et al., 2006; Mairiang and Mairiang, 2003). A standardized method of US was 
developed by WHO experts and researchers for assessing periductal fibrosis related to 
schistosome pathogenesis (Niamey Working Group., 2000). US image findings 
document pathologies of a mass, a bile duct dilatation due to mechanical obstruction; 
chronic cholecystitis: gall bladder wall thickening with or without gall stone or hydrop 
gall bladder due to inflammation (Mairiang et al., 1992) increased periportal echo-
prominence of echoes along the portal triad (Hatz et al., 1992). US of the liver and 
biliary tree are used as the initial examination in patient with suspected obstructive 
jaundice (Saini, 1997; Sharma and Ahuja, 1999). In opisthorchiasis patients, US 
demonstrates hepatobiliary pathologic changes. Additionally, ultrasound can identify 
obstruction and ductal dilatation with providing a direct image of pathologic changes 
and in some cases may be sufficient to diagnose CCA (Bloom et al., 1999). 
 
1.5.2 Computed topographies   
US examination is useful as an initial screening assessment in demonstrating early 
stages of morbidity, e.g. dilatation of all or part of the biliary tree in patient with 
obstructed jaundice (Mairiang and Mairiang, 2003). Abdominal computed topographies 
scanning (CT scan) are examinations for in-depth investigations of potential tumours, 
regional node involvement, particularly in suspected CCA patients. Furthermore, 
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percutaneous transhepatic cholangiography (PTC), endoscopic retrograde 
chanlangiopancreati-cography (ERCP), magnetic resonance imaging (MRI) and 
magnetic resonance cholangipancreatography (MRCP) are additional most suffisticated 
tools (Aljiffry et al., 1999). For suspected CCA patients, the extent of ductal involvement 
is best demonstrated MRI or MRCP providing a more accurate diagnosis than the 
invasive ERCP or PTC (Manfredi et al., 2001). Today, early diagnosis and resection are 
the only reliable therapies for CCA. If the tumour mass can be removed surgically, the 
prognosis remains poor. The non–jaundice CCA patients were shown to possess a 
significantly longer survival time than CCA patients with a jaundice (Aljiffry et al., 2009; 
Uttaravichien et al., 1999). 
 
1.6 Current control, treatment and potential drug candidates 
Today, there is no vaccine for the prevention of helminths infection (Hotez et al., 2007, 
McManus et al., 2009). Control efforts for O. viverrini, S. mekongi and STH infections rely 
on preventive chemotherapy accompanied with information education campaigns (IEC), 
improved sanitation and hygiene, access to clean water (de Silva et al., 2003; Lammie et 
al., 2006; Utzinger and Keiser, 2004). Molluscicide for control of S. mekongi was 
abandoned as it was not effective against the snail Neotricula in the huge masses of 
water of the Mekong (Muth et al., 2010). 
Benzimidazole, pyrantel pamoate and levamisole are recommended drugs by World 
Health Organization (WHO) for STH (i.e. A. lumbricoides, T. trichiura and hookworm 
infection) and trematode infections (i.e. schistosomiasis and opisthorchiasis) (Keiser et 
al., 2010; WHO, 2002b). Albendazole (ABZ) and mebendazole (MBZ) belong to the 
benzimidazoles carbamates, which are the most widely used anthelminthics in large-
scale control programmes (Utzinger and Keiser, 2004; WHO, 2002b). These drugs have 
an excellent safety profile with low frequency and generally mild adverse events. They 
can be administered by non-medical personnel, such as school teachers in school-based 
mass treatment campaigns (Keiser and Utzinger, 2010). Recent studies show that ABZ 
shows high efficacies against A. lumbricoides. However lower and often unsatisfactory 
efficacy against hookworms and T. trichiura. Furthermore, ABZ has a low-to-moderate 
efficacy against S. stercoralis (Keiser and Utzinger, 2008; Olsen et al., 2009; Steinmann et 
al., 2008b). Resistance to helminthic drugs has been widely reported in veterinary 
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medicine (Prichard, 1990; Wolstenholme et al., 2004). There is a danger that the wide 
effort of expanded mass drug administration programme against STH may lead to the 
emergence of drug resistance (Geerts and Gryseels, 2000). 
For many trematodiasis praziquantel (PZQ) is only drug available for the treatment 
(Keiser and Utzinger, 2010). Today, there is little incentives to develop new drugs. It is 
time-consuming and has financial limitations. The dependence on a single drug for 
treatment and control spur a concern about treatment resistance (Geerts and Gryseels, 
2000). Today there is no evidence on PZQ resistance against trematode infections in 
humans. Nonetheless, since the number of available dugs has been limited for the 
treatments of trematode infection, there is a pressing need for concerted effort to 
discover and develop new drugs against trematodiasis, notably opisthorchiasis, 
schistosomiasis and soil-transmitted helminthiasis (Keiser and Utzinger, 2010). 
Recent advances are being made with promising broad spectrum Chinese anthelminthic 
drug (tribendimidine) for the treatment of trematodes and other helminth infection in 
hamster models (Keiser et al., 2010). Tribendimidine is a derivative of amidantel, 
synthesized and developed by the National Institute of Parasitic Disease in Shanghai, PR 
China. It has been approved for human use in China. Tribendimidine possess a broaden 
spectrum against nematodes (i.e. A. lumbricoides, Enterobius vermicularis and 
hookworms) (Xiao et al., 2005). Furthermore in vitro and vivo studies in animal modesl 
indicated that mefloquine, artesunate, artemether and tribendimidine possess activities 
against O. viverrini infections (Keiser et al., 2009; Keiser et al., 2006; Keiser et al., 2008). 
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2. Aim and Objectives 
2.1. Aim 
 
2.2. Objectives 
 
The PhD thesis pursued the following 3 main objectives: 
1. To document of severe morbidity of parasitic infection such as C. philippinensis 
and S.  mekongi in Lao. 
2. To assess morbidity of trematode infections and resolution of morbidity after 
treatment. 
2.1 To document hepato-biliary and -splenic morbidity in areas where 
S. mekongi and O. viverrini are coendemic 
2.2 To assess dynamics of infection and morbidity resolution after 
praziquantel treatment in opisthorchiasis and schistosomiasis patients 
2.3 To assess O. viverrini-induced hepatobiliary morbidity including 
precursors lesions of cholangiocarcinoma in Lao PDR  
3. To assess efficacy of present anhtelmintic drugs and potential candidates. 
3.1 To assess the efficacy of a single oral dose of albendazole (400 mg) 
and mebendazole (500 mg) against hookworm infection among 
school-aged children in Lao PDR.  
3.2  To assess the efficacy and safety of mefloquine, artesunate, 
mefloquine–artesunate, and tribendimidine compared with that of 
praziquantel in patients with parasitologically confirmed O. viverrini 
infectio
The aim of this thesis is to deepen our understanding on the importance of 
helminthic parasitic infections in Lao PDR and challenges of their treatments by 
documenting severe morbidity due to parasitic infections in Lao PDR and 
assessing the effects of available and new treatments on infection and morbidity 
status of common helminth infections.  
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Figure 3.1 Field activities  
(A&C) A community-based survey on O. viverrini-induced hepatobiliary morbidity 
by use of abdominal ultrasonography in Saravane  province, Lao PDR 
(B&D) A Randomized controlled trial on efficacy and safety of mefloquine, 
artesunate, mefloquine-artesunate, tribendimidine, praziquantel against O. 
viverrini, Lao PDR  
A B 
D 
C D 
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Hospital-based study 
I. Case series report  
C. philippinensi & S. mekongi 
II. Retrospective study 
Records of suspected 
CCA 
II. Cross-sectional study 
- Morbidity of O. viverrini 
- Morbidity of S. mekongi 
- Co-morbidity of  
   S. mekongi and O .viverrini 
Community-based study 
Infection and morbidity: severe cases and infection and morbidity 
resolution dynamics after treat ment 
III. Treatment: assessment of efficacy and safety of anthelminthic drugs 
A randomized, exploratory open-label 
phase 2 trial 
Efficacy and safety of mefloquine, artesunate, 
mefloquine-artesunate and tribendimidine compared 
to praziquantel against O. viverrini 
A randomized, open-label trial 
Efficacy of single-dose Albendazole and 
Mebendazole against hookworm infections 
3.1 An overview of approach and methdology 
In this chapter and in Figure 3.1 an overview of the research approach and 
methodologies used in the thesis resaerch work will be provided. It will give 
information on the study area, study subjects, and approach and methods used. There 
are separately in the three parts of the Ph.D research activities: (i) severe morbidity of 
parasitic infections (C. philippinensis and S. mekongi), (ii) assessment of parasitic 
infections and morbidity resolution dynamics after treatment, and (iii) assessment of 
efficacy of present anthelmintic drugs and potential drug candidates. A final section 
provides information on ethical aspects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Severe morbidity of parasitic infections in Lao PDR 
Severe C. philippinensis cases: In two referral hospitals in Vientiane and Savannakhet 
in Lao PDR we identified three cases from patients’ admitted. A first case was reported 
from Savannakhet provincial hospital in 2006 (Figure 3.3). Savannakhet is located in the 
southern part of Laos (600 km to the south from Vientiane capital), on the shore of the 
Mekong River opposite of Mukdahan, Thailand. Savannakhet is the largest province 
Figure 3.2 Overview research approach of present PhD 
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from Lao PDR with a population of 824,662 inhabitants (NSC, 2005) living in 15 
districts. Two additional C. philippinensis cases were found in Sethathirath and Mahosot 
hospitals in Vientiane in 2007. Both hospitals are acting as referral and university 
hospitals. Vientiane Capital is the capital of Lao PDR, situated on the Mekong River with 
the population of 695,473 and the second largest province (NSC, 2005). 
Severe Schistosoma mekongi (S. mekongi) cases and follow-up: The severe cases of 
S. mekongi were identified during community-based survey in 2007 and subsequently 
annually re-visited until 2010. They were seen on Khong Island, southern Champasack 
province (Khong district, estimated population: 80,000) (Mouth., et al 2010, Sayasone S 
et al., 2011). Khong Island district is located in the southern part of the province (~120 
km from Pakse city), and borders Northeaster Cambodia (Figure 3.4). All patients were 
examined and followed up on a yearly basis for three to four years (2006-2010). The 
examination consisted of physical examination, abdominal ultrasound, and various 
blood tests, including hepatitis test as well as liver, and renal function tests. These 
examinations allowed evaluating the clinical and treatment response of the patients. We 
informed patients about any abnormalities and provided treatment in accordance to 
Lao standard case management, Ministry of Health, Lao PDR (Ministry of Health, 2004). 
Unfortunately, some cases were lost to follow-up due to temporary work task. 
 
3.3 Assessment of infection and morbidity resolution dynamics after 
treatment of S. mekongi and O. viverrini patients 
Assessment of infection and morbidity caused by S. mekongi and co-morbidity 
caused by O. viverrini after treatment in endemic areas, Lao PDR: We conducted a 
cohort study from 2006 to 2008 in three villages on Khong district, Champasack 
province. S. mekongi and O. viverrini and co-infection are endemic. It allowed us to 
investigate spleno- and hepatobiliary morbidity due to the two infections and document 
the infection and morbidity resolution dynamics. We used standard laboratory, Kato-
Katz thick smear techniques (3 stool samples each examined with single Kato-Katz 
smear, Katz et al., 1972), and formalin ether concentration technique (FECT, Marti et al., 
1990). A detailed description of the procedure of stool collection and examination is 
provided by Sayasone and his colleagues (Sayasone et al., 2009). A target abdominal 
ultrasound (US) examination focusing on hepato-biliar morbidity was carried out based 
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on the WHO guideline (Niamey working group, 2000) for assessing schistosomiasis-
related morbidity. Organometry (liver and spleen) was performed using Hackett score 
(Hackett score, 1944). All organ measurements determined by US were hight adjusted 
(Li et al., 2004). Yearly follow-up investigations (2008 and 2009) included the 
assessment of infection status and hepato-biliar morbidity in which infection and 
morbidity resolution dynamics after a single oral dose of praziquantel treatment (40 
mg/kg BW) was documented. 
Assessment of severe morbidity caused by O. viverrini: the study focused on 
documenting severe morbidity due to O. viverrini infection; in particular (suspected) 
cases of cholangiocarcinoma (CCA) and other hepato-biliar morbidity. Two sub-studies 
were conducted: In a first retrospective hospital-based study suspected cases of CCA 
were identified in patient records of all referral hospitals in Lao PDR. The study was 
limited to records between 2006 and 2010. The second community-based study, 
suspected CCA cases and other hepato-biliar morbidity were diagnosed by US in a cross-
sectional study in O. viverrini infected adult patients in endemic district of Saravane, 
Saravane province, Lao PDR (Figure 3.5), from February to March 2011. No 
internationally validated standard US guideline for assessing O. viverrini-related 
morbidity is available today (Mairiang et al 2011). The assessment of the liver 
parenchyma fibrosis was done by using a modified version of the Niamey protocol 
(Niamey working group, 2000) with information from community-based 
ultrasonographic studies from Khon Kean, Thailand (Mairiang et al., 2011; Sripa et al., 
2010). Eligible for this study were adult individuals with parasitologically confirmed O. 
viverrini infection, detected by stool examination using Kato-Katz thick smear technique 
and FECT (Katz et al., 1972; Marti & Escher, 1990). An O. viverrini-positive patient was 
defined as the presence of at least one O. viverrini egg in one of the quadruplicate Kato-
Katz fecal thick smears examined. Additional data on risk factors were obtained from 
each study participant.  
 
3.4 Assessment of efficacy of currently used anthelmintic drugs and 
potential new drug candidates 
We employed Kato-Katz thick smear (Katz et al., 1972) to detect helminth eggs, and 
FECT (Marti & Escher, 1990) was used to discriminating O. viverrini eggs from eggs of 
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other trematode. Standard procedure of stool examination is described elsewhere 
(Sayasone et al., 2010). Drug efficacy was determined by cure and egg reduction rates in 
both intention-to-treat (ITT) and per-protocol analysis (PPA). Adverse events were 
assessed at 3, 24 and 120 hours post-treatment.   
Efficacy of single-dose ABZ and MBZ against hookworm: The first study investigated 
the efficacy of single-dose ABZ and MBZ against hookworm using a randomized open-
label trial. The trial was conducted in two primary schools in Batieng district, 
Champasack province, southern Lao PDR from February to March 2009 (Figure 3.4). 
Bachieng is located on the Bolavan plateau and a district of Champasack Province (~10 
km far from the Pakse city). We compared the efficacy of single dose of 400 mg 
albendazole and 500 mg mebendazole against the hookworm infection. Other helminths 
endemic in the settings were also included for the efficacy evaluation such as 
O. viverrini, A. lumbricoides, and T. Trichiura.  
Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, 
tribendimidine, praziquantel against O. viverrini: With a randomized, exploratory 
open-label trial we assessed the efficacy and safety of mefloquine, artesunate, 
mefloquine-artesunate and tribendimidine against O. viverrini infection among 
schoolchildren, compared to the standard praziquantel treatment regimen. The trial 
was carried out in a secondary school in Attapeu Province, Lao PDR in 2010. Attapeu 
Province has a total area of 10,320 km2 and is the most south-easterly province of Lao 
PDR bordering Vietnam to the east and Cambodia to the south. Attapeu is one of the 
four poorest provinces of Lao PDR (Figure 3.3). Mass drug administration programme 
against O. viverrini has not started yet in Attapeu province, although the prevalence of 
liver fluke is known to be high (Rim et al., 2003). 
 
 3.5 Ethical considerations 
All study protocols were submitted to the Lao and international ethics committees prior 
to implementation, notably, the Lao National Ethics Committee for Health Research 
(NECHR), Ministry of Health, Vientiane, Lao PDR, the internal reviewing board (IRB) of 
the Swiss TPH, the ethics Committee of Basel, Switzerland (EKBB), and the ethical 
committee board of the World health Organization Pacific Region (WPRO), Manila, the 
Philippines. In addition, permission for field work was obtained from the Lao Ministry  
3. Approach and Methodology 
 
 
 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of Health, the provincial health departments and additionally the provincial education 
offices and other authorities concerned (chief of villages, school authorities, youth union 
and so on). 
Our study involved experimental trials on human subjects. At the onset of the study, 
participants were given detailed information on the study processes, and the possible 
Figure 3.4 map of Champasack province Figure 3.5 map of Sarvane distirct, 
Saravane province 
Figure 3.3 map of Lao PDR and stdy sites 
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risks and benefits were clearly explained to all study participants in Lao language. In 
case participants were illiterate or belonged to ethnic minorities, we had the chiefs of 
the villages, relatives or school teacher acting as a translator and witnesses. In 
particular, we made sure that each participant understood that he/she could receive a 
potentially unfavourable diagnosis and/or might experience drug-induced adverse 
events. If patients agreed to participate in the study, they voluntarily signed a consent 
form. In case of children under 18 years old, we obtained their assent and written 
consent of their patents.  
At the end of the study, helminth egg-positive individuals who were enrolled in our 
study were treated with with the adequate drugs, i.e., praziquantel (40 mg/kg) and/or a 
single oral of ABZ (400mg) according to the national scheme for mass drug 
administration in Laos (Ministry of Health, 2004). 
All participants with any precursor CCA and liver lesions were given additional 
counselling. They were informed about the diagnosis, its implication and the next 
possible diagnostic and treatment steps were explained. Additonally, informed consent 
form was required before any intervention took place. 
All cases that had adverse events were offered an adequate treatment at the 
provincial hospital or health centre depending on the severity of their condition. 
Further details of informed consent are provided in each chapter. 
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4.1 Abstract 
Capillaria philippinensis is a rare zoonotic intestinal parasite that emerged in the 1960s. 
The outcome of intestinal capillariasis may be fatal if untreated in due time. We report 
three cases of intestinal capillariasis in Lao People’s Democratic Republic (Lao PDR). 
The three patients were unrelated previously healthy young men (24, 26, and 27 years 
of age) with no underlying disease or immune depression. They had chronic diarrhea, 
abdominal pain, edema, and severe weight loss. Two of them acquired the infection in 
Thailand; the other patient had no travel history outside Lao PDR. All patients were 
seen several times in different hospitals before the diagnosis was made. All had 
concurrent parasite infections: Giardia lamblia, Entamoeba histolytica, Strongyloides 
stercoralis, Opisthorchis viverrini, and hookworm. The patients frequently consumed 
uncooked fish. After treatment with albendazole (400 mg/day for 21–30 days) all 
patients recovered. In Lao PDR, consumption of raw small freshwater fish is common. 
Therefore, the possibility of a capillariasis outbreak should be considered.  
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4.2 Introduction 
Intestinal capillariasis, which is caused by Capillaria philippinensis, is a rare food-borne 
nematodiasis that was first described in The Philippines in 1962 and emerged during 
the 1970s. It has received little attention and may be frequently overlooked or confused 
with Trichiuris trichuria infection. However, C. philippinensis infection is remarkable 
because of its potential severity and fatal outcome in cases of delayed diagnosis or 
inappropriate treatment. Thus, approximately 2,000 cases with almost 200 deaths have 
been documented worldwide, mostly from Asia.1 We report three cases of intestinal 
capillariasis in Lao Peoples’ Democratic Republic (Lao PDR).  
 
4.3 Case description  
The patients were three unrelated previously healthy young men (24, 26, and 27 years 
of age). They showed no underlying disease or immune depression. All patients had 
non-febrile, chronic diarrhoea associated with abdominal pain, oedema, and severe 
weight loss. Two of them had low levels of serum protein, albumin, and cholesterol, but 
a normal level of haemoglobin. All patients were negative for human immunodeficiency 
virus, and one was positive for hepatitis B surface antigen. Detailed information on the 
three patients is shown in Table 4.1. 
 
4.3.1 Case 1 
A 24-year-old man from Vientiane. In May 2007, he reported an eight-month history of 
recurrent diarrhoea associated with colicky pain that started after returning from 
southern Thailand where he was a seasonal migrant worker. Infections with Giardia 
lamblia, Trichomonas spp., and Trichuris trichiura were diagnosed and he was treated 
with standard regimens. Two months later (10 months after symptom onset), the 
diarrhea persisted and he had a weight loss of 12 kg. He was then admitted to 
Setthathirath Hospital in Vientiane. Clinical examination showed subcutaneous fat and 
muscle wasting, moderate dehydration, pallor, a soft non-tender, non-distended 
abdomen, and a marked pitting edema of the lower limbs. The liver and spleen were not 
enlarged. Stool examinations showed numerous eggs (1–2 eggs/10 × 40 microscopic 
field) that were elongated and peanut-shaped with flattened bipolar plugs, striated 
shells (46.1 × 22.1 μm), and Charcot-Leyden crystals. Eggs were identified as those of C. 
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philippinensis. Adult or larval C. philippinensis was not found in stool samples of all 
patients.  
Levels of serum protein and albumin were low (1.7 and 0.9 g/dL, respectively), and 
proteinuria was not detected. A chest radiograph and abdominal ultrasound did not 
disclose any specific abnormalities. Gastroscopy showed a non-specific duodenitis with 
superficial erosions. A biopsy specimen of the duodenum did not show any parasites or 
specific abnormalities. 
The patient reported eating small raw or insufficiently cooked fresh water fish and 
prawns in Lao PDR and Thailand. All other family members were healthy without any 
diarrhea. A routine stool examination performed for all family members showed 
negative results (no C. philippinensis eggs detected). The patient was given a one-month 
course of albendazole (400 mg/day) and he made uneventful and stable recovery.  
 
4.3.2 Case 2 
A 26-year old man from Vientiane. In December 2007, he came to the emergency 
department at Mahosot Hospital in Vientiane with a one-month history of profuse 
watery diarrhea. He was extremely emaciated and had severe prolonged dehydration. 
He was admitted for further investigations and treatment. During the preceding month, 
the patient had been repeatedly seen in district and military hospitals in Vientiane for 
the same symptoms. No diagnosis was made, including after stool examination, and 
multiple and empirical treatment regimens were given that did not relieve the 
symptoms.  
He had approximately 10 bowel movements per day of non-dysenteric, watery stools 
associated with abdominal pain, borborygmus, anorexia, and episodic vomiting. The 
patient reported a weight loss of 13 kg within the past 4 weeks. He admitted eating raw 
fish. Other family members remained free of symptoms. Two months before admission, 
he had returned from central Thailand where he had been a migrant worker for 
approximately one year.  
On physical examination, he appeared emaciated, pale, and in poor general health. He 
had subcutaneous fat and muscle wasting, marked pitting edema on the lower limbs, a 
temperature of 36°C, low blood pressure (80/50), a heart rate of 119 beats/minute, and 
a respiratory rate of 25 breaths/minute. The abdomen was distended. Results of chest 
4. Intestinal Capillariasis 
 
 
 40 
and heart examinations were normal. The patient received intravenous fluids to correct 
dehydration and electrolyte imbalance. 
Table 4.1 Laboratory investigations and treatments in three case-patients infected with C. philippinensis  
 Case 1 Case 2 Case 3 
Characteristic* First 
admission 
May 2007 
Second 
admission 
July 2007 
Follow-up 
October 
2007 
Admission 
December 
2007 
Follow- up 
January 
2008 
Admission 
September 
2005 
 
Hemoglobin (10.5-15 g/dl) 
WBCs (4000-9000/ μL) 
Neutrophils (50-65%) 
Lymphocytes (20-40%) 
Eosinophils (1-4%) 
Serum creatinin  
(0.6-1.3 mg/dl) 
Glycaemia (75-115 mg/dL) 
Serum Na (135-445 mmol/L) 
Serum K (3.5-4.1 mmol/L) 
Serum Cl (95-105 mmol/L) 
 
15 
8,800 
65 
30 
2 
1.2 
 
88 
122 
 
13.5 
10,800 
68 
35 
1 
1.4 
 
98 
132 
 
 
14.8 
5,200 
60 
39.3 
0 
1.1 
 
85.2 
122 
 
 
16.1 
5,400 
50 
48.5 
6 
1.3 
 
122 
115 
 
 
16 
6000 
55 
44 
0 
1.2 
 
120 
133.8 
 
 
11.3 
8700 
50 
17 
12 
ND 
 
ND 
ND 
 
TSP (6.0-8.5 g/dL) 1.7 1.7 7.2 1.5 6.5 ND 
Serum albumin (3.5-5.0 g/dL) 0.9 2.3 3.7 2.1 3.4 ND 
Cholesterol (119.7-220.1g/l) 104.2 173.2 169.2 112 159 ND 
ALT (0-40 U/L) 18 18 20 22 25 22.4 
Urine analysis Normal Normal Normal Normal Normal Normal 
 
 
 
Stool examination result 
 
 
Watery, 
WBC 100-
150 / 40 
power field, 
no RBC, 
mucus=1+ 
Stool 
culture 
negative 
 
Watery, 
Absence 
of Stool 
culture 
negative 
 
 
 
 
 
 
 
 
Watery, 
Stool 
culture 
negative 
 
 
 
 
 
 
 
 
 
 
 
 
Watery 
 
 
 
 
 
 
 
 
 
 
 
Parasites detected 
G. lamblia 
(cyst) 
Trichomona
s sp. 
E.histolytica 
(cyst) 
T. trichiura 
C. 
philippin-
ensis 
Negative C. philippin-
ensis, O. 
viverrini, 
hookworm 
Negative C. philippin-
ensis 
O. viverrini 
S. stercoralis 
(larvae), 
hookworm 
 
 
 
 
Treatment  
 
Antibiotics 
(metronida
-zole, 
ofloxacin), 
IV fluids 
and 
albumine, 
ABZ 400mg 
/ day / 3 
days 
 
Albendaz
ole400 
mg p.o. 
for 30 
days 
 
 
 
ND 
 
supportive 
care with IV 
fluid 
Albendazole 
400 mg p.o. 
30 days, 
PZQ 40 mg/ 
kg 
 
 
 
ND 
 
Albendazole 
400 mg 21 
days + PZQ 
40 mg/ kg 
and 
supportive 
care 
* Values in parentheses are normal ranges. ALT = alanine aminotransferase; TSP = Total serum protein; ND = not done 
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Stool examinations showed C. philippinensis eggs and parasitic co-infections (Table 4.1). 
A chest radiograph and an abdominal ultrasound were normal. Stool examinations were 
carried out for all family members; none showed parasitic infections. After a full month 
course of albendazole (400 mg/day), the patient fully recovered. At a one-month follow-
up visit, weight gain (8 kg), negative stool examination results, and normal levels of 
serum albumin were noted.  
 
4.3.3 Case 3 
A 27-year-old man (farmer) from southern Lao PDR (Phine District, Savannakhet 
Province). He was seen in September 2005 at Savannakhet Provincial Hospital with 
chronic diarrhoea of six months duration. On admission, he had at least six daily bowel 
movements, persistent abdominal pain, and episodic vomiting. He was wasted and 
emaciated, moderately dehydrated, and reported a weight loss of 10 kg during the past 
3 months.  
The patient had no history of travel outside his province. After the start of illness, he 
visited district hospitals and a neighbouring hospital in Vietnam where no diagnosis 
was made. Treatment with several anti-infective drugs, including ampicillin, 
sulfamethoxazole, and metronidazole, did not improve his condition. Results of stool 
examinations by the Kato-Katz (KK) thick smear technique and a formalin-ether 
concentration technique (FECT) were positive for C. philippinensis (1,696 eggs/gram [of 
feces] [epg] by KK and 346 epg by FECT). Moreover, Opisthorchis viverrini (336 epg by 
KK and 58 epg by FECT; 9 adult worms isolated after treatment with praziquantel and 
purgation), Strongyloides stercoralis (9 larvae), and hookworm (408 epg by KK and 14 
epg by FECT) were also present. The patient received albendazole, 400 mg/day for 3 
weeks, and showed gradual and significant improvement. He was lost to further follow-
up.  
 
4.4 Discussion 
The first case of capillariasis was diagnosed in 1962 in Luzon, The Philippines. Soon 
afterwards, several outbreaks were described in this country2 and in Thailand.3 Other 
Asian countries (Taiwan,4 South Korea,5 India,6 and Indonesia7) reported sporadic 
cases, followed by Middle East countries (Iran,8 United Arab Emirates,9 and Egypt10). 
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These results suggested that Capillaria spp are present in more areas than initially 
thought. In addition, C. philippinensis infections were imported into Europe.7–12 
The genus Capillaria is a nematode member of the superfamily Trichinelloidea, which 
includes Trichuris spp. and Trichinella spp.13 Among some 250 different Capillaria 
species, only three are human pathogens (C. hepatica and C. aerophila, which cause liver 
and a tracheo-bronchial disease, respectively, and C. philippinensis, which affects the 
intestinal tract). Capillaria philippinensis is the only species that causes severe disease. It 
may be endemic but also can cause epidemics.  
The life cycle of C. philippinensis involves a small fresh water or brackish water fish 
harbouring the infectious stages in their viscera. Natural definitive hosts are fish-eating 
birds. Human become infected when they consume raw or insufficiently cooked fish or, 
less often, ichthyophagic birds or fish eating birds. Handling fish under poor sanitary 
conditions may contaminate other foods and favor indirect transmission.14 In humans, 
the parasite is not opportunistic (disseminated) but is usually restricted to the small 
intestine where it develops, reproduces, and where the female lays eggs that mature 
into larvae. A notable feature is that these larvae may engage in a shorten auto-infection 
circle, which may produce high parasitic loads.  
The pathophysiology of this nematode is largely unknown, especially with regard to 
detail mechanisms of malabsorption. Parasitic products may interfere with ionic 
exchanges and carbohydrate and protein absorption of the intestinal epithelium, which 
produces a protein-losing enteropathy that is an outstanding feature of capillariasis.15,16 
Intestinal capillariasis has been known since 1973 to occur in Lao-neighbouring 
Thailand.3,17 It has been previously reported in travellers to Thailand.14 Two of our 
cases had stayed for several months in this country. This finding indicated that that they 
were infected in Thailand. However, one case from rural southern Lao PDR had no 
travel history out of this country. He must have been infected in Lao PDR, which 
documents that transmission of C. philippinensis infection also occurs in this country. 
Lao PDR and Thailand share many environmental, epidemiologic, and cultural features. 
In particular, the widespread habit of eating raw or insufficiently cooked fish, the main 
risk factor for infection with C. philippinensis, is common in both countries.  
To our knowledge, the cases reported here are the first to be documented in Lao PDR. 
The patients were active healthy men with no underlying disease or immune deficiency. 
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Clinical and laboratory features were comparable to those initially described in The 
Philippines 2 and elsewhere, i.e. chronic watery diarrhoea, abdominal pain, and notably 
pronounced weigh loss and pedal oedema, the latter as part of a malabsorption 
syndrome. The diagnosis was easily achieved by finding ova of characteristic size and 
shape in stool specimens. However, C. philippinensis eggs may be sparse or inconstantly 
shed in the stools. They also have a similar appearance to those of T. trichiura in size 
and peanut shape with two polar opercula, and are often mistaken for those of the latter 
species.  
The clinical presentation of capillariasis may be confused with those of other 
protozoans (Entamoeba histolytica), nematodes (S. stercoralis), trematodes (Fasciolopsis 
buski), or opportunistic parasites associated with acquired immunodeficiency syndrome 
(Microsporidium spp.). In addition, capillariasis may be confused with other chronic 
diarrhoeas of unclear origin such as tropical sprue, collagen colitis, adult celiac, or 
Crohn disease. Associated hypovolemic cardiac failure has also been described.18 It is 
important to note that intestinal capillariasis even when properly recognized and 
treated recurs frequently because of auto-infestation or reinfection.  
All three patients experienced clinical and biologic recovery (negative stool results for 
parasites, serum albumin levels returning to normal values) after completing the 3–4-
week regimen of albendazole. To avoid frequent relapses, high dosages and prolonged 
(3–4 weeks) or sequential treatments have been advocated.19 Several anti-helminthic 
drugs have been recommended for treatment of intestinal capillariasis. All compounds 
of the azole family of drugs are effective. However, several studies7,13,19-22 have 
consistently recommended albendazole as the drug of choice.  
Unawareness and delayed diagnosis may cause serious medical problems. This issue 
has been documented in South Korea, Egypt, and India, and may even be fatal (fatality 
rate up to 30% in an outbreak in The Philippines), which is an exceedingly uncommon 
outcome for other nematode infections.5,10,16,23,24 
Finally, food-borne parasites are an emerging public health problem, particularly in 
Southeast Asia.25 Intensified production of fish farming and the persisting habit of 
eating raw or undercooked fresh water fish contribute to increased transmission rates, 
including Capillaria spp.1,4,6,26 As an example, in Lao PDR, despite increased 
development, as many as 75% of the population still eat traditional raw fish dishes27 
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such as Koy Kung (prawn salad), Koy pa or lap pa (minced fish salad with spices), and 
Koy pa siew (raw Rasbora borapetenis). Therefore, C. philippinensis deserves particular 
attention in this and neighbouring countries that have similar environments and 
traditional behaviour patterns. Because this parasite is endemic in this region, the 
occurrence of outbreaks cannot be excluded.  
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5.1 Abstract 
Background.  In 2007, within the context of a community-based survey on helminth 
infections in three villages we identified severe cases of schistosomiasis mekongi in 
Southern Lao People’s Democratic Republic.  
Methodology.  We identified and treated nine patients with praziquantel and followed 
them for three years performing annually a clinical and parasitological examination, and 
ultradonographical assessment. Our report includes photo documents of the severe S. 
mekongi patients. 
Results.  Mean age of patients was 36 years (range: 5 - 66 years); 7 patients were male. 
The leading clinical features were cachexia, hepatosplenomegaly, ascites, splenic varices 
and rupture of oesophageal varices. Patients were co-infected with hookworm (n=7), 
Opisthorchis viverrini (n=6), and Strongyloides stercoralis (n=1). Three years follow-up 
and treatment showed improvements in three of them (case 5, 6, 9), the status of one 
adult patient remained unchanged (case ?) and one worsened (case ?). Two patients 
(case 4, 7) died due to oesophageal bleeding.  
Conclusions.  Liver pathology improved after treatment in young patients. Young 
children affected with severe S. mekongi infections document that transmission is 
ongoing. Current measures employed in Laos’ endemic areas are insufficient to stop 
transmission and eliminate schistosomiasis. A long-term control intervention including 
access to treatment and case management, health education, sanitation and 
infrastructure is warranted. 
Keywords. Schistosoma mekongi, case-report, Lao PDR, hepatosplenomegaly 
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5.2 Author summary 
The willow-leaflike, blood fluke, Schistosoma mekongi is a chronic parasitic diseases 
living inside the mesenteric vein of human. S. mekongi is focally limited epidemiology in 
the Lao PDR and Cambodia. It remains exclusively a major public health in this region. 
Since the largest effort of schistosomiasis control, using praziquantel, the prevalence of 
its infection was dramatically reduced and considered as under control among villagers 
in Khong Island and along the outlying Mekong. We aimed to report on nine severe S. 
mekongi, determined during a community-based survey on helminth infections from 
2007 to 2010 on three Khong islands in the district of Kong, southern Champasack 
province. Among nine patients, male was predominant sex. Mean age was 36 years. All 
patients had dwelled in Khong Island since birth. Patients had previously been treated 
with several praziquantel rounds. Most of patients developed hepato-splenic disease. 
Three patients improved after treatment, two adult patients remained unchanged or the 
status worsened. Two patients died due to digestive bleeding. Liver condition improved 
after treatment in particular in young aged patients. This case report raises awareness 
of the re-emerging of S. mekongi in this region. Hence schistosomiasis-morbidity control 
requires urgently attention. 
5. Severe Schistosomiasis 
 
 
50 
5.3 Introduction 
Schistosomiasis is a most common parasitic infection in human caused by blood flukes 
of the Schistosoma genus. Schistosomiasis-related morbidity poses a significant public 
health problem in endemic settings [1, 2]. More than 800 million people are at risk of 
infections, 200 million people are infected and 10% of whom develop severe hepato-
splenic morbidity [3]. Schistosoma mekongi has been identified first in the late 1960ties. 
It is exclusively confined in communities along the Mekong and its tributaries in several 
districts in the northern provinces of Kratié and Stung Treng in Cambodia and southern 
province of Champasack in Lao People’s Democratic Republic (Laos, Lao PDR). An 
estimated 140,000 people are at immediate risk for S. mekongi infection [4]. Chronic 
inflammation due to S. mekongi leads to a fibrotic liver disease, which is associated with 
fatal consequences of portal hypertension and digestive bleeding by the eruption of 
oesophageal bleeding. It was frequently observed in the endemic communities. In the 
1990ties substantial control efforts were undertaken which dramatically reduced 
infection and morbidity. Since 2005 schistosomiasis mekongi is considered under 
control [5]. Here we report on nine severe S. mekongi patients from southern Lao PDR 
diagnosed, treated and followed from 2007 to 2010. 
 
5.4 Methods 
5.4.1 Study area  
Khong district is the most southern district of Champasack province in Laos, and 
bordering Cambodia. It has 131 villages most of which are located on islands in the 
Mekong river. The district has a total population of 55,000 inhabitants. The majority 
belongs to the Lao Loum ethnic group. They are rice farmers and engaged in fishering, 
and tobacco planting. A recent study on helminthic infection in Khong Island showed 
Opisthorchis viverrini and S. mekongi infection’s prevalences were 92 and 68%, 
respectively [6]. 
5.4.2 Ethical consideration  
The study was approved by the Ethics Committee of Basel (no. 255/06) and National 
Ethics Committee, Ministry of Health (MOH) in Vientiane (no. 027/NECHR). Permission 
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for field work was obtained from the MOH, and Provincial and the District Health 
Offices. Prior to enrolment, all patients signed an informed consent form. Parents or 
legal guardians signed for children (< 16 years). 
5.4.3 Identification and follow-up of patients 
Patients were identified during a community-based survey on helminth infections in 
2007-2009 on three Khong islands (Don Long, Don Kaden and Loppadi) in Khong 
district [6]. Each year the patients were traced for a follow-up visit. At each visit a 
detailed clinical and ultrasonographical examination was performed including an 
interview. Stool samples of two consecutive days were examined on the presence and 
intensity of helminth infection using the Kato-Katz method [7]. The infection intensity of 
S. mekongi were classified as negative (0), mild (1-100 eggs per gram stool [EPG]), 
moderate (101-400 EPG), heavy (501-999 EPG) and very heavy (> 1000 EPG) [8]. 
O. viverrini infections were grouped in negative (0), light (1-500 EPG), moderate (501-
999 EPG), heavy (1000-1999 EPG) and very heavy (≥ 2000 EPG) infection intensity [9].  
Information on anaemia, liver function and co-infection with hepatitis B (HBV) and C 
(HCV) was obtained from a serum sample examination. All patients were interviewed 
on their history of bloody stool, onset of disease, family history of deaths due to 
schistosomiasis and the treatment with praziquantel (PZQ), and their water contract 
habits the Mekong river. 
Liver pathology was assessed about four hours after meal in supine position using an 
ALOKA SSD-900 (3.5 MHz convex probe) portable ultrasonography machine. Liver 
image pattern (IP) and periportal fibrosis (PPF) was scored and graded according to the 
Niamey protocol [10]. Patients were grouped in liver patterns A-F, depending on the 
extent of visible PPF around the portal bifurcation and in liver parenchyma. Grades A 
and B were considered normal patterns, whereas grades C, D, E, and F were 
manifestations of liver disease with increasing severity. The size of the left liver lobe 
(SLL) was measured with a longitudinal liver scan. The measurements were taken in the 
left parasternal line from the upper to the caudal margin. The portal vein diameter 
(PVD) was measured in the right oblique view along the axis of the vessel with 
measurement of the internal diameter of the portal vein at the entry point into the liver. 
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The size of spleen was measured in the left intercostals oblique view with the maximum 
length by measuring through the splenic helus. All organ measurements were height-
adjusted [11]. The organs were considered abnormal if the height-adjusted value 
exceeded two standard deviations (2SD) of the reference population (e.g., 0-2SD 
normal; 2-4SD enlarged and > 4SD much enlarged). Periportal hypertension (PH) score 
was calculated from the sum of three indicators [11]: (i) height-adjusted value of PVD (0 
normal, 4 enlarged and 6 marked enlarged), (ii) presence of collateral veins (0 absence, 
4presence), and (iii) presence of ascites (0 absence, 3 presence). The sum of these 
scores was categorized into four groups: 0 normal, 4 light hypertension, 6–8 moderate 
hypertension and 10–13 severe hypertension. 
5.5 Case description 
In Table 5.1 details of the examinations of the nine patients is displayed. They had a 
mean age of 36 years (range 5 – 66 years). Seven patients were male. Generally, at the 
first visit patients showed markedly deprived general and nutritional status with signs 
of portal hypertension (collateral circulation on abdomen), moderate to advanced 
splenomegaly and several with ascites. Two patients reported an episode of rupture of 
oesophageal varices. Ultrasound assessment revealed marked splenic varices, advanced 
ascites, present thickening of portal vein walls, and pronounced hepato-splenomegalies. 
In all patients except one an infection with S. mekongi could be confirmed by stool 
examination. Co-infections with hookworm (n=7), O. viverrini (n=6) and Strongyloides  
stercoralis (n=1) were diagnosed but no HBV and HCV infection was found.  
5.5.1 Case 1 
In March 2007 a 66-year old farmer (Figure 5.1) vomited a large amount of blood and 
emitted blood in stool. He was admitted to Khong district hospital. On admission, he was 
in shock, unconscious (temperature 35.5°C; pulse rate 108 pm; blood pressure 90/60 
mmHg) and highly anaemic (Hb 5 mg/dl). No cervical lymphadenopathy was noted. 
Abdominal palpation revealed an ascites, and a hepatosplenomegaly. In February 2008, 
physical examination showed poor condition, distended abdomen with a further 
developed ascites, and venous collateral veins. He was anorexic and had lost weight. 
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Abdomen had no palpable abnormality. Six months later he deceased in an episode of 
severe hematemesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5.2 Case 2 
A 46-year old farmer presented in 2007 with an ascites (Figure 5.2a). He reported that 
it developed over several years. He had no history of gastrointestinal bleeding. His 
younger sister suffered from the similar condition (case 5.4). He had no other illnesses 
or complaints. He reported to consume alcohol occasionally. He consulted two hospitals 
in Vientiane where a bypass operation was proposed, which he refused. On physical 
examination (2007) he showed pale conjunctivae, no jaundice, circulation collateral, 
ascites, splenomegaly, no other abnormalities were found. In 2009, the physical 
examination was unaltered (Figure 5.2b). In 2010 his condition had critically worsened 
with enlargement of abdomen and occurred liquid flowing from the umbilicus (Figure 
5.2c,d). The patient and surrogates refused recommended treatments and proposed 
interventions. The patient’s resistance was due to his younger sister (case 5.4), who 
underwent surgical intervention and died shortly afterwards. 
5.5.3 Case 3 
Figure 5.1: Case 1 found in March 2007 
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In March 2007 this 45-year old farmer (Figure 5.3) reported to suffer from a swollen 
abdomen since the age 9 years. He reported that on his island at that time several of his 
fellow children had the same symptoms. During childhood he was treated twice with 
anti-parasitic drugs (twice: 2 tablets x 2 days), thereafter he felt better.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2b: case  in March  2009 
 
Figure 5.2d: case in  March 2010 Figure 5.2c: case  in March  2010 
Figure 5.2a: case  in March  2007 
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Ten years ago venous collateral veins started to appear on his belly. He repeated 
anthelmintic treatments including PZQ two more times since then. On examination he 
was in good general condition but with marked spider angiomas (Figure 5.3), no ascites, 
but nodular liver (4 cm) was detected below costal margin and spleen extended (4 cm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
beyond the costal rim. The US of the abdomen revealed liver parenchyma with highly 
echogenic ruff around portal bifurcation and main stem (pattern D), splenomegaly and 
splenic varices present. The patient was lost to follow-up. 
 
5.5.4 Case 4 
In 2007, the 36-year old sister of case 2 (Figure 5.4) presented with an ascites. Clinical 
examination revealed general weakness, pallor with a severe anaemia (Hb: 7 mg/dL), 
markedly enlarged and distended abdomen with long surgery scars. The liver was not 
palpable. She underwent a bypass surgery at a central hospital in Vientiane in 2004. She 
reported no improvement after the intervention but an increase her ascites. In early 
2007, she suffered from a severe episode of haematemesis and melaena. She was 
admitted to the provincial hospital of Paksé and after one week referred to Mahosot 
hospital, Vientiane, where she received a blood transfusion (totally 7 units). In Mars 
2007 she died during an episode of haematemesis. 
Figure 5.3: case 3 in March 2007 
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5.5.5 Case 5 
The 27 years old son of case1 had no history of bloody diarrhoea, abdominal pain or 
jaundice of gastrointestinal bleeding, and did not receive anti-Schistosoma treatment 
before. In February 2008, he presented to the village health staff with complaints about 
abdominal swelling. He reported right upper quadrant pain (temperature was 37°C, 
pulse rate 66 pm; respiration rate 22 pm; blood pressure 100/60 mmHg). On 
examination he had anaemic conjunctivae, collateral circulations, an ascites, and 
hepatosplenomegaly. He was treated (PZQ 40 mg / kg BW; albendazole (ABZ) 400 mg 
single dose). In April 2009 his condition improved. US showed a lower liver fibrosis 
pattern (D, earlier F), and absence of ascites and hepatosplenomegaly. Stool 
examination revealed an infection with O. viverrini and hookworms. He was again 
treated with anti-helminthic drugs. In April 2010 his general condition was good, and 
better than a year before.  
 
 
 
Figure 5.4: case 4 in March 2007 (a sibling of case 2) 
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5.5.6 Case 6 
This 12-year old boy (Figure 5.5a) is a resident on the island since birth. In February 
2007 he presented with an ascites. The illness started at age of 5 years with repeated 
episodes of blood in stool. Soon after, his ascites gradually developed. He reported to be 
treated with (1.5 tablets of praziquantel) by health workers but his condition did not 
improve. On physical examination poor general nutrition status, pale conjunctivae, 
protruding belly button, collateral circulation, abdominal distend and painful was noted. 
Abdominal sonography disclosed hepato-splenomegaly, liver parenchyma with highly 
echogenic patches extending from the main portal vein and branches to the periphery 
(pattern E), plenty of free fluid in abdomen, splenomegaly and varices. In 2008 the 
patient was well and much better with diminished abdominal distension (Figure 5.5b). 
Ultrasound showed splenomegaly, liver parenchyma with highly echogenic ring echoes 
or pipe stems (pattern C), absent ascites, varices present. In 2010, stool examination 
showed a re-infection with O. viverrini and hookworms. US examination of the liver did 
not show constantly liver parenchyma and splenomegaly but varices at the splenic 
hilum were rather improved than the year recently. No ascites was detected (Figure 
5.5c-d). 
 
5.5.7 Case 7 
A 13-years old boy (Figure 5.6a-b) reported to swim twice a day in the Mekong River. 
He was diagnosed during a follow-up visit in 2009. As a one-year old boy, his mother 
noticed that his abdomen had swollen. He had no history of serious gastrointestinal 
pain. He received a treatment (unknown) in a nearby Cambodian health centre which 
did not improve his condition. Physical exam revealed that he looked weak and 
malnourished with being underweight (BMI, 14). Spleen extended beyond the costal rim 
(3 cm) and hepatomegaly was palpable. The boy was severely anaemic (Hb: 3.4 mg/dl). 
US examination detected a markedly ascites, hepato- and splenomegaly with dilated 
splenic varices. Stool examination revealed infections with S. mekongi, O. viverrini and 
hookworms. The boy was treated with PZQ (40 mg/kg BW) and ABZ (400mg/day/3 
days). His condition improved significantly (Figure 5.6c-d). In 2010, on physical 
examination a splenomegaly remained. A re-infection with O. viverrini and soil 
transmitted helminths was retreated. 
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Figure 5.5c: case 6 (Face) in March 2010 
 
Figure 5.5b: case 6 in March 2008 Figure 5.5a: Case 6 in March 2007 
Figure 5.5d: case 6 (profile) in March 2010 
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Figure 5.6 b case 7 in 2009 
 
Photo 5.6d: case 7 (profile) in 2010 Figure 5.6c: case (face) 7 in 2010 
 
Figure 5.6 a: case 7 in 2009 
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5.5.8 Case 8 
A 6-year old girl (Figure 5.7 a-b) reported frequent baths in the Mekong since early 
childhood. She reported frequent episodes of blood in stool, diarrhoea and abdominal 
pain. As a one year old, she developed an abdominal swelling. Clinical examination 
showed no abnormalities. Ultrasound examination revealed an ascites, a splenomegaly 
and splenic varices. In 2010, she was again infected with O. viverrini and hookworms. US 
examination showed a marked improvement since a year before (Figure 5.7 c-d). 
 
5.5.9 Case 9 
A 5-year old boy (Figure 5.8a-b) also reported frequent baths in the Mekong since early 
childhood. She reported frequent episodes of blood in stool, diarrhoea and abdominal 
pain. In early childhood she developed an abdominal swelling. Clinical examination 
showed no abnormality. US examination revealed an ascites, a splenomegaly and 
splenic varices. He could not be found in the later visits between 2008 and 2010. 
 
 
 
 
Figure 5.7 a: Case 8 (face) in 2009 Figure 5.7 b: Case 8 (profile) in 2009 
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Figure 5.7 c: Case 8 (profile) in 2010 Figure 5.7 d: Case 8 (face) in 2010 
Figure 5.8 a: case 9 (face) in 
2009 
Figure 5.8 b: case 9 (profile) in 
2009 
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TABLE 5.1: Laboratory, stool examination and ultrasonography results and treatment of nine severe S. mekongi patients, Khong District, 2007-2010 
 Case 1 
(male, 66y) 
Case 2 
(male, 46y) 
Case 3 
(male, 45y) 
Case 4 
(female, 36y) 
Case 5 
(male, 27y) 
Year 2007 
(died in 2008) 
 
2007 
April 
2009 
April 
2010 
 
2007 
2007 
(died 2008) 
 
2008 
 
2009 
Follow-up  
2010 
 
Hb (10.5-15 g/dL) 
WBCs (4000-9000l) 
Neutrophils (50-65%) 
Lymphocytes (20-40%) 
Eosinophils (1-4%) 
r- GT (0-40  U/L) 
T- BILI (0-1.2 mg/dl) 
AST ( 0-40 U/L) 
ALT (0-40 U/L) 
AKP (40-150 U/L) 
HBV 
HCV 
 
5 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
9.3 
16.1 
60 
45 
3 
20 
1.03 
58 
32 
35 
Neg 
Neg 
  
12.8 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
7.0 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
13.5 
18.800 
65 
32 
4 
32 
0.98 
44 
8.31 
88.32 
Neg 
Neg 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
Stool Exam 
 
S. mekongi 
 (666 epg), 
O. viverrini 
(371 epg) 
Hookworm 
(165 epg) 
 
 
ND 
 
hookworm 
(83 epg) 
 
 
ND 
 
 
S. mekongi 
(577 epg) 
 
 
 
ND 
 
S. mekongi 
 (774 epg), 
O. viverrini ( 340 
epg) hookworm 
(6,510 epg) 
 
O. viverrini 
(456epg) 
Hookworm 
(8,240 epg) 
 
O. viverrini       
(672 epg) 
hookworm (4,176 
epg) 
 
 
Ultrasound examination 
Pattern E, 
portal vein 16 
mm, enlarged 
spleen, splenic 
varices 
 
Pattern F, 
Ascites 
absent, 
splenomegaly 
marked 
splenic 
varices 
Pattern F 
Ascites, 
hepato- and 
splenomegaly 
absent, marked 
splenic varices 
 
Pattern F 
Markedly 
ascites, 
hepato- and 
splenomegaly 
absent, marked 
splenic varices 
Pattern D (Dc), 
fatty liver, 
splenomegaly, 
varices shunt 
Pattern F 
Ascites present, 
enlarged spleen, 
splenic varices 
present 
 
Pattern F, 
Ascites present, 
enlarged spleen, 
marked splenic 
varices 
 
Pattern D, 
ascites absent, 
enlarged spleen, 
splenic varices 
 
Pattern merely C, 
ascites absent, 
enlarged spleen, 
splenic varices 
 
Evaluation _ -- constant Worse  - -  Improved Improved 
 
 
 
 
Treatment 
PZQ (40 mg/ kg 
BW), ABZ 
(400mg / day / 
3 days) in 2006 
supportive care 
with IV fluid and 
transfusion 
 
 
Lasix 25 mg 
daily 
 
 
ABZ (400mg / 
day / 3 day) 
Lasix 25 mg daily 
 
 
 
ND 
 
 
PZQ (75 mg/ 
kg BW) 
 
 
Not given 
 
PZQ (75 mg/ kg 
BW), ABZ (400mg 
/ day / 3 days) 
 
PZQ (75 mg/ kg 
BW), ABZ 
(400mg / day / 3 
days) 
 
PZQ (75 mg/ kg 
BW), ABZ (400mg 
/ day / 3 days) 
ND Not Done, PZQ praziquantel, ABZ albendazole, BW body weight; IP score: Pattern A Normal texture; Pattern B Starry sky; Patter C highly echogenic “rings and pipe stems”, Pattern D highly echogenic 
“patches” extending from the main portal vein and branches to the periphery; E highly echogenic bands and streaks, extending from the main portal vein and branches to the periphery; Pattern F highly 
echogenic bands and streaks, extending from the main portal vein and bifurcation to the liver surface, retracting the surface “bide claw” pattern. 
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TABLE 5.1: Continued 
 Case 6  
(male, 12y) 
Case 7  
(male, 13y) 
Case 8  
(female, 6y) 
Case 9  
(male, 5y) 
Year  
2007 
April 
(2009) 
 
2010 
 
2009 
 
2010 
 
2009 
 
2010 
 
2007 
 
Hb (10.5-15 g/dl) 
WBCs (4000-9000l) 
Neutrophils (50-65%) 
Lymphocytes (20-
40%) 
Eosinophils (1-4%) 
r- GT (0-40  U/L) 
T- BILI (0-1.2 mg/dl) 
AST ( 0-40 U/L) 
ALT (0-40 U/L) 
AKP (40-150 U/L) 
HBV 
HCV 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
12.5 
10.000 
65 
34 
2 
31 
0.88 
38 
33 
89 
Neg 
Neg 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
3.4 
7.000 
60 
40 
6 
25 
1.11 
58 
32 
31 
Neg 
Neg 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
8.0 
9.500 
68 
35 
4 
28 
0.8 
40 
33 
38 
Neg 
Neg 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
7.0 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
Stool Exam 
 
 
S. mekongi (477 epg), 
O. viverrini (334 epg) 
hookworm (367 epg) 
 
O. viverrini (4,120 
epg), 
hookworm (289 
epg) 
 
O. viverrini       (264 
epg), 
hookworm 
(12,000epg) 
 
S. mekongi (99 epg), 
O. viverrini (462 epg) 
hookworm (15,0810 
epg) 
 
O. viverrini (224 epg) 
hookworm 
(16,200epg) 
Ascaris lumbricoides 
(2,200 epg) 
 
S. mekongi (88 epg), 
O. viverrini (660 epg), 
hookworm (6,600 
epg) 
 
O. viverrini 
(14,800epg) 
hookworm 
(14,640epg) 
 
S. mekongi (2,400 epg) 
O. viverrini (231 epg) 
S. stercoralis (larvae), 
hookworm (231 epg) 
 
 
 
Ultrasound 
examination 
 
Pattern E 
Ascites present, 
hepato-splenomegaly 
Marked splenic 
varices 
 
Pattern C 
hepato- 
splenomegaly, 
moderate splenic 
varices Ascites 
absent 
 
 
Pattern E 
Ascites present, 
hepato-
splenomegaly 
Marked splenic 
varices 
 
Pattern E 
Ascites present, 
enlarged spleen, 
marked splenic varices 
 
 
Pattern E, Gallbladder 
sludge 
Ascites absent, 
hepato-splenomegaly, 
No varices 
 
Pattern E 
Ascites present, 
enlarged spleen, 
splenic varices 
 
 
Pattern C 
No ascites, hepato-
splenomegaly 
Marked splenic 
varices 
 
 
 
ND 
Evaluation - Better Improved - Improved  - Improved - 
 
 
Treatment 
PZQ (20 mg/ kg BW x 
2 does, spaced 8 hrs 
interval), ABZ 
(400mg / day / 3 
days) 
 
PZQ (75 mg/ kg 
BW), ABZ (400mg 
/ day / 3 days) 
 
PZQ (75 mg/ kg 
BW), ABZ (400mg / 
day / 3 days) 
 
PZQ (75 mg/ kg BW), 
ABZ (400mg / day / 3 
days) 
 
PZQ (75 mg/ kg BW), 
ABZ (400mg / day / 3 
days) 
 
PZQ (75 mg/ kg BW), 
ABZ (400mg single 
dose) 
 
PZQ (75 mg/ kg 
BW), ABZ (400mg / 
day / 3 days) 
 
PZQ (75 mg/ kg BW), ABZ 
(400mg / day / 3 days) 
 
ND Not Done, PZQ praziquantel, ABZ albendazole, BW body weight; IP score: Pattern A Normal texture; Pattern B Starry sky; Patter C highly echogenic “rings and pipe stems”, Pattern D highly echogenic “patches” extending 
from the main portal vein and branches to the periphery; E highly echogenic bands and streaks, extending from the main portal vein and branches to the periphery; Pattern F highly echogenic bands and streaks, extending from 
the main portal vein and bifurcation to the liver surface, retracting the surface “bide claw” pattern. 
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5.6 Discussion 
To our knowledge, we reported on nine severe cases of S. mekongi from Southern Laos. 
These severe cases of S. mekongi were considered as the latest case report on S. mekongi 
from Khong district, Lao PDR, since the first S. mekongi case was discovered by Vic-
Dupont and colleagues in 1957, France. Few severe S. mekongi cases have been 
documented from the Khong island although they have been seen. We diagnosed our 
patients during the community survey on parasitic infections. All patients were 
examined and follow-up was performed to document their improvements after 
treatment from 2007 to 2010.  
 
Older patient pronounced demonstrating sequelae after treatment compared to younger 
aged patients. Most of younger patients tent to improve clinical and sub-clinical 
morbidity dramatically; however, liver, spleen and other lesions remained sequelae or a 
little subtly changed to unchanged especially disproportionately enlarged liver and its 
surface in severe cases were irregular and bosselated surface with slightly improved 
periportal fibrosis particularly cirrhosis like. The size and lesion of spleen were 
irreversible after treatment. Ascites were completely reversible similar to cases report 
from Cambodia [12, 13]. Some of our cases particularly in older patients may 
development to severe life-threatening disease and even death, others maintained 
sequelae with worsening. Children with severe disease (clinical and subclinical features) 
were documented ongoing transmission and its distribution within on island. The 
infection may widespread than we thought. Clinical management focusing on 
ultrasonography follow-up, stool examination and biological tests after first round of 
treatment with PZQ are required accordingly. Health services needs to improve 
preventive measures and clinical diagnosis and management. 
 
Portal hypertension attributable to chronic schistosmiasis mekongi resulting in rupture 
of gastro-oesophageal varices is common in endemic settings. Generally, there are three 
main aetiologies of portal hypertension, including upper the liver, within the liver and 
lower liver which is mainly due to the mechanism of venous blood flow [1, 2]. Clinically 
hypertension is unable to detect since pressures are increased [2]. In areas where 
schistosmiasis is endemic, most of the severe schistosmiasis cases were assumed due to 
the complication of schistosmiasis [1-3, 5]. Other further evidence for association cause 
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of liver chronic infection due to virus (mainly hepatitis B and C) and alcoholism are not 
clearly elucidated [14]. However, evolution to a more severe form is a co-infection with 
hepatitis and alcoholism which were not observe in our patients.  
S. mekongi has a complex life cycle. Eggs are released in the faeces and infect 
intermediate host snails, Neotricula aperta, possessing three strains (alpha, beta and 
gamma) [15]. N. aperta gamma-strain is the main intermediate host and distributed 
along the Mekong and its tributaries in southern Lao PDR. The molluscs shed cercariae 
which penetrate human skin. Buffalo, dogs and other mammals are suspected being 
reservoir animals but their contribution to the transmission is uncertain [15-17]. The 
peak of the transmission appears during the dry season during low–water period, 
especially from April to June [5, 18]. Human acquires infection by exposure to infected 
water bodies. 
The first case of S. mekongi was discovered in a Lao immigrant to France in 1957 [19]. 
Subsequently, cases were diagnosed in Thailand and Cambodia. A foci of S. mekongi was 
discovered in 1968 in the province of Kratie, northern Cambodia, and described in 1995 
[5]. An estimated 140,000 people are at immediate risk of S. mekongi infection in 
Cambodia and Lao PDR. The number of people at risk of S. mekongi in Khong Island and 
outlying villages was estimated to be as high as 60,000 people [5]. Clinical observations 
documented in the 1970s and extensive epidemiology surveys investigated in the 1980s 
[5] revealed that Lao people residing in Khong Island, Champasak province, were at high 
risk for S. mekongi infection. Subsequently a community-based intervention, carried out 
by WHO and the MOH of Lao PDR was carried out in the 1980s. Several mass drug 
administrations with PZQ (40 mg/kg BW) were executed in the target villages where the 
infection prevalence was beyond 25-50% [17]. This program was effectively reducing 
infection prevalence in villages along the Mekong in Khong district. However, the mass 
drug administration could not interrupted transmission [12]. Recent reports on S. 
mekongi infection revealed the prevalence was exceeded 68% in some villages in Khong 
Island [6, 12]. 
The control of schistosmiasis mekongi is similar to those in other schistosome species 
(Schistosoma japonicum, S. haematobium and S. mansoni). Preventive chemotherapy is 
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usedwith single treatment of PZQ. In addition, information, education and 
communication campaigns aim to reduce water contact and contamination by changing 
human behaviour. Improving sanitation and access to safe water supply is performed 
whenever economic conditions permit [5, 20].,. The elimination of schistosmiasis 
mekongi may be feasible in light of restricted geographical distribution. However, 
intersectorial approaches  are required to achieve this goal [18, 20].  
Our case series diagnosed in the last few years document that S. mekongi transmission is 
still ongoing, particularly on the Khong Islands where most of our cases reside. Of 
particular epidemiological importance are our observations on the youngest cases. They 
had no travel history and therefore had acquired the parasite in their residential 
villages, documenting that the transmission is on-going. We have diagnosed and 
followed patients with severe disease. Patients were predominantly males. Their age 
ranged from 5 to 66 years. The patients presented with symptoms associated with 
hepatic pathology. Dominant signs were ascites and other symptoms and signs 
associated with portal hypertension such as collateral veins, and splenic varices. Two 
patients (aged male, 66 and f, 36 years) died in the course of our follow-up due to 
rupture of oesophageal varices.  
Our cases were similarly to those described in the period when the parasite was 
discovered. Of nine cases, four patients were children [19]. All of them were originating 
from the Mekong Islands. Six cases (case 2&6, case 1&5, case 7&8) were from the same 
family. The majority cases (5 of 9) were diagnosed with an ascites. It is often being the 
most obvious sequelae resulting in chronic and severe S. mekongi infection. The 
consequence of S. mekongi liver disease is thrombocytopenia with the risk of bleeding. 
Two of our cases died (case 1 & 4) due to the complication of the rupture of oesophageal 
varices. Case 4 had a splenectomy which did not improve her condition but other patient 
it did [21]. However, it has been shown to be less effective and having limited benefit to 
this patient [5, 19]. 
Out of nine cases, seven (case 1, 2, 3, 5, 6, 7, 9) had marked liver parenchymal changes 
and typical network pattern E-F with periportal fibrosis, thickness of portal vein walls. 
The other significant findings were ascites, hepatosplenomegaly, and the development 
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of varices was markedly noted. Only one case (case 3) had a pattern D and absence of 
the additional complications. Liver parenchymal changes due to S. mekongi infection 
were found to be similar to morbidity patterns induced by S. japonicum [22, 23]. 
Ultrasonography is a non-invasive, rapid and relatively inexpensive tool that can be 
performed both at the hospital and in the community [24]. To date, it has become a 
important tool to diagnose various parasite-induced liver pathology, in particular used 
to diagnose liver fibrosis induced by trematode infections. Today, extensive experience 
with the US is available in schistosomiasis control. It shows that a major challenge is the 
standardisation of diagnosis and reporting, and comparability of the results. An 
international working group was established which developed a validated standard 
procedures for ultrasonographical diagnosis for S. haematobium and S. mansoni and 
later also for S. japonicum. S. mekongi is assessed using the S. japonicum approach.  
Praziquantel is the drug of choice for S. mekongi treatment [5]. In mass-drug 
administrations (MDA) a single dose of 40 mg / kg BW of PZQ is used [5, 25]. Adverse 
effects are generally quite frequent but are mild and transient [26]. PZQ treatment of our 
cases revealed not only improvements.  
Our case description documented substantial morbidity of chronic infection with 
S. mekongi including mortality. It shows that severe disease is still present in this 
district. Cases of children with severe manifestations document ongoing transmission in 
this area. A control program based on community-based MDA of praziquantel, combined 
health education and improved infrastructures has recently been started. In addition to 
an improved sanitation health services should also benefit for clinical training to 
manage current and future severe cases of this disease. Curative and preventive health 
services of S. mekongi endemic area need to be further strengthened to successfully 
combat this neglected tropical disease.  
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6.1 Abstract 
Background. Food and waterborne trematodiasis caused by Schistosoma mekongi and 
Opisthorchis viverrini are medically flukes importance in Southeast Asian, particularly 
afflicting the poorest in the poor-stricken settings. Chronic infections due to these flukes 
can lead to serious hepatobiliary and -splenic morbidity and mortality, from portal 
hypertension, hepato-splenomegaly and risk of rupture from oesophageal varices 
(S. mekongi) and cholangiocarcinoma (O. viverrini) if untreated.  
Methods/principle findings. A cohort study was carried out from 2006 to 2008 in three 
villages in Khong district, Champasack province, Lao PDR. In total 306 persons were 
screened for S. mekongi infections using Kato-Katz thick smear, 151 (49.3%) individuals 
were S. mekongi infected and underwent ultrasound examination. All individuals were 
treated with a single-dose of 40 mg/kg praziquantel and albendazole (500mg) at the 
baseline (2006). Repeated stool and ultrasonographic examinations were performed at 
11 months (mid-point) 24 months (end point) after treatment. At baseline co-infection 
with O. viverrini was diagnosed in 88.7%. The individuals did not demonstrate any 
severe sequelae. Overall, liver pathology was observed in a high prevalence of 37.1%. At 
midpoint follow up, two cases had developed ascites and one died due to rupture of 
oesophageal varices. There were significantly improvements such as reversals of 
periportal fibrosis among mild and moderate group (p<0.001) and a decreasing size of 
the left liver lobe, spleen and splenic veins (p<0.001). Re-infection with S. mekongi 
(54.3%) and O. viverrini (74.2%) were observed at the endpoint. Liver pathology at 
endpoint remained unchanged compared to midpoint.  
Conclusion/significance. Liver morbidity due to S. mekongi and co-infection with 
O. viverrini are substantial on Khong district. Ultrasonographic liver findings showed a 
significant reduction of morbidity after praziquantel treatment. However, severe 
morbidity and mortality due to S. mekongi were observed as well. Regular deworming 
programmes are needed to reduce the re-infection. Integrated and sustainable control of 
these two trematode infections is urgently needed on Khong district. 
6. Morbidity Resolution after Praziquantel 
 
 
73 
6.2 Introduction 
Trematode parasites, schistosomiasis and opisthorchiasis are an emerging but largely 
unrecognized public health and economic importance in the Mekong River basin 
concern (Andrews et al., 2008; Keiser and Utzinger, 2005; Muth et al., 2010). About 40 
million people are infected and 750 million people at risk of infection (Keiser and 
Utzinger, 2009). The infection caused by these flukes can lead to liver fibrosis and 
calcifications of portal venous system (schistosomiasis), which includes increased 
morbidity and mortality from portal hypertension, hepato-splenomegaly, and risk of 
rupture from oesophageal varices (Gryseels et al., 2006) and cholangiocarcinoma (Sripa 
et al., 2007). 
Schistosoma mekongi and Opisthorchis viverrini belong to the family plathyhelminth, 
which are cause schistosmiasis and opisthorchiasis. Both parasites cause hepatosplenic 
morbidity and mortality in the affected communities (Muth et al., 2010). They result in 
different liver parenchymal changes seen in ultrasound images (Hatz, 2001; Hirose et al., 
2007). Asian liver fluke, O. viverrini is prevalent in the Mekong River, namely Thailand, 
Lao PDR, Vietnam and Cambodia (Sithithaworn et al., 2011; Sripa et al., 2010b). Foci of 
blood dwelling fluke, S. mekongi was restricted to Lower Mekong Basin. The geographic 
overlap of S. mekongi and O. viverrini is a unique situation and represent an high socio-
economic burden in Lao PDR and Cambodia (Andrews et al., 2008; Keiser and Utzinger, 
2005; Muth et al., 2010). Preventive treatment with praziquantel (PZQ) is the mainstay 
of control today. However, it is not clear in how far liver morbidity induced by 
S. mekongi and O. viverrini is resolved after treatment. 
The objective of this study is to document the resolution dynamics of S. mekongi induced 
liver morbidity in a setting where co-infection with O. viverrini is prevalent. We carried 
out a cohort study for years following S. mekongi infected patients after an initial 
treatment with PZQ (40 mg / kg BW).  
 
6.3 Patients and Methods 
6.3.1 Study area and population  
A cohort study was conducted between June 2006 to June 2008 in three villages 
consisting of Long Khang, Long Song, Hang Long (on Don Long island) in Khong district, 
Champasak province, Lao PDR. 15-20 households (100 individuals) in each village were 
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randomly selected and screened for S. mekongi infection. The selection of household was 
based on the village family register. All members of selected household age ≥ 6 months 
were invited to participate in the study. 
Three villages are known to be S. mekongi and O. viverrini endemic area. Khong district 
is located in Champasack Province (~200 km), Southern Lao PDR and borders to 
Cambodia. In Khong district an estimated 80,000 people dwell adjacent to the Mekong 
River. 
 
6.3.2 Laboratory procedures  
For each individual, 3 stool samples were collected over 6 consecutive days. The stool 
samples were collected in the early morning between 7h00-9h00am and provided the 
empty container for the next day. All stool samples were shipped to district laboratory in 
the main island, Khong district. One Kato-Katz thick smear (41.7 mg) was prepared from 
each specimen (Katz et al., 1972) and allowed to clear for 30-40 minutes prior to 
examination under a light microscope. The number of eggs was counted and recorded 
for each parasite species separately. Exactly 300 mg of stool was placed in a small tube 
containing 10 ml of sodium acetate acetic-acid formalin (SAF) (Marti & Escher, 1990) 
and then analyzed by use of a formalin-ether concentration technique at the 
parasitological department of the Faculty of Medicine, University of Health Sciences 
(Vientiane, Lao PDR). Approximately 10% of the Kato-Katz thick smears were randomly 
re-examined for quality control, performed by laboratory staff from the Swiss Tropical 
and Public Health Institute (Basel, Switzerland). Helminth eggs were counted and 
recorded for each species separately. Finger pick for hemoglobin was performed for 
each individual using a hemoglobin meter (HemoCueB-Hemoglobin, Microvettes®)  
 
6.3.3 Abdominal ultrasonography examination 
Ultrasonography was performed, using a portable ultrasonographic machine (SSD-500, 
Aloka, Tokyo, Japan) with 3.5 MHz convex abdominal transducers. The US examination 
was conducted by an experienced radiologist of Mahosot hospital (a director of 
radiological department), Ministry of Health, Vientiane, Lao PDR and a physician who 
was trained in performing the ultrasound protocol, using the recent WHO guideline 
(Niamey Working Group, 2000). Both examiners were blinded with regards to 
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parasitological results. The image was recorded on a DVD disc, using a Sony DVD 
recorder (RDR-HX780).  
Liver image pattern (IP) was taken in supine position. IP was scored and graded 
according to Niamey document (Niamey Working Group., 2000). IP was designated as A 
to F: A as normal pattern; B as liver with defuse echogenic foci ‘starry sky’; C as liver 
with highly echogenic ‘rings and pipe stems’; D as liver with a highly echogenic ‘ruff’ 
around the portal bifurcation and main stem; E as liver with highly echogenic ‘patches’ 
extending from the main portal vein and branches to the periphery; and F as liver with 
highly echogenic bands and streaks, extending from the main portal vein and its 
bifurcation to the liver surface, where they retract the organ surface ‘bird’s claw’ 
pattern. The size of the left liver lobe (SLL) was measured by longitudinal liver scan. The 
measurements were taken in the left parasternal line from the upper to the caudal 
margin. This view is similar to the one used to demonstrate paraumbilical and coronary 
vein collaterals. The portal vein diameter (PVD) was measured in the right oblique view 
along the axis of the vessel with measurement of the internal diameter of the portal vein 
at the entry point into the liver. The size of spleen was measured in the left intercostals 
oblique view with the maximum length by measuring through the splenic helus. All 
organ measurements were high-adjusted. The cut-off numbers were based on the 
healthy uninfected Chinese population (Li et al., 2004). The organs were considered as 
abnormality if the height-adjusted value exceeded two standardized Deviation (2SD) of 
the referenced population (e.g., 0-2SD is normal; 2-4SD is enlarged and > 4SD is much 
enlarged). Finally, periportal hypertension (PH score) was calculated from the sum of 
the three indicators such as the height-adjusted value of portal vein diameter (PVD) 
(normal = 0, enlarged = 4 and marked enlarged = 6), the presence of collateral veins 
(absence = 0 and presence = 4) and the presence of ascites (absence = 0 and presence = 
3). The sum of these scores was categorized into four groups: 0 = normal, 4= light 
hypertension, 6–8 moderate hypertension and 10–13= severe hypertension and 
adjusted for each individual. Each study individuals was asked to fast at least 4 hours 
before examination. The examination was only performed in the study individuals with 
body height ≥ 80cm. 
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6.3.4 Questionnaire and physical examination 
Socio-economic characteristics of the study family, demographic (e.g., age, sex, 
education, and profession), and behavioral data (e.g., food consumption habits) were 
obtained with a questionnaire (Sayasone et al., 2011). Self-reported morbidity recalled 
within past two weeks was obtained from each individual. Each study individual 
underwent a physical examination by a general physician. The physical examination was 
subjected to a general condition of study individuals, skin abnormality observed, 
abdominal, liver and spleen palpation. The clinical classification of liver and spleen were 
based on the criteria modified by Hackett (Hackett, 1944). Moreover, an anthropometric 
assessment (body weight, body height and upper arm circumference) was done for each 
study individual. An electronic bathroom scale was used to measure the body weight of 
study participants. Body height was measured using a standard meter in standing 
position. Mid upper arm circumference was collected from each study individual using a 
measuring tape. 
 
6.3.5 Data management 
Data were double-entered and validated in EpiData version 3.1 (Epidata Association; 
Odense, Denmark). Statistical analyses were performed with STATA version 9 (Stata 
Corporation; College Station, TX). Only volunteers who completed abdominal US and a 
full set of 3 Kato Katz thick smears with parasitologically confirmed S. mekongi 
infections at the start of the cohort were evaluated in the final analysis. Age was 
categorized into seven groups: (i) < 6 years, (ii) 6–15 years, (iii) 16–30 years, (iv) 31-55, 
(v) > 55 years. Infections intensity with S. mekongi and soil-transmitted helminths 
(STHs) was classified in categories put forth by WHO (WHO, 1995): S. mekongi: 0; 1 – 
100; 101 – 400; > 400 egg per gram [EPG] hookworm, (1-1999 (EPG), 2000-3999 EPG, 
and ≥4000 EPG), A. lumbricoides, 1-4999 EPG, 5000-49,999 EPG. O. viverrini were 
grouped into negative, light infection, moderate infection and severe infection (0; 1 – 
999; 1.000 – 9.999; ≥ 10.000 epg) cut-offs put forward by Maleewong (Maleewong et al., 
1997).  
Descriptive analyses are presented as counts, percentages, means and standard 
deviations, as appropriate. Pearson’s x2 and Fisher exact test were applied to compare 
the baseline binary characteristics between three villages as appropriated. Negative 
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binomial regression was applied to calculate egg reduction rate ratio (ERRR) between 
the numbers of helminth eggs recovered in stool examination between three year 
follow-up. Random effects multinomial logistic regression model was fitted and 
employed to investigate the association between morbidity and parasitic infection at 
individual over the period of time. 
 
6.3.6 Ethical considerations  
The study was approved by the Ethics Committee of the Kanton of Basel (EKBB; 
reference no. 255/06) and the National Ethics Committee, Ministry of Health in 
Vientiane (reference no. 027/NECHR). Written informed consent was obtained from the 
heads of participating household and an individual prior to enrollment. An informed 
consent form was written and translated in Lao language, detailed on potential risks, 
benefits, procedures. An anti-spasmodic treatment and oral dehydration was provided 
in case of adverse effects due to drug administration. Once our study participants 
completed all the evaluations, including clinical, US, parasitological examination had 
been performed, they were treated with anthelminthic drugs in a corresponding to their 
current helminth infection. If any anormalities were observed during the examination, 
we informed and suggested for further investigation according to Lao Ministry of Health 
guideline. Additionally, at the first year and the end of the study, all individual in the 
three villages were administered a single dose of 400 mg albendazole and a single dose 
of 40 mg/kg praziquantel in respective to Lao national scheme for mass drug 
administration (Ministry of Health, 2004). 
 
6.4 Results 
6.4.1 Baseline characteristics.  
Of 409 participants randomly selected in three villages, we excluded 89 (21.8%) 
individuals since they provided only single stool sample and absence during the survey. 
In total 306 (100.0%) individuals were enrolled at baseline and examined by 3 Kato- 
Katz slides. While 81 (26.5%) individuals were excluded due to missing both stool 
samples and US examination, only 225 (73.5%) individuals were included with 
parasitologically confirmed S. mekongi in mid point follow-up (2007). 74 (24.2%) 
individuals could not be traced on the last follow-up. Overall, 151 individuals completed 
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the all data records (3x3 Kato-Katz thick smears, 3x US and 3 physical exams) at the final 
evaluation (Figure 6.1).  
Overall, demographic characteristics of study participants did not differ between the 
villages (Table 6.1). There were slightly more women (52.3%) than men (47.7%). Mean 
age (SD) was 23.2 years(18.5) ranging from 6 months to 87 years. Of these, children 
aged < 6 and elderly > 55 years accounted for 13.9 % and 6.6 % of the cohort, 
respectively. Most participants had a primary school education level (63.6%) while 
some were illiterate (26.5%) or reached a secondary school level (9.9%). Agriculture 
or/and fisherman were the main professional activity in three villages, while there were 
only few without any profession or housewifes and government employees.  
Table 6.2 summarizes signs and symptoms related to S. mekongi and O. viverrini 
infection. Study participants felt tiredness (14.6%), RUQ pain (23.2%), and repored 
blood in stool (6.6%), was significantly different with three year evaluation (2006 to 
2008) (P< 0.03). On physical exam the most frequent sign was a hepatomegaly (82.7%) 
and splenomegaly (48.7%) with statistical significance with three year evaluation (2006 
to 2008) (P<0.001).  
 
Table  6.1: Baseline characteristics 
Village   Long Kang 
(n= 52) 
Long Song 
(n=50) 
Hang 
Long 
(n=49) 
P-value 
Sex Male  42.3 52.0 36.7  
 Female  57.7 48.0 63.3 0.11 
Age Mean (year)   21.3 23.5 24.8  
≤ 5   21.1 10.0 10.2  Age groups 
(year) 6 – 15  34.6 42.0 36.7  
 16 – 30   7.7 12.0 14.3  
 31 – 55   32.7 30.0 28.6  
 >55   3.9 6.0 10.2 0.12 
Weight Mean (SD) kg  33.7 34.0 32.9  
Height Mean (SD) cm  134.4 133.6 135.9  
Education Illiterate  26.9 32.0 20.4  
 Primary school  55.8 62.0 73.5  
 Secondary  17.3 6.0 6.1 0.17 
Occupation No occupation  26.9 22.0 28.6  
 Farmer /Fisher  71.1 78.0 71.4 0.76 
Data are no; (%) of subject, otherwise indicated; MAUC, mid upper 
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Figure 6.1 Study participation and compliance. Flow diagram of cohort study on S. 
mekongi and co-infection with O. viverrini in three villages, Don long, Khong District, Lao 
PDR between 2006 and 2008.  
Baseline 2006 
Individuals with signed written 
informed consent and complete data 
records, i.e. 3 Kato-Katz thick smears 
and ultrasound examination  
(n=306; 150 males, 156 females) 
3 villages selected among villages in 
Khong district, 20-25 household were 
randomly selected in each village 
(n= 409; 192 males, 214 females) 
 
Excluded (n=103):  
Single stool examination (n= 75) 
Absence (n= 28) 
 
Lost- to-follow-up 
Kato-Katz thick smears (n= 25) 
Ultrasound examination (n= 25) 
Negative S. mekongi (n= 31) 
(n= 81; 40 males, 41 females) 
 
Follow-up 2007 
Individuals with 3 Kato-Katz thick 
smears and ultrasound examination 
(n= 225; 114 males, 111 females) 
 
Follow-up 2008 
Individuals with 3 Kato-Katz thick 
smears and ultrasound examination 
(n= 151; 79 males, 72 females) 
 
Lost to follow-up 
Kato-Katz thick smears (n= 45) 
Ultrasound examination (n=27) 
Ascites (n=1) 
Death due to oesophageal bleeding (n=1) 
(n= 74; 30 males, 34 females) 
 
Final analysis (2006-2008) 
Individuals with complete data records, 
i.e., 3 Kato-Katz thick smears and 
Ultrasound examination 
(n= 151; 79 males, 72 females) 
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6.4.2 Morbidity resolution dynamics 
Among our patients we observed the following hepatobiliary pathology: portal 
hypertension, enlargement of the left liver lobe, portal vein dilatation and splenomegaly. 
Table 6.3 summarizes the development of morbidity in the 2 years cohort. Overall liver 
morbidity decreased initially (2006-2007) but increased between 2007 and 2008 (P< 
0.001). 
 
 
 
6.4.3 Infection resolution dynamics  
At the baseline, among 151 infected with S. mekongi, 88.7% were infected with 
O. viverrini. Overall prevalence of hookworm, A. lumbricoides, T. trichiura were 56.0%, 
4.0% and 10.6%, respectively. Other helminthic infection such as Taenia spp., 
Strongyloides stercoralis and Enterobius vermicularis were 10.6%, 27.3% and 0.7%, 
Table 6.2: Medical history and physical among 151 residents in 3 villages of Don Long 
Island, Khong province, Champasak Province 
 2006 
(n=151) 
2007 
(n=151) 
2008 
(n=151) 
χ2-trend 
Medical History     
Morbidity reported (past 2 weeks)     
Lost weight 4.2 18.9 1.3 <0.001 
Tiredness 11.5 26.0 6.1 0.02 
RUQ pain  4.2 18.2 16.4 0.01 
Blood in stool  0.0 10.0 10.2 0.03 
Physical examination     
Good condition 96.2 94.0 100.0 0.32 
Jaundice 0 1.9 0.0 Na 
Pale conjunctiva 13.4 16.0 10.2 0.72 
Big belly 36.0 18.0 28.6 0.08 
Coronary collateral vein 1.8 0.5 0.9 0.89 
Hemoglobin, mean (SD) mg/dl 11.5 11.6 12.3 0.78 
Hepatomegaly     
1 31.3 71.5 91.7  
2 52.5 21.7 4.7  
3 15.0 5.8 2.4  
4 1.3 0 1.2 <0.001 
Splenomegaly (Hackett score)     
1 17.2 75.5 94.7  
2 66.9 23.2 4.6  
3 15.9 3.3 0.7 0.001 
Data are no; (%) of subject, otherwise indicated; RUQ- right upper quadrant pain at palpation; 
Hackett score (1944) 1-normal, 2-mild, 3- moderate; 4. large, coronary collateral vein-vessel on 
abdominal observation;   
6. Morbidity Resolution after Praziquantel 
 
 
81 
respectively. The S. mekongi and O. viverrini geometric mean egg counts obtained by 
Kato-Katz and FECT at baseline ranged from 879.2 to 565.4 and 2296.2-3970.7 EPG, 
respectively. At the end of the study, 54.3% were positive with S. mekongi and following 
by 63.6% were found egg positive for O. viverrini. There were statically significances 
observed between GM and over two years evaluation (Table 6.4). 
 
 
Table 6.3 Ultrasonographic findings in villages infected by co-infection of O. viverrini and/or 
S. mekongi following treatment by praziquantel 
 
 
  2006 
(n=151) 
2007 
(n=151) 
2008 
(n=151) 
χ2 – 
trend 
Image pattern A  39.7 4.7 5.3  
 B  23.2 35.1 35.8  
 C  19.2 43.7 41.7  
 D  11.3 6.6 9.9  
 E  3.9 6.6 4.0  
 F  2.7 3.3 3.3 < 0.001 
Portal hypertension       
 Normal  82.1 69.5 78.8  
 Light  0 27.2 0  
 Moderate  17.9 3.3 21.2 < 0.001 
Left liver lobe        
   Normal  10.6 17.9 21.9  
   Enlarged  54.3 38.4 48.3  
   Much enlarged  35.1 43.7 29.8 0.0002 
Portal vein diameter       
   Normal  88.7 63.6 64.9  
   Dilated  8.6 8.6 25.2  
   Marked dilated  2.7 27.8 9.9 < 0.001 
Spleen       
    Normal  88.7 66.9 86.1  
    Enlarged   7.3 6.6 11.3  
    Much enlarged  4.0 26.5 2.6 <0.001 
Other findings       
 GBST  1.3 3.1 1.3  
 GBWT  2.7 2.6 1.8  
 GBL (Mean)  5.3 5.6 6.0  
 GBWI  3.6 2.0 0.9  
 GBSL  0.4 1.6 1.8  
 Ascites  0 1.0 0.5  
Data are no; (%) of subject, otherwise indicated; GBST-gallbladder stone, GBWT-gallbladder wall 
thickening, GBL- gall bladder length (cm), GBWI-gallbladder wall irregular or with a halo, IHBDL: 
intra-hepatic bile duct dilated, GBSL-gallbladder sludge 
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Table 6.4 Prevalence of infection, diagnosed by Kato-Katz and formalin-ethyl-acetate concentration 
in three villages, Khong district, Champasack province 
 2006 
(n = 151) 
2007 
(n = 151) 
2008 
(n = 151) 
 
P-value 
Schistosoma mekongi a     
GM egg per gram of stool (range) 322.3 
(79.2-565.4) 
119.0 
( 38.8-199.3) 
486.1 
(234.4-737.9) 
 
0.09* 
Negative 0 66.9 45.7  
Light (1-999 EPG) 88.1 32.4 42.4  
Moderate (1000- 9999 EPG) 8.6 0.7 7.3  
Heavy (≥10,000 EPG) 3.3 0 4.6  
Opisthorchis viverrini  b     
GM egg per gram of stool  
(range)  
3133.4 
(2296.2-3970.7) 
2501.9 
( 1361.3-
3642.6) 
2443.0 
(1177.9-
3708.1) 
 
< 0.001* 
Negative 11.3 35.8 36.4  
Light (1-999 EPG) 41.7 45.7 41.7  
Moderate (1000- 9999 EPG) 38.4 13.9 18.6  
Heavy (≥10,000 EPG) 8.6 4.6 3.3  
Hookworm c     
GM egg per gram of stool (range) 476.6 
(358.3-594.9) 
534.8 
(343.6-726.0) 
275.6 
(164.4-350.8) 
 
0.94* 
Negative 44 (29.1) 91 (60.2) 60.3  
Light (1-1999 EPG) 103 (68.2) 56 (37.1) 40.0  
Moderate (2000- 3999 EPG) 4 (2.7) 4 (2.7) 39.7  
Ascaris lumbricoides d     
GM egg per gram of stool (range) 7268 
(5968.4- 
20504.4) 
1772.0 
(955.4-4499.4) 
552 
(381.9-
1485.9) 
 
0.04* 
Negative 9.0 96.0 96.0  
Light (1-4999 EPG) 2.7 3.3 2.7  
Moderate (5000- 49,999 EPG) 1.3 0.7 1.3  
Trichuris trichiura e       
GM egg per gram of stool (range) 139.5 
(52.9-331.9) 
140.0 
(72.5-207.5) 
228.9 
(24.6-482.5) 
 
0.001* 
Negative 89.4 92.1 91.4  
Light (1-999 EPG) 10.6 7.9 8.6  
Taenia spp.      
Negative 89.4 99.1 100  
Positive 10.6 92.0 0  
S. stercoralis     
Negative 72.7 84.8 100.0  
Positive 27.3 15.2 0  
E. vermicularis     
Negative 99.3 99.3 98.7  
Positive 0.7 0.7 1.3  
a According to guidelines put forth by WHO [xx], based on Kato-Katz thick smear examinations  
b According to Maleewong and colleagues [xx], based on Kato-Katz thick smear examinations 
Data are no; (%) of subject, otherwise indicated (95% confidence interval); EPG, eggs per gram of stool;  
GM, geometric mean; * ERRR, egg reduction rate ratio 
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Figure 6.2 Prevalence of periductal fibrosis (A - normal, B - ‘starry sky’, C - highly 
echogenic ‘rings and pipe stems’, D - highly echogenic ‘ruff’ around the portal 
bifurcation and main stem, E - highly echogenic ‘patches’ extending from the main 
portal vein and branches to the periphery, F - highly echogenic bands and streaks, 
extending from the main portal vein and its bifurcation to the liver surface moderate 
151 individuals infected with S. mekongi, underwent ultrasound examination by aged 
groups from 2006 to 2008. 
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Figure 6.3 Infection intensity (0- negative, 1- mild 2- moderate 3-heavy) among 151 
individuals infected with S. mekongi by aged groups from 2006 to 2008. 
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Figure 6.4 Prevalence of periductal fibrosis (A-normal, B- a liver with defuse echogenic 
foci ‘starry sky’, C -highly echogenic ‘rings and pipe stems’, D -highly echogenic ‘ruff’ 
around the portal bifurcation and main stem, E -highly echogenic ‘patches’ extending 
from the main portal vein and branches to the periphery, F-highly echogenic bands 
and streaks, extending from the main portal vein and its bifurcation to the liver 
surface moderate 151 individuals infected with S. mekongi, underwent ultrasound 
examination by gender from 2006 to 2008. 
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Figure 6.5 Infection intensity (0- negative, 1- mild 2- moderate 3-heavy) among 151 
individuals infected with S. mekongi by gender from 2006 to2008 
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6.5 Discussion 
This is the first community based study investigating dynamics of S. mekongi 
infection and related morbidity after praziquantel treatment. This cohort study was 
carried out in a setting where co-infection with other parasites are highly prevalent. In 
particular is also O. viverrini present which also produces significant hepato-biliar 
morbidity. We found that S. mekongi infection prevalence was reduced but increased 
again in the second year. On the morbidity side similar observations were made. 
Chronic infection with S. mekongi associated significantly with hepatosplenomegaly, 
granulomatous of liver or periportal fibrosis, portal hypertension, leading to rupture of 
oesophageal bleeding, which is a main cause of death due to this parasite (Biays et al., 
1999; Chiavalori et al., 2008). While O. viverrini contribute to a wide range of 
hepatobiliary disesses, including hepatomegaly, obstructive jaundice, gallbladder stones, 
cholecystitis, cholangitis and, most severely, a fatal bile duct cancer 
(cholangiocarcinoma) (Andrews et al., 2008; Sripa et al., 2010b). Little is known about 
the association and the underlying mechanism between S. mekongi and O. viverrini. 
Nevertheless, co-infections of these flukes might aggravate the host-organ pathology 
(Sayasone et al., 2011). 
Abdominal ultrasound (US) is a safe, simple, rapid diagnosis tool in hospital and 
communities studies (Hatz et al., 1992a; Hatz et al., 2001; Mairiang and Mairiang, 2003). 
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Figure 6.6 Infection intensity (0- negative, 1- mild 2- moderate 3-heavy) among 151 
individuals infected with S. mekongi by classification of periportal fribosis from 2006 to2008 
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A standard used of ultrasound, developed by WHO expert and researchers for a decade 
in detecting Schistosomiasis-related morbidity (Niamey Working Group, 2000). As 
morbidity due to S. mekongi was similar to findings in S. mansoni and S. japonicum 
infections (Hatz et al., 1992a; Hatz et al., 1992b). Today no standardized protocol is 
available for assessing morbidity due to S. mekongi and co-infecting O. viverrini. 
Researchers of the Southeast Asia region have adapted the Niamey protocol and added 
periductal fibrosis indicators specific for O. viverrini infection (Mairiang et al., 2011). 
Niamey protocol was developed for standardized protocols for the assessment 
ultrasonographical morbidity due to Schistosoma haematobium and Schistosoma 
mansoni (Niamey Working Group, 2000; Richter, 2000). 
Our study confirmed that the impact of praziquantel treatment reduces 
hepatosplenic diseases by decreasing significantly liver and spleen sizes. US findings 
demonstrated that enlargement of left liver lobe, spleen, splenic vein; sign of portal 
hypertension were improved. Other parameters such as periportal fibrosis and portal 
vein diameter started to regress. Similar achievement of pathology resolution were 
observed in Cambodia after several rounds of praziquantel treatment (Keang et al., 
2007; Stich et al., 1999). In our study population liver fibrosis remained unchanged.  
Prevalence of S. mekongi and O. viverrini were found to be highly prevalent before 
treatment, other soil transmitted helminths were also endemic. Rapid re-infection 
obviously occurred after praziquantel and albendazole treatment within a year. For 
example, prevalence of S. mekongi and O. viverrini reached pre-treatment level within 
subsequent years. Our finding was in line with a recent study, conducted in the school, 
which was the same study site as our study revealed the respective prevalence of S. 
mekongi; O. viverrini and hookworm were highly prevalent by 87.8%, 98.9% and 97.6%, 
respectively (Lovis et al., 2011, submitted to PLoS NTD).  
Our study confirmed the previous studies on eating raw or insufficient cooked fish 
(i.e., “Lap-pa” and “Koy-pa”) and having contact with infected water are the main key 
factor for re-infection (Grundy-Warr et al., 2011; Sayasone et al., 2011; Sayasone et al., 
2007; Sayasone et al., 2010b). Additional to behavior characteristics and water contact, 
socioeconomic, and environmental characteristics such as infrastructures and sanitation 
are key determinants for prevalence and intensity of several parasitic infections 
(Sayasone et al., 2011; Steimann et al., 2011). For example in 2007 in our study survey of 
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four villages (Long Kang, Long Song, Hang Long and Hauo Long), on Khong district, only 
14.5% of the households possessed latrines and 76.0% reported daily use of the Mekong 
River for bathing (K. Phongluxa, pers. communication). Given the fact that snail 
population control by application of molluscicide and limited mammal reservoirs (i.e., 
dog, cat and beaver) might be not feasible to curb Schistosome and Opisthorchis-
induced morbidities (Muth et al., 2010; Thamkeo and Pholsena, 2003). Nonetheless, 
without elimination with snail, the control of S. mekongi could be possible (Ohmae et al., 
2004). In our current work, improved Infrastructure and sanitation are being carried 
out on four villages, Don Long Island this intervention would considerably help to cease 
the transmission of these parasites (S. Sayasone, pers. communication).  
In Lao PDR, a community-based intervention against schistosomiasis mekongi has 
been performed in the late 1980s. The program was led by Lao Ministry of health and 
World Health Organisation using a single dose of 40 mg/kg praziquantel for treatment of 
schistosomiasis. Since then, the public health problem had only been resolved partially. 
Today, there is a raising concern on re-emerging of S. mekongi transmission in Lao PDR, 
since nine sever cases of S. mekongi with signs and symptoms of schistosomiasis 
mekongi have recently determined during the epidemiological helminth surveys on 
Khong District, Champasack Province (Soukhathammavong., in preparation for PLos 
NTD). Our study further documents that re-infection and re-emergence of morbidity is 
rapid and occurs already 1 year after treatment. Therefore, an effective community 
intervention must operate at an annual basis, i.e. annual preventive treatment.  
A single dose of 40 mg/kg praziquantel and 500 mg albendazole are well-tolerated 
and recommended by WHO (WHO, 2002) as a drug of choice for the use of mass drug 
administration against mainly food-and waterborne trematodiasis and soil transmitted 
helminth in endemicity, particularly emphasis was placed in population at risk (Muth et 
al., 2010; Utzinger and Keiser, 2004). In our population study showed periductal fibrosis 
were regressed and significantly improved after treatment, notably in mild (pattern A) 
and moderate (pattern B to C) periportal fibrosis groups. On contrary, among advanced 
periductal fibrosis group were remained the same as pretreatment but ascites were not 
detected after treatment. 
We have encountered limitations, for example alcohol consumption is commonly 
observed in Laos and is known to be a potential risk factor for cirrhosis (Gatto et al., 
6. Morbidity Resolution after Praziquantel 
 
 
88 
2010). Frequency and onset had been difficult to estimate because villagers had started 
at early ages. Additionally, viral infections caused by HVB and HVC could not be ruled 
out in our population, which are mainly prevalent in Southeast Asia and considered as a 
risk factor leading to liver cancer (Gatto et al., 2010; Shin et al., 1996), however, no data 
have been documented in Laos. The images resulting from these risk factors may be 
confused with a liver US imaging attributable to S. mekongi (Kardorff et al., 1999) and 
may aggregate liver pathogenesis for co-infection with O. viverrini. Lost-to-follow-up or 
participant compliance was an issue found in our study, since people had to leave their 
home for work. 
In conclusion, our findings underscore that morbidity and remerging of S. mekongi 
and co-infection of O. viverrini are of particular concern on Khong district. Co-infection of 
these trematodes might deteriorate the pathogenesis of host organs. Follow-up and 
monitoring of schistosmiasis and opisthorchis induced morbidity in endemic areas are 
warranted. Multi-component integrated and sustainable control disease control 
programme on prevention strategies are fundamental (Utzinger et al., 2010; Utzinger et 
al., 2003), for instance promoting health education campaigns, improved sanitation and 
hygiene, better access to clean water are needed to reinforce. 
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7.1 Abstract  
Background.  Hepatobiliar morbidity including cholangiocarcinoma (CCA) are outcomes 
of chronic Opisthorchis viverrini liver fluke infection. Detailed information on hepatobiliar 
morbidity associated with O. viverrini infection including CCA is scare in Laos although 
O. viverrini infection is highly prevalent. We assessed O. viverrini-related hepatobiliar 
morbidity using abdominal ultrasonography (US) in confirmed O. viverrini infected adult 
patients in Saravan province, southern Laos. 
Principle findings.  A random sample of 431 O. viverrini patients from 10 villages 
underwent abdominal US. Mild, moderate and markedly advanced periductal fibrosis was 
diagnosed in 7.0%, 66.5%, and 17.0%, respectively. Normal liver parenchyma was seen 
only in 9.5% of patients. Presence of gall stones (13.2%), sludge (1.4%), gall wall 
thickening (1.2%), bile duct dilatation (1.6%), fatty liver (12.0%), and kidney stones 
(8.6%) and cysts (7.9%) were seen in considerable frequencies. In five patients (1.2%) 
hepatobiliary lesions suggesting CCA were diagnosed. The diagnosis of CCA cases could 
not be confirmed. Tumour markers, i.e., Interleukin-6, plasminogen activator inhibitor, 
and carbohydrate antigen 19-9 were within normal range. 
Conclusion.  High prevalence of CCA suspected liver masses and hepatobiliar diseases 
related to O. viverrini infection were seen among clinically asymptomatic adult patients in 
the endemic areas of Laos. Creation of awareness highlighting routes of infection and 
cultural culinary preference from very early ages, improved infrastructure and 
surveillance of population in distinct endemic settings are warranted, in order to reduce 
and prevent opisthorchiasis-related morbidity including a liver fatal cancer, 
cholangiocarcinoma. 
Keywords Opisthorchis viverrini, hepatobiliar morbidity, cholangiocarcinoma, 
ultrasonography
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7.2 Introduction 
In Laos, information on morbidity due to O. viverrini infection is scare and virtually 
absent for cholangiocarcinoma (CCA), a bile duct cancer associated with chronic 
Opisthorchis viverrini infection. A recent study documented morbidity associated with 
liver flukes O. viverrini and Schistosoma mekongi infections in Southern Laos [1]. 
However, CCA cases and precursor lesions were not assessed. Endemicity levels of 
O. viverrini in the country [1,2] suggest that hepatobiliar morbidity and CCA incidence in 
Laos are at least as high as or higher than in Northeast Thailand. 
CCA is a rare bile-duct cancer with a poor prognosis [2,3]. Chronic O. viverrini liver fluke 
infection is a main risk factor for CCA [4]. The highest CCA incidence worldwide is 
recorded in O. viverrini endemic areas in Northeast Thailand where on average 119 
cases per 100,000 persons occur per year in adults aged 35 to 64 [5], with 
approximately five thousand cases are diagnosed per year [6]. Costs associated to CCA 
and O. viverrini fluke infection amount to an estimated USD 120 millions in Thailand 
alone [7]. 
Opisthorchiasis is a fish-borne trematode infection belonging to the neglected tropical 
diseases (NTDs) [8–10]. Almost 67 million people are at risk of infection, and an 
estimated 10 million people infected live in Northeast Thailand and Lao People’s 
Democratic Republic (Laos, Lao PDR). In Laos, a third of the 5.5 million inhabitants are 
infected [8,11]. Infections occur in all provinces [2] but highest rates are seen in the 
Central and Southern parts with rates reaching up to 90% of the population [12–14]. 
Although burden of infection is high public health control activities are largely lacking.  
We assessed hepatobiliar morbidity and found lesions suspicions of CCA in O. viverrini 
infected adults in rural communities of Southern Laos.  
7.3 Methods  
7.3.1 Ethical considerations 
Ethical approval was granted by the Lao National Ethics Committee for Health Research 
(NECHR, N° 278/NECHR) and Ethical Review Group of the World Health Organization-
Western Pacific Region in Manila, Philippines for investigating hepatobiliary morbidity. 
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The Lao National Ethics Committee for Health Research (NECHR, N° 169/NECHR) 
Vientiane, Lao PDR and the Ethical Committee Board, World Health Organization, 
Geneva, Switzerland to assess O. viverrini infection status.  
Study aims, procedures and potential risks and benefits were explained to village 
authorities and all selected villagers in Lao language. Prior to enrolment informed 
written consent was obtained. Patients were informed on any abnormal ultrasound 
result and referred to treatment according to standard health care of the Lao Ministry of 
Health [15]. All patients with lesions suspecting CCA were given additional counseling 
and a free follow-up investigation was proposed. All patients were treated with 
praziquantel (40 mg/kg, single oral dose).  
7.3.2 Study Design and Area 
From January to April 2011 a cross-sectional study was carried out in adults (aged ≥ 20 
years) of ten O. viverrini endemic villages in Saravan district, Saravan province, 
Southern Laos. Approximately 350,600 inhabitants live in the province (9 districts, 168 
villages); 15.5% are children under five-years of age [Pers. Communication, Saravan 
Statistic Division, Saravan District Health Office]. Parasitological studies in the district of 
Saravan documented high O. viverrini infection rates in the general population of above 
50% [3]. 
For this study, 840 participants from randomly selected households were screened for 
O. viverrini infection (Figure 1) of whom 85.0% had an O. viverrini infection. Abdominal 
ultrasonography examination was performed in adults (431, 51.3%). 
7.3.3 Laboratory Analysis of Stool and Blood 
Stool examination followed a standard procedure. In brief, each participant provided 
two fresh stool samples on consecutive days. Stool containers were transferred to the 
laboratory in the morning. From each sample, two Kato-Katz thick smears were 
prepared using standard 41.7 mg templates and examined under a light microscope 
(100 x magnification) [16]. Number of O. viverrini eggs per slide was recorded. Slides 
were read within 30-45 min after preparation. Ten percent of smears were re-examined 
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for quality control [17]. An O. viverrini-positive patient was defined as the presence of at 
least one O. viverrini egg in at least one of the four Kato-Katz fecal thick smears. 
From patients with CCA suspected lesions a 30 mL venous blood sample was drawn. 
Tumor markers, i.e., carbohydrate antigen 19-9 (CA 19-9), Interleukin-6 (IL-6) and 
plasminogen activator inhibitor (PAI) were assessed in Khon Kaen University’s 
reference laboratory [18,19]. 
From each patient demographic data were recorded (i.e., sex, age, place of residence, 
contact details and occupation) and information on abdominal symptoms and raw fish 
consumption was obtained. 
7.3.4 Assessment of Hepatobiliary Morbidity 
Abdominal US examination was performed in the study village using a portable US 
machine (SSD-500, Aloka, Tokyo, Japan) with a 3.5 MHz convex abdominal transducer. 
Patients were asked to fast 8 hours before US examination. Liver parenchyma fibrosis 
was assessed using an adapted examination protocol from Niamey [20] in combination 
with the standard protocols used in earlier in community-based studies [19]. Liver 
parenchyma pattern was graded as normal or no echoes (=0), starry sky (=1+), rings 
and pipe stems (=2+), and as highly echogenic ‘patches’ extending to peripheral areas 
(=3+). Patients were grouped to “none or mild advanced periportal fibrosis” and 
“advanced fibrosis” according to the US grade (equal ≤1 versus ≥2). Gallbladder was 
examined once before and 30 minutes after consumption of a fatty meal (a sterilized 
milk of 250 mL and two boiled eggs).  
US examiners (PAS, VR) were blinded with regard to the laboratory results. Images 
were recorded on a DVD (Sony DVD recorder RDR-HX780) for quality control 
conducted by senior radiologists (OR, EM).  
7.3.5 Statistical Analysis 
Data were double-entered and validated in EpiData, version 3.1 (Epidata Association; 
Odense, Denmark). STATA software, version 10.1 (Stata Corp., College Station, TX, USA) 
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was employed for analysis. O. viverrini infections were grouped in light (1-500 eggs per 
gram stool [EPG]), moderate (501-999 EPG), heavy (1000-1999 EPG) and very heavy (≥ 
2000 EPG) infection intensity. Descriptive statistics was used (counts, percentages, and 
means and standard deviations [SD]). Kruskal Wallis rank test was used to compare egg 
counts of O. verrini among patients with liver lobe enlargement and patients without 
this condition. ANOVA, logistic regression and multinomial logistic regression was used. 
A P-value below 5% was considered significant.  
7.4 Results 
7.4.1 Patients’ Characteristics 
Ultrasound examination was performed in 431 O. viverrini infected adults (Figure 7.1). 
Enrolled patients had mean age of 43.2 years (SD 0.5 years, range 20 to 86 years); 
30.2% were between 30 and 39 years old; 31.0% older than 50 years (Table 1). There 
were more women (57.8%) than men (42.2%). Most patients were farmers (99.1%) and 
illiterate (95.8%). Patients’ mean weight was 49.8 kg (SD 3 kg). Overall, O. viverrini 
geometric mean egg counts were 3961 EPG (range 24 – 69,648 EPG); 40.1%, 14.7%, 
14.2% and 31.1% had a light, moderate, heavy and very heavy O. viverrini infection 
intensity, respectively. 
Patients reported abdominal discomfort (75.6%), pain in the right upper quadrant 
(RUQ, 60.5%), and having “hot sensations” around the RQU (25.0%). Two patients had a 
jaundice and reporting skin itching. Most patients (99.5%) had consumed Pa dek (raw 
fermented fish sauce) within the last week; three quarters (75.8) reported regular 
consumption of raw Koy-pa and Lap-pa (meal based on raw fish). Twenty five percent 
reported to have a latrine at home but less than 5% use it regularly but defecate outside. 
7.4.2 Hepatobiliary Morbidity 
Only forty one patients (9.5%) had a normal liver parenchyma (Table 7.2); in 66.6% and 
16.9% moderate and advanced periductal fibrosis was diagnosed (Figure 7.2). 
Gallbladder abnormalities were observed such as wall thickening (1.2%), gallbladder 
wall irregularities (0.5%), and sludge (1.4%). Gallbladder stones were observed 
frequently (13.2%). Other pathologies were diagnosed in considerable frequencies: 
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fatty liver (12.0%), kidney stones (8.5%), kidney cysts (7.8%), and cirrhosis-like 
condition (0.7%).  
We did not identify any significant association between the O. viverrini infection 
intensity and the left liver lobe enlargement (P=0.27), gallbladder retraction capacity 
after meal (length difference pre- and post-fatty meal, P= 0.46), grade of periductal 
fibrosis (P=0.38), presence of gall stones (P= 0.44) and other pathogenesis (i.e., kidney 
stone(s) and kidney cyst(s), P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 Study flowchart detailing the study participants in 10 villages, Saravane 
district, Saravane province, Lao PDR 
 
 
Eligible with stool 
examination in 10 villages 
(n=840) 
Ultrasound examination 
(n=431) 
Excluded (n =283):  
- Age < 20 years old (n=249) 
- Cholecytectomie (n=9) 
- Other reasons (n=25) 
O. viverrini positive patients 
 (n=714) 
Patients with lesions 
suspected 
Cholangiocarcinoma 
(n=5) 
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Table 7.1 General characteristics of study participants (n = 431) 
Characteristics 
 
  n (%) 
Age (years]   
 20-29 75 (17) 
 30-39 130 (30) 
 40-49 92 (21) 
 ≥ 50+ 134 (31) 
Sex   
 Male 182 (42) 
 Female 249 (58) 
Ethnic group   
 Lao Loum 294 (68) 
 Lao Theung 137 (32) 
Profession   
 Farmer 427 (99) 
 Other  4 (1) 
Education   
 Illiterate 413 (96) 
 Primary 8 (2) 
 Secondary, and above 10 (2) 
O. viverrini infection 
intensity 
  
 GM egg counts (EPG) 3961 
 Min – Max of egg counts (EPG) 24 – 69,648 
     Intensity groups a   
 Light (≤ 500 EPG) 173 (40) 
 Moderate (501-999 EPG) 63 (15) 
 Heavy (1000-1999 EPG) 61 (14) 
 Very heavy (≥ 2000 EPG) 134 (31) 
Data are numbers and (%) of subjects; a according to Sripa and colleagues [18], based on 
Kato-Katz thick smear examinations; GM- geometric mean, EPG eggs per gram stool 
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7.4.3 Prevalence of Suspected CCA  
Five patients had liver masses suspected for CCA diagnosed by ultrasonography, 
representing 1.2% of the random sample of O. viverrini infected patients (Table 7.2, 7.3). 
These patients, 2 men and 3 women, had a mean age of 52 years (range 36 – 67 years). 
They were referred to the regional hospital in Pakse (Champasack province) for further 
examinations. All had abnormal renal function tests that did not allow performing 
further diagnostic procedures such as e.g. endoscopic retrograde 
cholangiopancreatography. Hence, no further targeted diagnosis could be performed. 
 
Two patients had a heavy and three had very heavy O. viverrini infection intensity 
(Table 7.3). All cases had normal liver function tests (AST, ALT, ALP, bilirubine), except 
one male and one female patient with markedly increased levels of AST, ALT, ALP 
(248.16 mg/dl) and bilirubine (13.3 g/l), indicating that pathology may develop to 
prevent the biliary circulation (Figure 7.3). In none of the cases a hepatitis B or C was 
diagnosed. Tumor markers of all five patients, namely IL-6, PAI and CA19-9, were in a 
normal range.  
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Table 7.2 Hepatobiliary morbidity in Opisthorchis viverrini infected adult 
patients (n=431) 
Morbidity 
 
 n (%) 
Height of left liver lobe (cm)  Mean (SD) 5.4 (1.0) 
   
Normal parenchyma Grade 0 41 (9) 
Mild periductal fibrosis Grade 1+ 30 (7) 
Moderate periductal fibrosis Grade 2+ 287 (67) 
Advanced periductal fibrosis Grade 3+ 73 (17) 
   
Suspected lesion of CCA   5 (1) 
Cirrhosis  3 (1) 
   
Fatty liver  52 (12.1) 
Length pre-fatty meal (cm)  Mean (95% CI) 6.9 (6.8-7.1) 
Length, post-fatty meal (cm)  Mean (95% CI) 5.5 (6.9-7.1) 
“Pre” minus “post” fatty meal (cm)   1.4 
   
Gallbladder pathologies   
     Wall thickness  5 (1) 
     Wall irregularity  2 (0.5) 
     sludge present  6 (1) 
     stone present  57 (13) 
   
Bile duct dilated  10 (2) 
Intra hepatic duct stone   1 (0.2) 
Data are numbers; (%) of subjects, unless otherwise indicated 
 
 
 
 
7. Suspected Cholangiocarcinoma 
 
 
103 
Table 7.3 Follow-up examination of five suspected CCA cases 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Age (years), sex 65, m 48, m 36, f 45, f 67, f 
Liver function tests      
     AST(IU/l) 127 39 49 30 23 
     ALT (IU/l) 47.0 35.9 45.9 37.9 16.7 
     Total bilirubine  13.3 8.6 9.5 8.5 10.3 
     Albumin (g/l) 6.8 4.9 5.3 4.3 3.3 
     ALP 248.16 75.2 55.4 65.34 74.8 
     GGT (IU/l) 147.9 10.3 6.8 9.9 8.8 
     AFP (IU/l) 0.8 0.3 0.2 0.04 0.1 
     Creatinine (mg/dl) 1109.0 173.0 1335.0 1128.0 1278.0 
Tumor markers      
     IL-6 (pg/ml) <10 <10 < 10 11.5 <10 
     PAI (pg/ml) 5700.8 14249.6 9891.1 19840.9 16826.5 
     CA 19-9 25.0 20.0 12.9 12.8 14.6 
Infections      
     O. viverrini (EPG) 
     (infection intensity) 
1968 
(heavy) 
2878 
(very heavy) 
3734 
(very heavy) 
1752 
(heavy) 
4680 
(very heavy) 
     HBsAg-HBV neg. neg. neg. neg. neg. 
     HCsAg-HCV neg. neg. neg. neg. neg. 
Reported ill health 
 
Intense jaundice Absence Absence Absence Moderate 
jaundice, mass 
palpabal at 
RUQ 
Ultrasonography 
findings 
Liver categorized 
as grade 2+, liver 
mass in segment 
7, markedly 
dilated bile duct, 
intrahepatic 
stones 
Liver 
grade 2+, liver 
mass in 
segment 5, no 
dilated bile duct 
detected 
Liver 
grade 3+, 
liver mass in 
segment 5, 
no dilated 
bile duct 
detected 
Liver 
grade 2+, fatty 
liver mass 
presence in 
segment 5 of 
liver, no dilated 
bile duct 
detected, left 
hydronephosis 
Liver 
grade 3+, fatty 
liver mass 
presence in 
segment 5 of 
liver , no 
dilated bile 
duct detected 
Data are no; (%) of subject; EPG, egg per gram faeces, ALT alanine aminotransferase; AFP Alpha fetoprotein; ALP alkaline phosphatase; AST 
aspartate aminotransferase; CA 19-9 Carbohydrate antigen 19-9; f female; GGT Gamma-glutamyl transferase (GGT); HBsAg hepatitis B surface 
antigen; HCsAg hepatitis C surface antigen; IL-6 Interleukin 6, m male; neg. negative; PAI plasminogen activator inhibitor; RUQ right upper quadrant 
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Figure 7.2: Liver parenchyma fibrosis observed: (1+) starry sky (top, left); (2+) rings 
and pipe stems (top, right); (3+) highly echogenic ‘patches’ extending to peripheral 
(bottom) areas 
 
 
 
 
7. Suspected Cholangiocarcinoma 
 
 
105 
 
 
 
Figure 7.3: Patient (male, age 65 year): (A) with solid mass lesion with well-defined 
contour in right liver lobe; (B) Mechanical bile duct dilatation due to the mass 
 
7.5 Discussion 
We assessed the degree of hepatobiliary pathology including lesions suggestive of CCA 
in rural communities in Southern Laos where O. viverrini infection is highly endemic. 
Among a random sample of O. viverrini infected adult individuals of 10 villages, we 
identified a rampant prevalence of clinically hepatobiliar pathology, i.e., 83.5% had a 
moderate or advanced periportal fibrosis; only 9.5% of the examined persons had a 
normal liver parenchyma. Fatty liver were very frequent (12.5%). In five patients 
representing 1.2% of the sample such lesions were observed. This is the first study 
reporting on suspecting CCA lesions in communities in Laos. 
O. viverrini infection leads to variety of hepatobiliar diseases [21,22] ranging from non-
specific or asymptomatic cases, such as upper right quadrant pain or abdominal 
irritations to severe manifestations, namely cholangitis, obstructive jaundice, 
cholelithiasis, gall stones and liver periductal fibrosis, and the most severe outcome of a 
chronic infection, a fatal bile-duct cancer (cholangiocarcinoma). The clinical 
manifestations in our study were similar to previously reported manifestations. 
B 
A 
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However, they were diagnosed in rampant prevalence rates. In our study advanced 
periportal fibrosis was seen in 83.5% of participants, which is three times higher 
compared with reports from neighboring Thailand [18,21]. Also, gallbladder and 
intrahepatic stones, bile duct dilatation and fatty livers were diagnosed in high 
frequencies. Of note, 9 of the identified study participants could not be enrolled due to 
their precedent cholecystectomy which is further documenting the excess hepatobiliar 
pathology burden in our setting. The heavy O. viverrini infection intensity in our setting 
is the most likely explanation for the high level of morbidity. The mean infection 
intensity of 3961 eggs per gram of stool was observed and 45% of the patients had 
heavy or very heavy infection intensity.  
O. viverrini infection has been classified as Group 1 carcinogen agent triggering CCA 
development [23]. In Northeast Thailand an estimated 60% of CCA cases are due to 
O. viverrini infection [6,24]. Direct irritations from the fluke in the bile ducts and 
immunopathological pathways of the parasite toxins are recognised mechanisms. 
Nonetheless, cholangiocarcinoma has multi-factorial origins [25]. Various additional 
stressors such as N-nitrosamide from foodstuff such as fermented fish sauce “Pa dek” 
[26], have been identified as important determinants. All the stressors reported in 
Thailand are also highly prevalent in our study setting in Southern Laos.  
The world’s highest CCA prevalence and incidence is recorded in Northeast Thailand 
[25,26] where 71% of primary cancer is CCA [4,6]. In our study, of 431 subjects five 
patients had lesions suspicious of CCA. The suspected diagnosis was based on invasively 
growing liver masses. They were typical for those seen in confirmed CCA patients. 
Furthermore, all patients had a heavy or very heavy O. viverrini infection intensity 
which is a known determinant of CCA development [4,6]. In addition, all five cases 
reported other ill health problems such as high blood creatinine level, and liver function 
test. All had advanced periductal fibrosis (case 1, 5 = Grade 3+: case 2, 3, 4 = Grade 2+). 
These observations are typical signs in CCA patients in Thailand [21,24].  
Early clinical signs and symptoms of CCA patients are related to biliary obstructions, 
jaundice, pale stool, dark urine, and puritus. In addition, other symptoms are increased 
liver mass, right upper quadrant pain, fever and weight loss [27,28]. Of five suspected 
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CCA cases, two of suspected CCA cases showed moderate to intense jaundice with bile 
duct dilatation detected by US.  
Liver function tests performed on suspected CCA patients were with the normal range. 
In CCA patients liver function is preserved over a long period of time in illness [29]. The 
proposed tumor markers for CCA, i.e., IL-6, CA 19-9 and PAI were also in the normal 
range. Biochemical test are not specific for CCA except for CEA and CA19-9 [30, 31]. A 
recent case control study focused on the parasite-specific interleukin-6 (IL-6) promising 
marker in detecting the pathogenesis of advanced periductal fibrosis in individuals 
infected with chronic O. viverrini [18]. Given that these markers measures advanced CCA 
[19], their values indicate that our cases might still be in an earlier stage of 
development.  
A final diagnosis for our suspected CCA cases could not be confirmed. High blood 
creatinine levels were measured in all patients which is a contraindication for imaging 
diagnosis, namely CT scan, and Endoscopic Retrograde Cholangiopancreatography 
(ERCP). These imaging techniques include the use of iodinated radiocontrast through 
intravenous injection, which can lead to renal failure in patient with high blood 
creatinine.  
In the absence of these further diagnostic results we can not definitively conclude on a 
CCA diagnosis. Hence, these suspected CCA lesions are currently the best available 
information on CCA in communities in Laos. In a recent ultrasonographical 
hepatobiliary morbidity survey in Champasack province a similar prevalence of 1% (8 
among 800 examined) suspected CCA lesions were recored (pers. communication, Dr. 
Bouasy Hongvanthong). These findings warrant further investigations with 
confirmation of CCA. 
We noted Opisthorchis-associated nephropathy in our population study such as kidney 
stone(s) (8.6%), kidney cyst(s) (7.9%), and hydronephosis (1.6%) among individuals 
infected with O. viverrini. Only kidney cyst showed association with APF. This finding is 
consistent with recent reports on kidney pathogenesis observed in hamsters with 
infected O. viverrini [32]. 
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In our study a relative small number of study participants were included. As O. viverrini 
infections occur in clusters, larger studies in settings with varying prevalence rates are 
required to assess the region specific morbidity and cancer risks, and hence to assess 
the Lao morbidity burden. In a recent global burden of disease initiative the burden of 
food-borne trematodiasis was estimated at 665,352 DALYs (479,496 - 859,051 DALYs) 
[33]. This is most likely crude underestimation of the burden as it did not take into 
account the actual burden as they were missing in high endemic areas.  
However, this study documents the importance of liver fluke infection in terms of mild 
to severe hepatobiliary morbidity. CCA diagnosis is not possible in Laos due to the lack 
diagnostic (i.e., imaging techniques, liver biopsy) and adequate case management 
facilities. Suspected cases diagnosed in hospitals in Vientiane and elsewhere in Laos are 
referred to hospitals in Thailand, i.e. to Khon Kaen, Oubon Ratchathani, and Mukdahan. 
For those confirmed with a CCA symptomatic treatment is proposed.  
Mass lesions could have resulted from other common malignant hepatobiliary, namely 
hepatocarcinoma or hepatitis B and C viruses which are also common in Southeast Asia 
and possible risk factor for CCA [34]. Furthermore, there is evidence that other 
predisposing factors for CCA such as primary and secondary sclerosing cholangitis, 
malformations (choledochal cyst, Caroli’s disease), thorotrast, alcohol consumption, 
obesity, and smoking may play a role [35,36]. Differential diagnosis of morbidity must 
thus be investigated in more detail in further studies. 
This study is a first attempt to quantify mild to severe morbidity including the presence 
of malignant lesions in rural communities in Laos where the prevalence of O. viverrini 
infection is high. The absence of a conclusive diagnosis for the severe sequelae is 
hampering the estimation of the CCA burden in Laos. Furthermore, the facilities of 
advanced and less invasive diagnostic procedures such as ERCP, MRI and MRCP for 
suspected CCA cases are warranted to investigate the burden of hepatobiliary 
morbidities in O. viverrini-endemic settings in Laos.  
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8.1 Abstract  
Cholangiocarcinoma poses a significant public health problem in Southeast Asia. 
Chronic infection due to liver fluke, Opisthorchis viverrini is believed to be a key risk 
factor to develop CCA. O. viverrini is known to be prevalent in Lao PDR, no 
epidemiological-based evidence of CCA has been determined in Lao PDR. A hospital-
based, retrospective study was carried out in all referral hospitals in Lao PDR, including 
4 representative hospitals in the center, one in the north and one in the South. All 
medical records of patients admitted during 2006-2010 to the hospital and diagnosed 
with suspected CCA were retrospectively reviewed and based on selected criteria. In 
total 247 were suggestive to CCA lesion detected by ultrasound and CT scan. Male 
gender and age of 50 years and above were predictors of suspected cases. The majority 
of suspected CCA case was admitted at the hospitals in the central (58.0%) and 
southern (29.6%) parts of Laos accompanied by abdominal pain (48.5%) and jaundice 
(14.2%). Of the 274 individual records, 267 (97.4%) of the patients had dilated bile 
duct; 40 (74.1%) had gallstone or intrahepatic stone, and 33 (12%) were 
parasitologically confirmed with O. viverrini. This study provides the first estimated 
numbers of suspected CCA admitted at the hospitals in Lao PDR. Definite diagnosis of 
CCA was not possible. Therefore, case diagnosis and good registration of suspected CCA 
cases are warranted as evidence for large-scale studies, and to develop preventive and 
curative health services. 
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8.2 Introduction 
Cholangiocarcinoma (bile duct cancer, CCA) is a rare cancer in the world but poses a 
significant public health importance in Southeast (Andrews e al., 2008; Keiser  and 
Utzinger, 2009; Sripa et al., 2010). CCA has been recognized as primary cancer of the 
epithelial cell of hepatic bile ducts. The main risk factor is a chronic infection with a liver 
fluke (Opisthorchis viverrini) (Keiser  and Utzinger, 2009; Sripa et al 2007). other risk 
factors such as dietary intake of nitrate and nitrosamines, aflatoxin B1, smoking, 
excessive alcohol consumption, obesity as well as chronic hepatitis B and C (HBV and 
HBC) infection also contribute to increase a risk of CCA, however, the exact etiology is 
unclear (Shin et al., 2010). 
Today, no cancer registration exists in Lao PDR and the incidence of CCA, precancerous 
lesions and precancerous conditions of CCA are unknown. However, given the high 
infection rates with O. viverrini which are similar (Chai et al., 2005; Rim et al., 2003; 
Sripa et al., 2007) or beyond the rates in neighboring Thailand, the incidence of CCA is 
believed to be comparable to north-eastern Thailand or beyond. The incidence of CCA 
and O. viverrini in Thailand from 1990-2001 account for 118.8 per 100 000 person years 
(Sripa et al., 2007). 
Here, we aimed to investigate the estimated numbers of suspected CCA cases in 
hospital-based settings in Lao PDR. 
 
8.3 Methods 
8.3.1 Study site and patients 
Observations were made with all medical records retrospectively reviewed of patients 
admitted and diagnosed with suspected CCA at the central hospitals in North, Central 
and South of Lao PDR. There were totally 6 hospital representatives. Of six hospitals, 
three hospitals are located in Vientiane capital, which are part of the university 
hospitals. Each suspected case of the records was filled into a questionnaire form. 
Demographic data (sex, age, village of residence), other pathologies and diagnosis 
techniques employed were filled into the questionnaire. For the sample size, we went 
through the patient record archives (all records) of the referral hospitals to identify all 
patients with ultrasound, CT scan (and other imagine device) and clinical information 
on suspected CCA. Records of patients who visited the hospitals between 1 January 
2006 and 31 December 2010 were reviewed and included in the study. 
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8.3.2 Case definition to identify suspected CCA patients 
The definitions of the CCA cases were based on the previous studies performed in 
endemic areas where the prevalence of CCA is high (Mairiang et al., 2011; Sripa et al., 
2010a). (i) Confirmed CCA case: the final histopathological results must be confirmed 
(with biopsy). This diagnosis is not performed in Lao PDR. (ii) Suspected CCA case: As 
indicators of morbidity the following clinical features related to CCA were used: (a) a 
single/multiple mass (es), (b) a dilated intrahepatic duct, or (c) a hydrop gall bladder 
found by U/S, CT scan, Magnetic resonance imaging (MRI), ERCP or MRCP; Biochemical 
test required related to CCA were serum alkaline phosphatase (ALP), gamma-
glutamyltransferase (γ-DT), CEA and CA19-9 and AFP. In addition, other data were 
collated from the records including: the sex and age of each patients, original province 
of patients, hospital complaints on admission, onset of symptoms, individual and family 
past history, laboratory data collected during their hospitalization, location or the 
tumour detected by ultrasound, CT scan, MRI, ERCP, MRCP, final histopathological 
results, final diagnosis and prognosis, appropriated treatment. In records of ultrasound 
examination and CT scans of abdominal tract hepatobiliar abnormalities were reported: 
dilation of biliary tree, mass in liver associated +/- gall bladder anormalities (Gall 
bladder stone (GBS) and bile duct stone; any evidence of intrahepatic duct dilatation 
(IHDD), extrahepatic duct dilatation diagnosed was transcribed from records to the 
study questionnaire.  
 
8.3.3 Data management and analysis 
Data was double-entered and validated in Epidata 3.1 (Epidata Association; Odense, 
Denmark). Statistical analyses were performed with STATA statistical software, version 
10.1 (Stata Corp.; College Station, TX, USA). Descriptive data were presented in 
percentage and numbers. 
 
8.4 Results  
Of 274 suspected CCA patients admitted at the 6 referral hospitals across the country, 
namely one hospital in the Northern, 3 hospitals in central and 2 hospitals in the 
southern part of Lao PDR. Male (74.8%) was the most predominant among the 
suspected cases versus female (25.3%). Median age was 57 years, with peak of age 
group was among those > 50 years (76.3%). The overall admission of cases was the 
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referral hospitals in the capital city (66.5%). The average of year of documentation 
archives at the hospital was 3.3 years. Half of cases were found mostly in the central 
part of Lao PDR (43.1%) (Table 8.1). Additionally, we found 58% of patients were 
originally from the central part, 29.6% from the south and 12.4% from the north part of 
the country made by their permanent residency (Figure 8.1). 
 
 
Table 8.1 Patients’ characteristics 
  N° of patients 
(n= 274) 
Age [years]   
 Median 57 
 20-29 0 (0) 
 30-39 8 (2.9) 
 40-49 57 (20.8) 
 50+ 209 (76.3) 
Sex   
 Male 205 (74.8) 
 Female  
Hospitals   
 Luang Prabang Hospital  15 (5.47) 
 Savanakhet Hospital 22 (8.3) 
 Champasak Hospital 55 (20.1) 
 Mahosot hospital* 77 (28.1) 
 Friendship hospital* 55 (20.1) 
 Sethathirath hospital* 50 (18.3) 
Original province of patients   
 Oudomxay 1 (0.36) 
 Xieng Khouang Province 4 (1.46) 
 Luang Prabang Province 25 (9.12) 
 Sayaboury Province 4 (1.46) 
 Vientiane Province 29 (10.58) 
 Vienitane capital Province 118 (43.07) 
 Bolikhamxay Province 5 (1.82) 
 Khammouane Province 7 (2.55) 
 Savanakhet Province 25 (9.12) 
 Champasack Province 51 (18.61) 
Number of years included 
related to patients’ record  
  
[Years] Luang Prabang Hospital  2 
 Savanakhet Hospital 5 
 Champasak Hospital 4 
 Mahosot hospital 2 
 Friendship hospital 2 
 Sethathirath hospital 4 
Data are no; (%) of subjects, otherwise indicated [year], *  centered hospitals in Vientiane capital 
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North, 12.4%
Center, 58.0%
South, 29.6%
North Center South
Figure 8.1 Records of suspected CCA patients diagnosed at the referral hospitals of Lao 
PDR from 2006-2010 by area 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Of 274 suspected CCA cases, 57 (20.8%) patients were previously admitted to a 
hospital. Suspected CCA patients had also abdominal pain (48.5%), jaundice (20.9%) 
and jaundice with abdominal (14.2%) (Table 6). All CCA suspected patients (100%) 
underwent ultrasonography examination, however, CT scan results was found only in 
55 cases (20.1%). 267 patients (97.4%) had a bile duct dilatation, 40 patients (74.1%) 
presented either stone in the gall bladder or intrahepatic ducts (Table 8.2).  
The biochemistry of suspected CCA patients was shown in Table 8.3. Most of levels of 
liver function test ALT, AST, and ALP were increased among the advanced pathology 
cases. All patients were negative for HBsAg-HBV and HBcAg-HCV. Of 222 cases with 
parasitological examination, 33 (12.0%) cases were infected with O. viverrini. 
Histopathology is not performed for any suspected CCA case because it was not 
available in Lao PDR. Only symptomatic treatments were offered to patients. No 
resectable tumor and other surgical bypass namely palliative plastic or metal stents 
were available at the hospitals across the country.  
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Table 8.2 Results of patients’ investigations 
 Total N° of patients 
(n= 274) 
Chief of complaints (n= 274)  
Jaundice or icteric skin  57 (20.9) 
Abdominal pain  133 (48.5) 
Fever  31 (11.3) 
Jaundice and abdominal  39(14.2) 
Others (abdominal mass, fatigue, constipation, ect)  14(5.1) 
History of hospitalization (n= 274)  
Previous admission  57 (20.8) 
None  217 (79.2) 
Symptoms and diagnosis for previous discharge (n= 57)  
Cholecystitis  12 (21.0) 
Hepatitis  5 (8.8) 
Suspected Cholangiocarcinoma  18 (31.6) 
Dyspepsia  9 (15.8) 
Hepato-carcinoma cellulaire  11 (19.3) 
Others  2 (3.5) 
Patients underwent the U/S examination  (n= 274)  
Yes  274 (100.0) 
Mass characteristics (n= 274)  
Single mass  46 (16.8) 
complex masses  228 (83.2) 
Location of mass(es) in liver performed by U/S (n= 274)  
Segment 1   
Yes  2 (0.7) 
No  272 (99.3) 
Segment 2   
Yes  3 (1.1) 
No  271(98.9) 
Segment 3   
Yes  4 (1.5) 
No  270 (98.5) 
Segment 4   
Yes  26 (9.5) 
No  248 (90.5) 
Segment 5   
Yes  40 (14.6) 
No  234 (85.4) 
Segment 6   
Yes  32 (11.7) 
No  242 (88.3) 
Segment 7   
Yes  47 (17.2) 
No  227 (82.8) 
Segment 8   
Yes  29 (10.6) 
No  245 (98.4) 
Undefined segment   
Yes  174 (63.5) 
No  100 (36.5) 
Data are no; (%) of subjects¸ CT scan- computerised tomography scan; U/S- ultrasonography 
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Table 8.3 Performance characteristics of laboratory among 274 suspected CCA cases 
 
Liver function test 
 Total 
(n=274) 
Number of patient 
with normal value 
Numberof patient 
anormal value 
WBC     
 Mean (SD) 13768.1 (6992.1) 4.1-10.9x103/µL 168 (62.7) 
 Range 4.3-6.1 x103   
SGOT/AST(IU/l)     
 Mean (SD) 153.4(144.8) 0-35 IU/l 266 (97.1) 
 Range 23-1022   
SGPT/ALT (IU/l)     
 Mean (SD) 112.1 (113.11) 0-45 IU/l 215 (78.5) 
 Range 8.3-934   
Total bilirubine      
 Mean (SD) 23.5 (42.0) 2-17 μmol/l 256 (95.2) 
 Range    
ALP     
 Mean (SD) 530.2 (617.4) 30-120 IU/l 241 (88.0) 
 Range 14.7-4899   
GGT(IU/l)  (n=23)   
 Mean (SD) 166.4 (114.9) 0-30 IU/l 22 (95.7) 
 Range 28.0-513.0   
AFP (IU/l)  (n=49)   
 Mean (SD) 10.32 (56.9) 0-44 ng/mL 1 (2.0) 
 Range 0.02-400   
HBsAg-HBV  (n=268)   
 Yes   265 (98.9) 
 No   3 (1.1) 
HBcAg- HCV  (n=269)   
 Yes   266 (99.6) 
 No   1 (0.4) 
Stool exam  (n=274)   
 Yes   265 (96.7) 
 No   9 (3.3) 
Stool results  (n=265)   
Negative    220 (83.6) 
Hookworm    4 (1.5) 
Opisthorchis viverrini    33 (12.0) 
Trichomonas hominis    1 (0.4) 
Strongyroid 
stercolaris 
   5 (1.8) 
Ascaris    2 (0.7) 
Data are no; (%) of subject, otherwise indicated (standard deviation); WBC- white blood cell count, SGOP/ AST-
Aspartate aminotransferase; SGPT/ALT-Alanine aminotransferase; ALP-Alkaline phosphatase; HBsAg- surface antigen 
of the Hepatitis-B-Virus (HBV) ; HBcAg- surface antigen of the Hepatitis-C-Virus (HCV) ; AFP-Alpha-Fetoprotein serum; 
GG- Gamma GT 
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8.5 Discussion  
We investigated the incidence of suspected CCA cases using hospital records of 
reference hospitals in Lao PDR. To our knowledge this study has not been documented 
to date in Lao PDR. The diagnosis of CCA in Laos is likely to be very difficult due to lack 
of diagnostic tools and accessibility of treatment. All suspected cases admitted at the 
hospitals had undergone abdominal ultrasound, then CT or ERCP. Most of suspected 
cases admitted at the hospitals, in particularly from provincial hospitals need to refer 
their patient for further investigations at the central hospitals in Vientiane, for instances 
biologic marker test, CT scan and recently ERCP has been available at Mahosot Hospital, 
Vientiane Capital, Lao PDR. Our finding found that all records, patients were treated 
only symptomatic treatment for suspected CCA mitigation. None of further palliative 
treatment were not applicable, such as chemo- and radiotherapy, palliative plastic or 
metal stent (biliary stenting), PTBD (percutaneous biliary drainage), respectable tumor 
bypass which allow to relieve biliary obstruction and pain for the CCA patients (Aljiffry, 
2009; Khan, 2005). PTBD and plastic or metal stent or pre-operative biliary drainage 
are widely used over the past few decades in the treatment of biliary diseases especially 
those due to unresectable malignant tumors for instance CCA, primary sclerosing 
cholangitis, cholangitis secondary (Aljiffry, 2009; Panpimanmas, 2011). At present, 
suspected CCA case numbers presented at the admission are accompanied with typical 
jaundice and right upper quadrant pain as confirmed in our studies. Some of them were 
seen annually through check-ups at the hospital.  
In the diagnosis of CCA the first diagnostic imaging procedure is sonography which is 
the most useful tool for initial screening assessment guide to demonstrate the bile duct 
dilatation (Saini, 1997; Sharma, 1999). Abdominal computed tomography is the next 
examination for the extent to the tumour and the regional node involvement. In some 
case ultrasound can identify obstruction and ductal dilatation with providing a direct 
image of pathologic changes and in some cases may be sufficient to diagnose CCA. All 
suspected cases in our study had been initially examined by abdominal ultrasound, then 
CT (computed tomography), PTC (percutaneous transhepatic cholangiography), ERCP 
(endoscopic retrograde chanlangiopancreaticography), MRI (magnetic resonance 
imaging) and MRCP (magnetic resonance cholangiopancreatography). MRI along with 
MRCP provides more accurate diagnosis comprisable to invasive cholangiographic 
technique, namely ERCP or PTC (Manfredi, 2001; Varghese, 1999). This study showed 
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58.0%, 29.6% and 12.4 % of patients were admitted in the center, south and north at 
the referral hospital, accompanied with jaundice which is the main clinical 
manifestation of CCA. This observation was in line with the main cause of patient’s 
hospitalization due to CCA that accounted for 60% of northeast hospital in Thailand 
(Mairiang, 2003; Sripa et al., 2010b). The majority of patients referred to central 
hospital (the central part of Laos) (i.e., Mahosot, Sethathirath and Friendship hospitals) 
which could be explained by affordability, reliable medical provider and enable to 
access the health care facility. 
The prevalence of CCA liver increases according to the infection intensity of O. viverrini 
is the most exposure to CCA (Keiser and Uzinger, 2009; Sripa et al., 2010a; Sripa et al., 
2010b). However, our findings were shown only 12% patients infected with O. viverrini. 
These numbers underestimate the true infection rates among patients admitted as 
hospitals have been conducted on fecal fresh examination which has only a low 
sensitivity. Viral hepatitis B and C has known to be prevalent in Southeast Asians and a 
risk factor for CCA (Honjo et al., 2005). The prevalence of hepatitis is unknown in Laos. 
This study reported 19.3% suspected hepatocarcinoma, of whom no case reported 
hepatitis B and C infection. 
In short, we have a shortage of standard medical records. Number of records available 
keeping in archives at the hospitals was short. Quality of records depended on hospitals, 
facilities and medical. Hospitals had very limited data storage, which were mostly 
available only hard file.  Little information on final diagnosis, treatment and evaluation 
of patients were performed. Demographic information were not originally defined the 
patients’ residence when they admitted. Therefore, improvement of hospital 
information system as well as health information will provide crucial information on 
impact of hepatobiliary disease induced by O. viverrini in terms of crude incidence and 
spark interest to conduct the further broaden investigation. 
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9.1 Abstract 
Background: Albendazole and mebendazole are increasingly deployed for preventive 
chemotherapy targeting soil-transmitted helminth (STH) infections. We assessed the 
efficacies of single oral doses of albendazole (400 mg) and mebendazole (500 mg) for 
the treatment of hookworm infection in school-aged children in Lao PDR. Since 
Opisthorchis viverrini is co-endemic in our study setting, the effect of the two drugs 
could also be determined against this liver fluke. 
Methodology/Principal findings:  We conducted a randomized open-label, two-arm trial. 
In total, 200 children infected with hookworm (determined by quadruplicate Kato-Katz 
thick smears derived from two stool samples) were randomly assigned to albendazole 
(n=100) and mebendazole (n=100). Cure rate (CR; percentage of children who became 
egg-negative after treatment), and egg reduction rate (ERR; reduction in the geometric 
mean fecal egg count at treatment follow-up compared to baseline) at 21-23 days 
posttreatment were used as primary outcome measures. Adverse events were 
monitored 3 hours posttreatment. Single-dose albendazole and mebendazole resulted 
in CRs of 36.0% and 17.6% (odds ratio: 0.4; 95% confidence interval: 0.2-0.8; P=0.01), 
and ERRs of 86.7% and 76.3%, respectively. In children co-infected with O. viverrini, 
albendazole and mebendazole showed low CRs (33.3% and 24.2%, respectively) and 
moderate ERRs (82.1% and 78.2%, respectively). 
Conclusions/Significance: Both albendazole and mebendazole showed disappointing CRs 
against hookworm, but albendazole cured infection and reduced intensity of infection 
with a higher efficacy than mebendazole. Single-dose administrations showed an effect 
against O. viverrini, and hence it will be interesting to monitor for potential ancillary 
benefits of preventive chemotherapy targeting STHs in areas where opisthorchiasis is 
co-endemic. 
Clinical Trial Registration: Current Controlled Trials ISRCTN29126001 
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9.2 Author Summary 
Parasitic worms remain a public health problem in developing countries. Regular 
deworming with the drugs albendazole and mebendazole is the current global control 
strategy. We assessed the efficacies of a single tablet of albendazole (400 mg) and 
mebendazole (500 mg) against hookworm in children of southern Laos. From each 
child, two stool samples were examined for the presence and number of hookworm 
eggs. Two hundred children were found to be infected. They were randomly assigned to 
albendazole (n=100) or mebendazole (n=100) treatment. Three weeks after treatment, 
another two stool samples were analyzed for hookworm eggs. Thirty-two children who 
received albendazole had no hookworm eggs anymore in their stool, while only 15 
children who received mebendazole were found egg-negative. The total number of 
hookworm eggs was reduced by 85.3% in the albendazole and 74.5% in the 
mebendazole group. About one third of the children who were co-infected with the 
Asian liver fluke Opisthorchis viverrini were cleared from this infection following 
albendazole treatment and about one forth in the mebendazole group. Concluding, both 
albendazole and mebendazole showed disappointing results against hookworm, with 
albendazole performing somewhat better. The effect of these two drugs against 
O. viverrini should be studied in greater depth. 
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9.3 Introduction 
Infections with the three common soil-transmitted helminths (STHs), Ascaris 
lumbricoides, Trichuris trichiura, and hookworm (Ancylostoma duodenale and Necator 
americanus), are a global public-health concern, particularly in areas where poor 
sanitation prevails [1,2]. STH infections are among the most widespread of the 
neglected tropical diseases (NTDs) [3]. Indeed, more than a billion people are currently 
infected with one or several STH species, even though growing efforts are underway to 
control these parasitic worm infections [4]. In terms of their estimated global burden, 
hookworm is the most important among the STHs, as it might cause the loss of over 20 
million disability-adjusted life years (DALYs) among the estimated 600 million infected 
people worldwide [1,5]. Chronic hookworm infection cause intestinal blood loss and 
result in poor iron status and iron-deficiency anemia, particularly in children, and 
women in reproductive age [1,6,7]. As a consequence, permanent impairment, including 
delayed physical and cognitive development, has been described [8]. 
In the absence of a vaccine, the global strategy to control STHs and other NTDs is to 
reduce morbidity through repeated large-scale administration of anthelmintic drugs, a 
strategy phrased preventive chemotherapy [8]. At present, the World Health 
Organization (WHO) recommends four drugs against STH infections, whereas 
albendazole and mebendazole are the two most widely used for preventive 
chemotherapy [9]. In 2008, in the Western Pacific Region, 33.4 million children were 
given anthelmintic drugs [10]. According to the Lao national scheme for school 
deworming, there is a treatment round at the beginning of the first semester 
(September-December) and in the second semester (January-April). Mebendazole 
(single 500 mg oral dose) is annually distributed to all school-aged children since 2005 
[11]. Recent efforts have been made to provide mebendazole also to preschool-aged 
children through the Expanded Program on Immunization (EPI) and vitamin A 
distribution [4,12]. However, the efficacy of mebendazole and albendazole against STH 
infections in Lao PDR remains to be determined, and such locally derived evidence is 
important to guide national treatment policies. 
The liver fluke Opisthorchis viverrini is co-endemic in Lao PDR, and particularly high 
prevalences have been observed in the southern provinces [13-16]. Praziquantel is the 
current drug of choice against O. viverrini [3]. Previous work has shown that multiple 
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doses of albendazole also show some effect [17,18]. Hence, in areas where STHs and 
O. viverrini co-exist and preventive chemotherapy targeting STHs are under way, it will 
be interesting to monitor for potential ancillary benefits on opisthorchiasis. 
The purpose of this study was to assess the efficacy of a single oral dose of albendazole 
(400 mg) and mebendazole (500 mg) against hookworm infection among school-aged 
children in Lao PDR. In addition, the effect on other STHs (i.e., A. lumbricoides and 
T. trichiura) and O. viverrini in co-infected children were assessed. Our study 
complements a recent investigation, done in the People’s Republic of China comparing 
single and triple dosing with albendazole and mebendazole against the three common 
STHs [19]. 
 
9.4 Methods 
9.4.1 Ethical Considerations and Treatment 
The research protocol was approved by the Ethics Committee of Basel, Switzerland 
(EKBB; reference no. 146/08) and the Lao National Ethics Committee for Health 
Research (NECHR), Ministry of Health, Vientiane, Lao PDR (reference no. 170/NECHR). 
The trial is registered with Current Controlled Trials (identifier: ISRCTN29126001). 
Written informed consent was obtained from parents/legal guardians of eligible 
children. Participation was voluntary and children could withdraw from the trial at any 
time without further obligation. 
At completion of the trial, all children of the two primary schools and participants who 
were still found positive for hookworm (or other STHs) were treated with albendazole 
(400 mg). O. viverrini-infected children were administered praziquantel according to 
national guidelines [20]. 
 
9.4.2 Study Area and Population 
A randomized open-label trial was carried out between February and March 2009 in 2 
primary schools (Oudomsouk and Nongbok Noi) in Batieng district, Champasack 
province, southern Lao PDR. Children in the 2 schools were treated with mebendazole 
5-6 months prior to the start of our study. The schools are located approximately 15 km 
southeast of Pakse town, on the Bolaven plateau at an altitude of approximately 1000 m 
above sea level (geographical coordinates: 105°56’53” N latitude, 15°14’59” E 
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longitude). The rainy season lasts from May to mid-October. A census done in 2007 
revealed that 43,651 people lived in the 95 villages of Batieng district (Dr. Nanthasane 
Vannavong, Champasack Provincial Health Department; personal communication). 
More than three-quarter of the households (77.5%) lack appropriate sanitation. 
Drinking water is primarily obtained from unprotected boreholes or wells. Most 
villagers live on subsistence rice farming and rubber plantations (Dr. Nanthasane 
Vannavong, Champasak Provincial Health Department; personal communication). 
Infections with STHs and O. viverrini are common in Batieng district; a recent study 
revealed infection prevalences above 50% and 20%, respectively [21]. 
 
9.4.3 Study Design 
We designed a randomized, open-label trial comparing albendazole (single 400 mg 
dose) and mebendazole (single 500 mg dose) in the treatment of hookworm infection. 
The sample size was calculated based on results of a meta-analysis on the efficacy of 
current anthelmintic drugs against common STH infections, which reported cure rates 
(CR; defined as percentage of helminth-positive individuals who became helminth-egg 
negative after treatment) of 75% and 15% for albendazole (400 mg) and mebendazole 
(500 mg), respectively against hookworm infection [9]. In order to account for the large 
variation (uncertainty) of the observed efficacies of mebendazole in the individual 
studies (CRs of 8-91% were found in the six randomized controlled trials), we more 
than tripled the mean efficacy of mebendazole (50% instead of 15%). Assuming 
superiority of albendazole (1-tailed test) and taking into account a 90% power, and an 
alpha error of 5%, we obtained a sample size of 85 children per treatment group. 
Furthermore, we assumed a drop-out rate of 15%, which resulted in a total sample size 
of 200 hookworm-positive school-aged children. 
 
9.4.4 Field and Laboratory Procedures 
The teachers of the 2 primary schools, the children, and the staff of the National 
Institute of Public Health, Centre of Malaria, Parasitology and Entomology, Centre for 
Laboratory and Epidemiology, the Provincial Department of Health, the Provincial 
Hospital and the Malaria Station of Champassak, and the village authorities were 
informed 1 week in advance on the study aims and procedures. Potential risks and 
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benefits were explained to all children and their parents/guardians. An informed 
consent form was distributed to all parents/guardians and signed. Children assented 
orally. 
At baseline screening the consenting children (n=465) of the 2 schools, aged 6-12 years, 
provided two fresh stool samples within a period of 3 days. Stool containers were filled 
by children and transferred to a laboratory in the early morning (between 08:00 and 
09:00 hours). All collected specimens were worked up on the day of collection. From 
each stool sample, duplicate Kato-Katz thick smears were prepared on microscope 
slides, using standard 41.7 mg templates [22]. Kato-Katz thick smears were 
quantitatively examined under a light microscope for helminths with a 100x 
magnification. Slides were read within 30-45 min after preparation. A random sample of 
approximately 10% of the Kato-Katz thick smears were re-examined by 2 senior 
technicians for quality control purposes. In case of discrepancies (i.e., positive vs. 
negative results; egg counts differing by >10%), results were discussed with the 
respective technicians, and the slides re-examined until agreement was reached. 
In addition, a questionnaire was administered to each participating child to obtain 
sociodemographic data (i.e., sex, age, parent’s education and occupation, ethnic group, 
and sanitation infrastructure), and behavioral data (i.e., wearing shoes, sources of 
drinking water, food consumption, personal hygiene). Hookworm-positive children 
(defined by the presence of at least one hookworm egg in one of the quadruplicate Kato-
Katz thick smears examined per child) were invited for treatment (n=200). 
At enrollment, a clinical examination, which included measurement of weight (using an 
electronic balance measured to the nearest 0.1 kg), height (using a measuring tap fixed 
to the wall and measured to the nearest cm), and axcillary temperature (using battery-
powered thermometers, measured to the nearest 0.01°C), anemia assessment (finger 
prick capillary blood sample) was conducted and a medical history taken. Children were 
excluded if they had fever, or showed signs of severe malnutrition. Additional exclusion 
criteria were the presence of any abnormal medical condition such as cardiac, vascular, 
pulmonary, gastrointestinal, endocrine, neurologic, hematologic (e.g., thalassaemia), 
rheumatologic, psychiatric, or metabolic disturbances, recent history of anthelmintic 
treatment (e.g., albendazole, mebendazole, pyrantel pamoate, levamisole, ivermectin, 
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and praziquantel), attending other clinical trials during the study, or reported 
hypersensitivity to albendazole or mebendazole. 
At follow-up, 21-23 days after drug administration, 2 stool samples were collected from 
each child and transferred to a hospital laboratory within 1 hour after collection. Each 
stool specimen collected at follow-up was subjected to the same procedures as during 
the baseline survey. Hence, duplicate Kato-Katz thick smears were prepared from each 
stool sample, examined under a microscope within 30-45 min by experienced 
laboratory technicians, and helminth eggs were counted and recorded for each species 
separately. Quality control was in place as during the baseline survey. 
 
9.4.5 Randomization 
Children were randomly assigned to a single dose of albendazole (400 mg) or 
mebendazole (500 mg), using a block randomization procedure (six blocks each 
containing four treatment allocations), generated by an independent statistician who 
was not otherwise involved in the trial. The sequence of blocks was determined using a 
random number table. In addition, schools were decoded by a researcher to assign 
children either to albendazole or mebendazole. Eligible children were randomly 
assigned and allocated to treatment by an epidemiologist. Children and drug 
administrators were not blinded for drug treatment. Laboratory personnel and 
clinicians monitoring the adverse events were blinded throughout the study. 
 
9.4.6 Drugs and Adverse Events 
Albendazole (400 mg; Albendazole®, South Korea) was obtained from the Ministry of 
Health, Vientiane, Lao PDR. Mebendazole (500 mg; Vermox®, Italy) was donated by 
Johnson & Johnson Pharmaceuticals, provided through the Ministry of Health and the 
Ministry of Education, Vientiane, Lao PDR. At treatment day, both groups received the 
drugs under direct medical supervision on an empty stomach. Children were monitored 
for at least 3 hours after drug administration and asked to report for any drug-related 
adverse events using a standard questionnaire administered and graded by study 
physicians. 
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9.4.7 Statistical Analysis 
Data were double-entered and validated in EpiData version 3.1 (Epidata Association; 
Odense, Denmark). Statistical analyses were performed with STATA, version 10.1 (Stata 
Corp, College Station, TX, USA). Efficacy was calculated for both intention-to-treat (ITT) 
and per-protocol (PP) analyses. ITT analysis was based on the initial treatment intent. 
PP analysis included only those children who had complete data records (i.e., 
quadruplicate Kato-Katz thick smear reading before and after treatment, and full 
treatment compliance). 
Infections with hookworm, A. lumbricoides, T. trichiura, and O. viverrini were grouped 
into light, moderate, and heavy infections, according to WHO guidelines (for STHs) and 
cut-offs put forward by Maleewong et al. (for O. viverrini) [23-24]. Infection intensity 
classifications are as follows: hookworm, 1-1999 eggs per gram of stool (EPG) (light), 
2000-3999 EPG (moderate), and ≥4000 EPG (heavy); A. lumbricoides, 1-4999 EPG 
(light), 5000-49,999 EPG (moderate), and ≥50,000 EPG (heavy); and T. trichiura and 
O. viverrini, 1-999 EPG (light), 1000-9999 EPG (moderate), and ≥10,000 EPG (heavy). 
Primary outcome measures were CR and egg reduction rate (ERR), the latter defined as 
the positive group’s reduction of geometric mean (GM) fecal egg count at posttreatment, 
divided by the GM fecal egg count at pretreatment, multiplied by 100. Additionally, 
changes in class of infection intensities were determined following treatment. Negative 
binomial regression was applied to compare ERRs observed between both treatment 
groups. A Wilcoxen test was employed for the matched pair’s analysis. We determined 
egg reduction rate ratio (ERRR) and 95% confidence interval (CI). Pearson's χ2-test and 
Fisher's exact test, as appropriate, were used to assess the baseline binary 
characteristics between the treatment arms. Statistical significance was estimated using 
a likelihood ratio test (LRT). P-value below 5% was considered significant. 
 
9.5 Results 
9.5.1 Study cohort 
Four hundred sixty-five school-aged children were enrolled in the baseline screening. 
Two hundred children (43.0%), 130 boys and 70 girls with a parasitologically 
confirmed hookworm infection, were randomly assigned to one of the two treatments. 
Data of these 200 children were included in the ITT analysis. The remaining 265 
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children were excluded because they had no hookworm eggs in their stool (n=235) or 
provided only a single stool sample (n=30). Overall, One-hundred-and-seventy-one 
children (85.5%) had complete baseline data, received treatment and completed follow-
up examinations, and hence were utilised for PP analysis. Twenty-nine children (14.5%) 
were lost to follow-up, 18 in the mebendazole and 11 in the albendazole group (Figure 
1). One-hundred-and-seventy-one children were included in the primary analysis. Their 
parents most commonly had completed primary school only, namely 77.5% of parents 
for the albendazole group and 80.5% for the mebendazole group. The most common 
profession of patients' parents was farming with 49.4% and 62.2% for albendazole and 
mebendazole treatment groups, respectively. The 2 groups were similar in terms of 
household assets, source of drinking water and consumption of cooked foods as well as 
raw fish (data not shown). More specifically, the consumption of raw fish was reported 
by 61.8% and 58.5%, respectively, and included dishes like “Pa Dek” (fermented fish 
sauce), “Lap Pa” and “Koy Pa” (raw, fish-based dishes). 
 
9.5.2 Baseline Characteristics 
At baseline, characteristics of the two treatment groups were similar (Table 9.1), 
including age (albendazole recipients, mean (standard deviation, SD) age 8.4 (2.1) 
years; mebendazole recipients 8.7 (2.1) years), weight (mean (SD) 23.8 (5.8) kg and 
25.0 (5.9) kg, respectively), height (mean (SD) 123.8 (11.0) cm; 126.9 (11.0) cm, 
respectively) and hemoglobin (Hb) concentration (mean (SD) 11.8 (10.1) mg/dl; 11.9 
(10.4) mg/dl, respectively). In both treatment groups, children (82.0%) were diagnosed 
with a light hookworm infection, whereas the remaining children had moderate or 
heavy infection intensities. The hookworm GM fecal egg counts in the mebendazole and 
albendazole groups were 707.0 and 859.1 EPG, respectively (Table 9.2). 
The overall infection rates of A. lumbricoides, O. viverrini and T. trichiura were 34.0%, 
48%, 45.0% respectively. O. viverrini GM fecal egg counts were 84.9 EPG (albendazole) 
and 120.8 EPG (mebendazole) (Table 9.3). 
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Figure 9.1: Flow chart detailing the study participation and compliance. Children who 
completed 2 stool samples were included in the final analysis for assessing the efficacy 
of single albendazole and mebendazole treatment against hookworm and concomitant 
helminth infections in Bachieng district, Champasack province, southern Lao PDR. 
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Table 9.1 Baseline characteristics 
 
 
Albendazole 
(n=89) 
Mebendazole 
(n=82) 
   
Boys/girls 56/33 49/33 
Mean (±SD) age, y 9.0 (2.1) 9.0 (2.1) 
Mean (±SD) weight, kg 24.0 (6.0) 25.2 (6.0) 
Mean (±SD) height, cm 124.1 (11.0) 127.0 (11.0) 
Mean (±SD) hemoglobin, mg/dL 11.85 (10.1) 12.04 (10.3) 
Anemia (<11.5 mg mg/dL): n, % a 23 (57.5) 17 (42.5) 
Latrine facility present 5 (5.6) 1 (1.2) 
Parasitic infections   
Hookworm b    
Light (1-999 epg) 72 (80.9) 67 (81.7) 
Moderate (1000- 9999 epg) 9 (10.1) 7 (8.6) 
Heavy (>10 000 epg) 8 (9.0) 8 (9.7) 
Co-infection with:    
Ascaris lumbricoides b    
Negative 61 (68.5) 53 (64.6) 
Light (1-999 epg) 18 (20.2) 18 (22.0) 
Moderate (1000- 9999 epg) 7 (7.9) 8 (9.8) 
Heavy (>10 000 epg) 3 (3.4) 3 (3.7) 
Trichuris trichiura b    
Negative 51 (57.3) 39 (47.6) 
Light (1-999 epg) 38 (42.7) 43 (52.4) 
Moderate (1000- 9999 epg)  4 (4.5) 0 
Heavy (>10 000 epg) 0 0 
Taenia spp    
Negative 78 (87.6) 79 (96.3) 
Positive 11 (12.4) 3 (3.7) 
Opisthorchis viverrini c   
Negative 44 (49.4) 50 (61.0) 
Light (1-999 epg) 41 (46.1) 25 (30.5) 
Moderate (1000- 9999 epg) 4 (4.5) 7 (8.5) 
Heavy (>10 000 epg) 0 0 
a According to guidelines put forth by WHO regarding definition of anemia [42] 
b According to guidelines put forth by WHO [24], based on Kato-Katz thick smear examinations  
c According to Maleewong and colleagues [23], based on Kato-Katz thick smear examinations 
Data are no; (%) of subject, otherwise indicated (95% confidence interval); EPG, eggs per gram of stool; GM, 
geometric mean 
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9.5.3 Efficacy Against Hookworm 
In the ITT analysis, the CRs of albendazole and mebendazole against hookworm 
infections were 32.0% and 15.0%, respectively. Overall, 124 children (73%) remained 
hookworm-egg positive; 68 treated with albendazole and 85 in the mebendazole 
treatment group. Si9.milar results were obtained with the PP analysis (Table 9.2). A 
statistically significant difference was observed when comparing the observed CRs 
using albendazole vs. mebendazole (OR=0.4; 95% CI 0.2-0.8; P=0.01). The hookworm 
GM fecal egg counts obtained at follow-up were 63.0 EPG in albendazole recipients and 
147.3 EPG mebendazole recipients (ITT analysis 96.5 EPG and 210 EPG, respectively). 
The respective ERR for albendazole and mebendazole were 86.7% and 76.3% (ERRR 
1.0; 95%CI 0.7-1.6; P=0.9). In children with moderate infection intensities (2000–3999 
EPG), the effect of albendazole and mebendazole was significantly different (P=0.04). 
 
9.5.4 Effect of Albendazole and Mebendazole Against A. lumbricoides, T. trichiura, 
and O. viverrini 
Table 9.3 shows the effect of albendazole and mebendazole against A. lumbricoides, 
T. trichiura and O. viverrini. At baseline, GM infection intensities of A. lumbricoides were 
1567 EPG in albendazole recipients and 1584 EPG in mebendazole recipients. Both 
albendazole and mebendazole treatments achieved high CRs above 90% and resulted in 
almost complete egg elimination. The CRs of albendazole and mebendazole obtained 
against T. trichiura were 33.3% and 27.9%, respectively. The respective ERRs were 
67.0% and 66.0%. No statistically significant difference was observed for CR and ERR 
between the 2 treatments (OR=0.8; 95% CI 0.3-1.9; P=0.6 and ERRR=0.7; 95% CI 0.3-
1.2, P<0.2). Finally, CRs against O. viverrini achieved with albendazole and mebendazole 
were 33.3% and 24.2%, respectively (OR=0.7; 95% CI 0.3-1.9; P=0.6). The respective 
ERRs were 82.1% and 78.2% (ERRR=0.8; 95% CI 0.2-3.9, P<0.8). 
 
9.5.5 Adverse Events 
Monitoring of children within 3 hours after drug administration revealed no drug-
related adverse event, neither in the albendazole nor in the mebendazole group. Hence, 
both treatments were well tolerated. 
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Table 9.2 Per-protocol (PP) analysis of hookworm infection prevalence and cure rate of albendazole and mebendazole at baseline and follow-up 
 
 Pretreatment Posttreatment 
   
 Albendazole 
(n=89) 
Mebendazole 
(n=82) 
Albendazole 
(n=89) 
Mebendazole 
(n=82) 
No. of hookworm infected patients 89 (100) 82 (100) 57 (64.0) 67 (81.7) 
No. of children cured (cure rate) n.a. n.a. 32 (36.0) 15 (17.6) a 
Light infection (1-1999 EPG) 72 (80.9) 67 (48.2) 55 (61.8) 59 (72) 
No. of children cured (cure rate) n.a. n.a. 17 (19.1) 8 (9.8) b 
Moderate infection (2000-3999 EPG) 9 (18.0) 7 (46.7) 2 (2.2) 6 (7.3) 
No. of children cured (cure rate) n.a. n.a. 7 (7.9) 1 (1.2) c 
Heavy infection (≥ 4000 EPG) 8 (1.1) 8 (1.1) 0 (0) 2 (2.4) 
No. of children cured (cure rate) n.a. n.a. 8 (9) 6 (7.3) d 
GM fecal egg count (range), EPG 859.1 (699.0-1057.0) 707.0 (559.0-894.3) 63.0 (34.0-116.0) 147.3 (90.0-242.0) 
Egg reduction rate n.a. n.a. 86.7% 76.3% e 
     
aOR 0.4 [95% CI (0.2-0.8; P=0.01)] comparison of treatment outcomes between mebendazole vs. albendazole 
bP =0.13; c  P=0.04;  d P=0.46 
eERRR 1.0 [95% CI (0.7-1.6; P=0.9)] comparison of treatment outcomes between mebendazole vs. albendazole 
Note. Data are number; (%) of children, unless otherwise indicated (95% confident interval); GM, geometric mean; EPG, eggs per gram of stool; ERRR egg reduction rate ratio; OR 
odds ratio; n.a. not applicable 
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Table 9.3 Infection rate and cure rate of albendazole and mebendazole: A. lumbricoides, T. trichiura, O. viverrini at baseline and follow-up 
 
 Pretreatment Posttreatment 
   
Parasitic infection Albendazole Mebendazole Albendazole Mebendazole 
A. lumbricoides (n=58) (n= 28) (n= 30) (n= 28) (n= 30) 
No. of A. lumbricoides infected children 28 (100) 30 (100) 2 (7.1) 2 (6.7) 
No. of patients cured (cure rate) n.a. n.a. 26 (92.9) 28 (93.3) a 
GM fecal egg count (range), EPG 1567.0 (553.0- 4444.0 ) 1584.0 (528.0-4751.0) 0 0 
ERR n.a. n.a. 100.0% 100.0% b 
T. trichiura (n=82) (n= 39) (n= 43) (n= 39) (n= 43) 
No. of T. trichuris infected children 39 (100) 43 (100) 26 (66.7) 31 (72.1) 
No. of patients cured (cure rate) n.a. n.a. 13 (33.3) 12 (27.9) c 
GM fecal egg count (range), EPG 94.1 (48.3-184.0) 65.2 (39.3-108.3) 75.0 (42.2-133.2) 48.0 (25.0-93.0) 
ERR n.a. n.a. 67.0 66.0 d 
O. viverrini (n=77) (n= 45) (n= 32) (n=45) (n= 32) 
No. of O. viverrini infected children 45 (100) 32 (100) 30 (66.7) 25 (75.8) 
No. of patients cured (cure rate) n.a. n.a. 15 (33.3) 8 (24.2) e 
GM fecal egg count (range), EPG 84.9 (41.8-184.0) 120.8 (48.9-297.9) 73.0 (34.3-155.7) 114.4 (48.9-267.3) 
ERR n.a. n.a. 82.1 78.2f 
     
a OR 0.8 [95% CI (0.2-2.6; P=0.7) comparison of treatment outcomes between mebendazole vs. albendazole 
b ERRR n.a. 
c OR 0.8 [95% CI (0.3-1.9; P=0.6)] comparison of treatment outcomes between mebendazole vs. albendazole 
d ERRR 0.7 [95% CI (0.3-1.2; P<0.2)] comparison of treatment outcomes between mebendazole vs. albendazole 
e OR 0.7 [95% CI (0.3-1.9; P=0.6)] comparison of treatment outcomes between mebendazole vs. albendazole 
f ERRR 0.8 [95% CI (0.2-3.9; P<0.8)] comparison of treatment outcomes  between mebendazole vs. albendazole  
Note. Data are number; (%) of children, unless otherwise indicated (95% confident interval); GM, geometric mean; EPG, eggs per gram of stool; ERRR, egg reduction rate ratio; OR odds ratio; n.a. 
not applicable 
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9.6 Discussion 
This current head-to-head comparison of single-dose albendazole vs. mebendazole 
against hookworm infection in Lao school-aged children - to our knowledge the first 
trial in this Southeast Asian country - shows sobering results. Indeed, the standard 
single oral doses of albendazole (400 mg) and mebendazole (500 mg) that are 
recommended in preventive chemotherapy campaigns targeting STHs resulted in low 
CRs against hookworm infection. However, ERRs were moderate, 86.7 and 76.3% 
respectively.  
A sizeable number of children were co-infected with A. lumbricoides, T. trichiura and 
O. viverrini, which allowed us to determine the effect of albendazole and mebendazole 
against these helminth species. With regard to A. lumbricoides, high efficacy of both 
drugs was confirmed. However, disappointing efficacy was confirmed against 
T. trichiura [25]. 
While the results obtained with mebendazole against hookworm and the efficacy 
observed with both drugs against A. lumbricoides and T. trichiura is in line with previous 
studies [19,26,27] and in agreement with overall CRs estimated through a meta-analysis 
[9], the low CR (36.0%) achieved with albendazole in the treatment of hookworm 
infection is somewhat surprising. Indeed, in the aforementioned meta-analysis, 
randomized controlled trials of single-dose albendazole (400 mg) revealed an overall 
CR against hookworm of 75% [9]. The reasons for the considerably poorer efficacy of 
albendazole observed in our study are unclear. Quality control of drug samples 
performed in our laboratories revealed that disintegration, dissolution and 
concentration of the albendazole tablets used in our trial were comparable to Zentel® 
(data not shown). The hookworm species (and strains) endemic in southern Lao PDR 
might be an explanation. However, there is a paucity of information on which 
hookworm species is predominant in Southeast Asia. Indeed, in our study setting the 
infection rates of N. americanus and A. duodenale are not known. Furthermore, recent 
studies documented that in Southeast Asia humans are at risk of acquiring 
A. ceylanicum, which is endemic in dogs and cats of the region and its importance in 
humans might be underestimated [28,29]. Hence, further analysis on the circulating 
parasite species is required to elucidate this issue. In addition, day to day variability in 
hookworm egg counts from individuals is a well described phenomenon [30]. Finally, 
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the study’s sample size is rather small and therefore a few incidental effects such as 
failure of some children to swallow the pill correctly, might have contributed to low 
efficacy of albendazole for the treatment of hookworm infection. To sum up, differences 
in strain and species susceptibilities, host factors, and co-infections with other 
helminths are factors that might all play a role in explaining treatment failures [27,31]. 
However, at present, we cannot rule out that albendazole resistance is developing in our 
study setting. To date, nematode resistance in humans has not been reported. On the 
other hand, drug resistance is a major threat in veterinary public health [32,33]. The 
development of broad spectrum anthelmintic resistance, in particular resistance of 
nematodes to benzimidazoles, has been recognized in ruminants for decades [33,34]. 
Extensive studies on the underlying mechanisms of drug resistance have been carried 
out [35]. Further investigations on failure of the drugs to completely cure the patients 
are necessary in our study setting to substantiate this suspicion. 
It is interesting to note that the 2 drugs employed, even at single oral doses, showed 
some effect against O. viverrini. Although CRs were low (33.3 and 24.2%), the moderate 
ERRs of 82.1 and 78.2% are encouraging. At present, praziquantel is the drug of choice 
against opisthorchiasis [36,37]. Studies carried out in the 1980s in O. viverrini-infected 
hamsters and patients infected with O. viverrini documented opisthorchicidal properties 
of albendazole and mebendazole [18,38]. However, long treatment courses of up to 7 
days were recommended in view of these initial laboratory and clinical findings. 
Experiences with long treatment courses have been reported from a hospital-based 
randomized trial; albendazole given at dosages of 400 mg twice daily for 3 and 7 days 
resulted in CRs of 40% and 63%, respectively, and corresponding ERRs of 92% [18]. 
Furthermore, mebendazole in dosages of 30 mg/kg daily for 3 or 4 weeks resulted in a 
CR of 94% against O. viverrini. Long treatment courses compromise compliance, 
increase costs and are feasible for community-based control, which might explain that 
albendazole and mebendazole were not further promoted for O. viverrini treatment 
[38]. 
It should be noted that in our study Kato-Katz thick smears served as method for 
helminth diagnosis. However, this diagnosis approach does not allow differentiating the 
eggs of O. viverrini from minute intestinal flukes [39,40]. In addition, since the emphasis 
of our research was on hookworm, the efficacy of albendazole and mebendazole against 
9. Efficacy of Albendazole and Mebendazole against Hookworm 
 
 
144 
other STHs and O. viverrini could not be compared with the appropriate sample sizes. 
Finally, mostly light O. viverrini infections were present in our study and the sample of 
O. viverrini infected patients was not representative of the overall community as 
hookworm infection was the leading selection criteria. Hence, additional clinical 
investigations are warranted to assess the opisthorchicidal properties of albendazole 
and mebendazole in comparison to praziquantel. 
Since the anthelmintic drug tribendimidine, in a recent open-label exploratory trial 
carried out in Lao PDR resulted in high CR and ERR against O. viverrini [41], a four-arm 
study might be designed, comparing praziquantel (treatment of choice) with 
tribendimidine, albendazole and mebendazole. 
In conclusion, we have assessed the efficacy of albendazole and mebendazole against 
hookworm infection in Lao PDR and provide further evidence of effects of these drugs 
against other helminth co-infections. Both drugs showed a similar profile, with low 
efficacy against hookworm and, additionally, low efficacy against T. trichiura and high 
efficacy against A. lumbricoides. The low efficacy of single dose of albendazole against 
hookworm should be followed-up closely and further explored as this drug is widely 
used for mass drug administration to treat infections with STHs. Furthermore, the 
effects of the 2 drugs against O. viverrini warrants further investigations.  
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10.1 Summary  
Background. Praziquantel is the only drug available for treatment of Opisthorchis 
viverrini, although in-vivo studies point to activity of mefloquine, artesunate, and 
tribendimidine against this liver fluke. We aimed to assess the efficacy and safety of 
these drugs compared with that of praziquantel in patients with O viverrini infection. 
Methods. We did a randomised open-label trial between February and April, 2010, in the 
Saysetha district, Attapeu Province, Laos. Eligible patients were school children aged 
10–15 years who had O viverrini infections. Patients were randomly assigned to one of 
five different treatment groups by use of a computer-generated randomisation code. We 
assessed efficacy as cure rate and egg reduction rate in intention-to-treat and per-
protocol analyses. The trial was registered with Current Controlled Trials, 
ISRCTN23425032. 
Results. 125 children were randomly assigned: 25 received mefloquine, 24 artesunate, 
24 mefloquine–artesunate, 27 tribendimidine, and 25 praziquantel. 19 patients were 
lost to follow-up. In the intention to treat analysis, 14 patients receiving praziquantel 
were cured compared with none with mefloquine, one with artesunate (odds ratio 0·03, 
95% CI 0·004–0·29), one with mefloquine–artesunate (0·03, 0·004–0·29), and 19 with 
tribendimidine (1·87, 0·60–5·85). Egg reduction rate was 98·4% for praziquantel, 
30·2% for mefloquine (egg reduction-rate ratio 1·61, 95% CI 0·21–0·72), 31·5% for 
artesunate (0·43, 0·23–0·80), 41·3% for mefloquine–artesunate (0·60, 0·31–1·10), and 
99·3% for tribendimidine (1·00, 0·44–2·30). Most adverse events were mild or 
moderate and affected all treatment groups; serious adverse events—vertigo, nausea, 
vomiting, and anxiety—were reported only by patients taking mefloquine or 
mefloquine–artesunate. 
Interpretation. Tribendimidine seems to be at least as efficacious as the drug of choice, 
praziquantel, for the treatment of O viverrini infections; both drugs were well tolerated. 
Mefloquine, artesunate, and mefloquine–artesunate did not show an effect. 
Tribendimidine should be further investigated with large clinical trials. 
Funding. Swiss National Science Foundation, University of Basel. 
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10.2 Introduction 
Opisthorchiasis is a neglected tropical disease caused by the liver fluke Opisthorchis 
viverrini that affects the poorest people in Cambodia, Laos, northeastern parts of 
Thailand, and Vietnam.[1,2] An estimated 67 million people are at risk, and 9 million are 
infected.[1] In Laos, the highest prevalence (50% in school children and up to 90% in 
adults) of O viverrini has been reported in villages adjacent to the Mekong river, 
particularly in the southern and central provinces.[3,4] Although most infections are 
asymptomatic, chronic O viverrini infection can cause obstructive jaundice, ascending 
cholangitis, cholecystitis, gallstones, hepatomegaly, and increased risk of cholangio-
carcinoma.[5-7] Cholangiocarcinoma is a serious and fatal complication that is incurable 
at an advanced stage, hence early diagnosis and treatment is imperative.[6, 8, 9, 10] 
Control of morbidity through periodic treatment with praziquantel is key for 
opisthorchiasis;[11,12] praziquantel is the only available drug for this infection, so if drug 
resistance evolves no active drug will exist unless other treatments are developed. The 
antimalarials artemether, artesunate (two semisynthetic derivatives of artemisinin), 
mefloquine, and tribendimidine (used as an anthelmintic drug in China) have 
opisthorchicidal properties in rodents.[13-15] Artesunate and artemether at a dose of 400 
mg/kg given to hamsters infected with O viverrini resulted in worm-burden reductions 
of 77.6% and 65.5%, respectively.[13] Similarly, high worm-burden reductions were 
reported in hamsters given a single 300 mg/kg oral dose of mefloquine for juvenile and 
adult O viverrini in vivo.[15] Finally, a 400 mg/kg oral dose of tribendimidine achieved a 
worm-burden reduction of 95.7% in O viverrini infected hamsters. [14] We aimed to 
assess the efficacy and safety of mefloquine, artesunate, mefloquine–artesunate, and 
tribendimidine compared with that of praziquantel in patients with parasitologically 
confirmed O viverrini infection. 
 
10.3 Methods 
10.3.1 Patients 
The study was done in the Saysetha district, Attapeu Province, Laos, from February to 
April, 2010. The province has an area of 10 320 km2 and is the most southeasterly 
province of Laos. Prevalence of O viverrini is estimated to be about 21% in primary-
school children in Attapeu.4 The province has about 112 120 inhabitants, most of whom 
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belong to the ethnic group Lao Theung and are mainly engaged in subsistence rice 
cultivation.16 The Saysetha upper and lower secondary school was selected for our 
study; 957 secondary-school children were enrolled during the academic year 2008–
2009. A preliminary survey showed that the prevalence of O viverrini infection in this 
school was higher than 50% (Thongsom Keopaseurt, Provincial Hospital, Attapeu; 
personal communication). 
The study was approved by the institutional research commission of the Swiss Tropical 
and Public Health Institute, (Basel, Switzerland), and the Ethics Committee of Basel (no 
209/09). Ethical clearance was obtained from the National Ethics Committee, Ministry 
of Health, Vientiane, Laos (no 279/NECHR). The trial was registered with Current 
Controlled Trials, ISRCTN23425032. Permission for field work was provided by the 
Ministry of Health, the Provincial Health Department, and the Provincial and District 
Education Office (DEO). Written informed consent was obtained from the parents or 
legal guardians of each child. We also informed the participants and their parents that 
tribendimidine is currently registered only in China, and, as such, considered to be an 
investigational drug in Laos. We explained risk and benefits on the consent form in Lao. 
 
10.3.2 Randomisation                                                                                                         
Children who gave consent and met all study criteria were randomly assigned to one of 
the five different treatment groups by use of a computer-generated randomisation code. 
A random number sequence was generated with Stata version 10.1 by an independent 
member, who had no other involvement in the study. Patients were randomly assigned 
and allocated treatment by the pharmacologist according to the randomisation list in 
sequential order. Patients and study pharmacologist were not masked to treatment 
allocation, but the study clinicians and laboratory team were masked throughout the 
study.  
 
10.3.3 Procedures 
One week before the baseline screening survey the National Institute of Public Health, 
Centre of Malaria, Parasitology, and Entomology, Centre for Laboratory and 
Epidemiology, the Provincial Department of Health, the Provincial Hospital of Attapeu, 
and the teachers were informed about the study objectives, procedures, benefits, and 
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potential risks. 214 school children aged 10–15 years were invited to participate. From 
each consenting and participating child at least two stool samples were collected within 
5 days consecutively. Children with a parasitologically confirmed O viverrini infection 
(at least two of four slides positive) had a full clinical examination, including 
measurement of weight (measured with an electronic balance to the nearest 0·1 kg), 
and axillary temperature (measured with battery-powered thermometers to the nearest 
0·01°C). Additionally, a finger-prick blood sample was taken from each child for a rapid 
malaria test (Paracheck Pf, Orchid Biomedical System, Goa, India) and a urine sample 
from all girls for pregnancy testing (Innovacon, San Diego, CA, USA). Clinical malaria 
was defined as fever (axillary temperatures ≥37.5°C) and parasitaemia (≥100/μL).17 
Exclusion criteria were presence of clinical malaria, pregnancy, presence of any 
abnormal medical disorder (ie, hepatomegaly and splenomegaly, jaundice), history of 
any acute or severe chronic disease, psychiatric and neurological disorders, use of 
artesunate, artemether, any artemisinin-based combination therapy, mefloquine, or any 
anthelmintic treatment within the past month, and weight below 20 kg. 
Mefloquine (mephaquine 250-mg/lactab) and mefloquine–artesunate (artequin) were 
obtained from Mepha AG (Aesch, Switzerland). Artesunate (50 mg tablets) was donated 
by Dafra Pharma (Turnhout, Belgium). Tribendimidine (200 mg tablets) was obtained 
from Shandong Xinhua Pharmaceutical Corporation (Zibo, Shandong, China); it is 
registered in China where its safety and efficacy against soil-transmitted helminths have 
been documented in thousands of patients.[18,19] Praziquantel (600 mg tablets) was 
purchased from Inresa (Bartenheim, France). 
Mefloquine and mefloquine–artesunate were given according to recommended malaria 
treatment schedules. Mefloquine 25 mg/kg single-dose was given to patients with a 
bodyweight less than 30 kg or a split-dose spaced by 6 h for patients with a bodyweight 
above 30 kg (e.g, at bodyweight 30–34 kg, two lactabs were given followed by one 
lactab 6 h later). Mefloquine–artesunate was given as one tablet of 100 mg artesunate 
and one lactab mefloquine 250 mg once daily for 3 days consecutively. Mefloquine and 
praziquantel were given to the nearest half tablet according to the calculated dose per 
kg bodyweight. For artesunate we used a previously defined malaria treatment 
schedule (10 mg/kg as three split doses within 12 h).20 Tribendimidine was given 
according to the manufacturer's instruction for the treatment of soil-transmitted 
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helminth infections: 200 mg (age below 14 years) or 400 mg (age above 14 years) as a 
single dose. Finally, praziquantel was given according to national policies in Laos: 75 
mg/kg in two divided doses of 50 mg/kg and 25 mg/kg spaced by 6 h. All children 
received a biscuit and water before drug administration to improve tolerability and 
increase bioavailability.21 
Children were supervised for at least 3 h after treatment and were asked to report any 
potential drug-related signs and symptoms at 24 h, 48 h, and 120 h after the first dose 
by use of a standardised questionnaire. A full clinical examination was done by a study 
physician in case children reported adverse events and appropriate treatment was 
given. Intensity of adverse events was graded as mild, moderate, severe, serious, or life-
threatening, as judged by study physicians. At the end of the study, O viverrini egg-
positive children who were enrolled in our study were treated with praziquantel (40 
mg/kg). All school children received a single oral albendazole (400 mg) according to the 
national scheme for mass drug administration in Laos.[22, 23] 
Filled stool containers were collected from children between 0800 h and 0900 h and 
replaced with empty containers to obtain at least two stool samples from each child 
within a period of 5 days. Stool containers were then taken to the laboratory at the 
provincial hospital. From each stool sample two Kato-Katz thick smears were prepared 
with the standard 41.7 mg template and were quantitatively examined with light 
microscopy for helminth eggs with a magnification of 100 times. Each Kato-Katz slide 
was read within 30–45 min after preparation. Number of O viverrini eggs and soil-
transmitted helminths eggs (ie, Ascaris lumbricoides, hookworm, Trichuris trichiura, and 
Taenia spp) were counted and recorded for each parasite species separately. 10% of 
slides were re-examined for quality control by a senior microscopist. 
Cure rates and egg reduction rates at 21–22 days after treatment were assessed as 
efficacy outcomes. Cure rate was defined as the percentage of the children excreting 
eggs before treatment, but in whom no eggs were identified when re-examined. Egg 
reduction rate was defined as the groups' reduction of geometric mean egg output after 
treatment divided by the geometric mean of the same patients before treatment, 
multiplied by 100. 
Additionally, four stool samples (two pretreatment plus two posttreatment) were 
preserved in 10 mL sodium acetate-acetic acid-formalin solution, which contained 
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exactly 500 mg of stool for examination by the formalin-ether concentration technique; 
this allows differentiation of O viverrini and minute intestinal fluke infections.[24, 25] 
Specimens from patients, for which pretreatment and post-treatment samples could be 
preserved (per-protocol analysis), were shipped to a referral laboratory at the Khon 
Kaen University, Thailand. For analysis with the formalin-ether concentration 
technique, the sample was centrifuged, and the sediment analysed with light 
microscopy at magnifications of 40 and 100 times.26 
 
10.3.4 Statistical analysis 
Sample size was based on a suggested sample size of 12 patients per group for proof-of-
concept trials, as recommended by Julious.27 To account for patients dropping out we 
aimed to recruit 20–25 children per group. All data were double entered with EpiData 
software (version 3.1). Statistical analyses were done with Stata (version 10.1). Efficacy 
and safety were assessed with intention-to-treat and per-protocol analyses. Intention-
to-treat was defined as an analysis based on the initial treatment intent and per-
protocol analysis was defined as children who completed the entire clinical trial. 
Prevalence of O viverrini was stratified according to the classification of infection 
intensities proposed by Maleewong and colleagues28—light infections (1–999 eggs per g 
of faeces), moderate (1000–9999), and severe (>10 000). Logistical regression models 
were used to examine cure rates of O viverrini infection and hookworm infection in 
different treatment groups (comparison of odds of parasite clearance between 
treatment groups). Negative-binomial regression was applied to compare egg reduction 
rates between the numbers of O viverrini eggs recovered from stool examination of 
patients treated with mefloquine, artesunate, mefloquine-artesunate, and 
tribendimidine with that for praziquantel. 
Pearson's χ2 test was applied to compare the baseline binary characteristics and 
proportion of reported adverse events between the treatment groups. Statistical 
significance was estimated with a likelihood-ratio test. Negative-binomial models were 
fitted to compare the number of adverse events in the treatment groups. Significance 
was defined as p-value less than 0.05. 
 
 
10. Efficacy and Safety of Five Drugs against Opisthorchis 
 
 
156 
10.3.5 Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the decision to submit for 
publication. 
 
10.4 Results 
Of 214 school children screened with the Kato-Katz method, 197 (92.1%) were O 
viverrini positive (Figure 10.1). We excluded 72 children (36.5%), because 70 provided 
only a single stool sample, one had fever, and another had splenomegaly. 125 patients 
were randomly allocated to five treatment groups and were included in the intention-
to-treat analysis. Groups were not equal in size (24 children in the artesunate and 
mefloquine–artesunate group vs 27 in the tribendimidine group) because two patients 
were erroneously assigned to the tribendimidine group, instead of the artesunate and 
mefloquine–artesunate treatment group. Of 125 patients, 19 (15.2%) were lost to 
follow-up at the end of study. Four stool samples (two before treatment and two after 
treatment) were available from 106 patients for per-protocol analyses. 
All baseline characteristics of treatment groups were similar, but there were more boys 
in the mefloquine treatment group (Table 10.1). Overall 63 boys and 62 girls, mean age 
13.4 years (SD 1.4), were included in the study. Intensity of O viverrini infections was 
mild to moderate in most children. O viverrini geometric mean egg counts ranged from 
609.1 to 3917.7 eggs per g of faeces. Overall prevalence of A lumbricoides, T trichiura, 
and Taenia spp was below 16.0%, hence these parasites were not included in the 
efficacy assessment. Prevalence of hookworm infection ranged from 71% to 83%. 
Results of analyses with the formalin-ether concentration technique confirmed the 
presence of O viverrini infection in all patients. O viverrini geometric mean baseline egg 
counts identified by this technique ranged from 82.5 to 639.0 eggs per g of faeces 
(n=106; data not shown). Co-infections with minute intestinal flukes in two patients and 
intestinal protozoa in nine patients were reported. 
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Fig.10.1 Trial profile 
 
In the intention-to-treat analysis (Table 10.2), the highest cure rate was seen in patients 
treated with tribendimidine, followed by praziquantel. No significant difference was 
shown between the cure rates of tribendimidine and praziquantel (Table 10.3). No child 
receiving mefloquine was cured, and very low cure rates were calculated for artesunate 
and mefloquine–artesunate. Both tribendimidine and praziquantel treatments resulted 
in almost complete egg elimination (Table 10.2). By contrast, egg reduction rates were 
significantly lower for mefloquine and artesunate. The egg reduction rate was lower for 
mefloquine–artesunate, which was, however, not significant (Table 10.3). 
Results of the per-protocol analysis (Kato-Katz data) were similar to those of the 
intention-to-treat analysis (Table 10.2, Table 10.3, Table 10.4). Analysis of stool samples 
with the formalin-ether concentration technique showed much higher cure rates 
(tribendimidine 96%, praziquantel 95%, mefloquine–artesunate 47%, artesunate 33%, 
and mefloquine 21%) and egg reduction rates (tribendimidine 99%, praziquantel 99%, 
mefloquine–artesunate 75%, artesunate 60%, and mefloquine 71%) than those 
obtained with the Kato Katz method. Although no significant difference was reported 
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between cure rates and egg reduction rates of tribendimidine and praziquantel (Table 
10.3), these rates were significantly lower for the antimalarials mefloquine and 
artesunate. Additionally, the cure rate of mefloquine–artesunate was significantly 
lower; however, no significant difference was seen between egg reduction rates of 
mefloquine–artesunate and praziquantel (Table 10.3, Table 10.4). 
Mefloquine, artesunate, mefloquine–artesunate, and praziquantel had no effect against 
hookworms, whereas tribendimidine achieved cure rates of 65.0% (both intention-to-
treat and per-protocol analyses; (Table 10.2, Table 10. 4). 
Adverse events were assessed at 3 h, 24 h, 48 h, and 120 h after the first dose (Table 
10.5). No symptoms were reported before treatment. Most symptoms were mild 3 h 
after treatment, then increased in severity and subsided 48 h after treatment. In total, 
92 (74%) mild adverse events, 47 (38%) moderate, 23 (18%) severe, 12 (10%) serious 
were reported (Table 6). No life-threatening adverse events were reported. 120 h after 
treatment, children were re-examined by the same physicians; none of them reported 
any adverse events.  
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Table 10.1 Demographic and laboratory baseline characteristics of 125 schoolchildren infected with Opisthorchis viverrini at inclusion 
 
 Drugs 
Characteristics Mefloquine Artesunate Mefloquine-
artesunate 
Tribendimidine Praziquantel 
 (n = 25) (n = 24) (n = 24) (n = 27) (n = 25) 
Boys 16 13 12 10 12 
Girls 9 11 12 17 13 
Mean (SD) age, years 13.4 (1.2) 13.3 (1.6) 13.4 (1.6) 13.3 (1.3) 13.6 (1.3) 
Mean (SD) weight, kg 39.5 (5.4) 38.8 (6.8) 38.0 (6.3) 40.6 (7.0) 39.4 (5.6) 
Parasite infections      
Opisthorchis viverrini infection *        
Overall GM eggs per g of stool 
GM eggs per g of stool (range) 
1159.7 
(609.1- 2208.0) 
1368.0 
(745.3- 2510.9) 
1207.8 
(715.1-2040.0) 
1968.1 
(988.7 -3917.7) 
1925.4 
(970.2-3821.2) 
  Number of light infection (1-999 eggs per g of stool)   14 (56%) 11 (46%) 11 (46%) 9 (33%) 11(44%) 
Number of moderate infection (1000- 9999 eggs per 
g of stool)  
9 (36%) 12 (50%) 11 (46%) 14 (52%) 9 (36%) 
Number of heavy infection (>10 000 eggs per g of 
stool) 
2 (8%) 1 (4%) 2 (8%) 4 (15%) 5(20%) 
Co-infection with  soil-transmitted helminths      
Hookworm 19 (76%) 20 (83%) 17 (71%) 20 (74%) 20 (80.0) 
Ascaris lumbricoides 0 (0) 0 (0) 0 (0) 3 (11.1) 4 (16.0) 
Trichuris trichiura 1 (4%) 1 (4%) 0 (0) 1 (3.7) 0 (0) 
Taenia spp 2 (8%) 1 (4%) 1 (4%) 1 (3.7) 3 (12.0) 
 Data are no; (%) of subject, unless otherwise indicated. GM-geometric mean. *  According to guideline’s classification put forward by WHO, based on Kato-Katz analysis 
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Table 10.2 Intention-to-treat analysis of prevalence and cure rate of mefloquine, artesunate, mefloquine-artesunate, tribendimidine and 
praziquantel schoolchildren infected with Opisthorchis viverrini at follow-up, with Kato-Katz smear technique 
 
Intention-to-treat analysis  
Mefloquine 
(n = 25) 
Artesunate 
(n = 24) 
Mefloquine-
artesunate 
(n = 24) 
Tribendimidine 
(n = 27) 
Praziquantel 
(n = 25) 
Opisthorchis viverrini      
Patient cured/ 0/25 (0) 1/24 (4%) 1/24 (4%) 19/27 (70%) 14/25 (56%) 
Patients infected      
GM egg per g of  1052.2 1229.4 653.9 578.5 159.9 
Stool (range) (537.8- 2058.4) (625.1-2417.7) (323.9-1320.1) (47.7-7009.5) (38.1- 671.2) 
Egg reduction rate 30.2 31.5 41.3 99.3 98.4 
Co-infection with hookworm      
Patient cured/ 3/17 (18%) 4/20 (20%) 3/15 (20%) 11/17 (65%) 2/17(12%) 
Patients infected      
Note. Data are no; (%) of patients, unless otherwise indicated (95% confident interval). GM-geometric mean. 
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Table 10.3 Comparison of treatment outcome between groups 
 
 Intention-to-treat analysis 
 MQ vs PZQ P AS vs PZQ P MQ-AS vs PZQ P TBD vs PZQ P 
Kato-Katz thick smear 
technique 
        
Opisthorchis viverrini         
OR na na 0.03 (0.004-0.29) 0.002 0.03 (0.004-0.29) 0.002 1.87 (0.60-5.85) 0.29 
ERRR 0.40 (0.21-0.72) 0.003 0.43 (0.23–0.80) 0.008 0.60 (0.31-1.10) 0.08 1.00 (0.44-2.30) 0.98 
Co-infection with hookworm         
                             OR 1.61 (0.23-11.09) 0.63 1.88 (0.30-11.78) 0.50 1.88 (0.27- 13.09) 0.52 13.75 (2.32-81.49) 0.004 
 Per-protocol analysis 
 MQ vs PZQ P AS vs PZQ P MQ-AS vs PZQ P TBD vs PZQ P 
Kato-Katz thick smear 
technique 
        
Opisthorchis viverrini         
OR na na 0.02 (0.003-0.22) 0.001 0.04 (0.004-0.32) 0.003 2.17 (0.58-8.08) 0.25 
ERRR 0.36 (0.19-0.68) 0.002 0.42 (0.22 -0.80) 0.008 0.54 (0.28-1.03) 0.06 1.00 (0.44-2.31) 0.98 
Co-infection with hookworm         
OR 1.88 (0.27-13.09) 0.53 1.88 (0.30-11.78) 0.50 1.50 (0.18-12.46) 0.70 13.75 (2.32-81.49) 0.004 
FECT technique         
OR 0.01 (0.001-0.13) <0.001 0.02 (0.003-0.21) 0.001 0.04 (0.005-0.39) 0.005 1.10 (0.06-18.64) 0.95 
ERRR 0.54 (0.43-0.67) <0.001 0.81 (0.70-0.94) 0.009 0.87 (0.72-1.04) 0.14 1.00 (0.86-1.16) 0.99 
Note. Data are odds ratios (OR, 95% confidence intervals) of parasite clearance; ERRR, egg reduction rate ratio; na, not applicable; MQ: mefloquine; AS: artesunate; MQ-
AS Mefloquine-artesunate; TBD tribendimidine; PZQ Praziquantel 
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Table 10.4 Per-protocol analysis of prevalence and cure rate of mefloquine, artesunate, mefloquine-artesunate, tribendimidine and praziquantel 
schoolchildren infected with Opisthorchis viverrini at follow-up 
 
 Per-protocol analysis 
 Mefloquine 
(n = 19) 
Artesunate 
(n = 24) 
Mefloquine-
artesunate 
(n = 17) 
Tribendimidine 
(n = 24) 
Praziquantel 
(n = 22) 
Kato-Katz thick smear technique      
Opisthorchis viverrini      
No. of patients cured (%) 0 (0) 1 (4.2) 1 (6.0) 19 (79.2) 14 (63.6) 
GM epg (range)  1114.1 (498.9-
2488.1) 
1229.4 (625.1-
2417.7) 
669.1 (320.8-
1395.7) 
44.7 (11.6-
171.7) 
43.1 (16.6-111.7) 
ERR (%) 28.7 31.5 36.6 99.3 98.4 
Co-infection with hookworm      
No. patients of sole hookworm 
infection (n = 81) 
(n = 15) (n = 20) (n = 12) (n = 17) (n = 17) 
No. of patients cured (%) 3 (20.0) 4 (20.0) 2 (16.7) 11 (65.0) 2 (13.0) 
FECT technique      
Opisthorchis viverrini      
No. of patients cured (%) 4 (21.1) 8 (33.3) 8 (47.1) 23 (95.8) 21 (95.5) 
GM epg (range) 182.3 (77.0-433.5) 156.2 (82.2-297.0) 114.0 (69.2-187.3) na Na 
ERR (%) 71.0 60.0 75.0 99.1 99.0 
Note. Data are no; (%) of subject, otherwise indicated (95% confident interval); GM, geometric mean; epg, eggs per gram of stool; ERR, egg reduction rate; ; na, not applicable 
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Table 10.5 Clinical symptoms reported 3-48 hour after drug administration among 125 schoolchildren, stratified by treatment group 
 
 No, (%) individuals with adverse event  
 Mefloquine Artesunate Mefloquine-artesunate Tribendimidine Praziquantel 
 (n = 25) (n = 24) (n = 24) (n = 27) (n = 25) 
Adverse event / 
Grade 
3 24 48 
At any 
time point 
3 24 48 
At any 
Time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
Fatigue                      
Mild  3 4 2 7 (28.0) 2 3 2 6 (25.0) 4 5 7 12 (50.0) 2 3 2 5 (18.5) 5 8 2 11 (44.0) 
Moderate 0 0 3 3 (12.0) 0 1 1 2 (8.3) 3 1 2 5 (20.8) 0 0 0 0 0 0 0 0 
Severe 0 0 2 2 (8.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Asthenia                     
Mild  0 4 0 4 (16.0) 0 2 0 2 (8.3) 0 4 0 2 (8.3) 0 1 1 1 (3.7) 0 0 1 1 (4.0) 
Moderate 0 6 0 6 (24.0) 0 1 0 1 (4.2) 0 3 0 3 (12.5) 0 0 0 0 0 0 0 0 
Severe 0 8 0 8 (32.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 (4.0) 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Headache                     
Mild  4 3 2 7 (28.0) 6 8 2 12 (50.0) 6 9 6 14 (58.3) 4 10 1 12 (44.4) 12 7 2 16 (64.0) 
Moderate 1 2 4 6 (24.0) 1 2 1 4 (16.7) 1 3 4 8 (33.3) 0 0 0 0 0 2 0 2 (8.0) 
Severe 0 1 3 3 (12.0) 0 1 0 1 (4.2) 1 1 1 1 (4.2) 0 0 0 0 0 2 0 2 (8.0) 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Vertigo                     
Mild  6 3 1 9 (36.0) a 3 5 1 7 (29.2) 3 8 6 12 (50.0) 4 6 0 9 (33.4) 11 8 2 16 (64.0) 
Moderate 1 13 4 15 (60.0) 1 0 0 1 (4.2) 1 7 4 10 (41.7) 0 1 1 1 (3.7) 0 2 0 2 (8.0) 
Severe 0 0 3 3 (12.0) 0 1 0 1 (4.2) 1 1 0 1 (4.2) 0 0 0 0 0 0 0 0 
Serious 0 1 1 1 (4.0) 0 0 0 0 0 1 0 1 (4.2) 0  0 0 0 0 0 0 
Vomiting                     
Mild  0 1 0 1 (4.0) 0 1 0 1 (4.2) 0 2 3 4 (16.7) 0 1 1 1 (3.7) 0 2 1 2 (8.0) 
Moderate 0 7 6 10 (40.0) 0 0 0 0 0 3 1 3 (12.5) 0 0 0 0 0 1 1 1 (4.0) 
Severe 0 6 1 6 (24.0) 0 0 0 0 0 5 2 6 (25.0) 0 0 0 0 0 0 0 0 
Serious 0 5 0 5 (20.0) 0 0 0 0 0 4 0 4 (16.7) 0 0 0 0 0 0 0 0 
Nausea                     
Mild  2 4 1 6 (24.0) 2 3 2 5 (20.8) 7 6 6 14 (58.3) 3 7 0 9 (33.3) 5 5 1 10 (40.0) 
Moderate 1 8 5 11 (44.0) b 0 0 1 1 (4.2) 0 5 3 8 (33.3) 1 0 1 2 (7.4) 1 0 1 2 (8.0) 
Severe 0 2 1 2 (8.0) 0 0 0 0 0 3 0 3 (12.5) 0 0 0 0 0 0 0 0 
Serious 0 2 1 2 (8.0) 0 0 0 0 0 2 0 2 (8.3) 0 0 0 0 0 0 0 0 
a Significantly different from PQZ-treated children (p< .02); b Significantly different from PQZ-treated children (p< .007); c Significantly different from PQZ-treated children  
(p< .001) 
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Table 10.6  Summary of clinical symptoms recorded at 3-48 hour after drug administration, stratified by treatment group 
 
 Treatment group 
Adverse event arisen after 
treatment 
Mefloquine 
(n =25 ) 
Artesunate 
(n =24 ) 
Mefloquine-
artesunate 
(n =24 ) 
Tribendimidine 
(n =27 ) 
Praziquantel 
(n =25 ) 
Total 
(n=125) 
At least 1 adverse event 22 (88.0) 16 (66.7) 23 (95.8) 20 (74.1) 20 (80.0) 101 (80.8) 
Mild 18 (72.0) 15 (62.5) 20 (83.3) 19 (70.4) 20 (80.0) 92 ( 73.6) 
Moderate 19 (76.0) 5 (20.8) 16 (66.7) 2 (7.4) 5 (20.0) 47 (37.6) 
Severe 12 (48.0) 2 (8.3) 4 (16.7) 1 (3.7) 4 (16.0) 23 (18.4) 
Serious 4 (8.3) 0 8 (33.3) 0(0) 0(0) 12 (9.6) 
Note. Data are no; (%) of subject 
10. Efficacy and Safety of Five Drugs against Opisthorchis 
 
 
165 
At least one adverse event was reported by patients treated with artesunate (67%), 
tribendimidine (74%), praziquantel (80%), mefloquine (88%), and mefloquine–
artesunate (96%; Table 6). No significant difference was identified in the frequency of 
any adverse event in tribendimidine, praziquantel, and artesunate treatment groups. 
Most reported events in the tribendimidine treatment group were mild and included 
headache, vertigo, nausea, and fatigue (Table 10.5). Vertigo and nausea were 
significantly more common in children treated with mefloquine (p=0.02 and p=0.007, 
respectively) than in any other treatment group. Additionally, dizziness was more 
common in patients who received mefloquine (p=0.02), and mefloquine–artesunate 
(p=0.001) than in those who were treated with praziquantel. 12 children treated with 
mefloquine or mefloquine–artesunate had serious adverse events including anxiety, 
nausea, vertigo, and vomiting, and were transferred to either the provincial or local 
hospital. These children received a full clinical examination and proper medical 
treatment, including parenteral transfusion, antiemetic drugs, and paracetamol or oral 
rehydration. Children were closely monitored, and after 48 h of treatment in hospital all 
children had recovered and could be discharged. 
 
10.5 Discussion 
In our open-label, randomised, phase 2 study, tribendimidine seems to be at least as 
efficacious as the standard treatment praziquantel for the treatment of O viverrini 
infection; both drugs were well-tolerated. Mefloquine, artesunate, and mefloquine–
artesunate were not effective in patients with this infection. To our knowledge the 
efficacy of the antimalarial drugs mefloquine, artesunate, mefloquine–artesunate, and 
the anthelmintic drug tribendimidine, for the treatment of O viverrini infection has not 
been studied previously (see panel). Of note, another antimalarial drug, chloroquine, 
was historically used for treating opisthorchiasis; however, the cure rates and egg 
reduction rates were unsatisfactory.[29] Praziquantel served as reference, because it is 
the drug of choice for treatment of O viverrini infection.[23] Adverse events after 
praziquantel treatment are generally mild and transient, as confirmed by our study.[11] 
Single doses of 40 mg/kg praziquantel are widely used for community mass drug 
administration in southeast Asia. In Laos, such mass treatment was initially introduced 
in the 1980s in high-risk areas, under the close collaboration with the Lao Ministry of 
10. Efficacy and Safety of Five Drugs against Opisthorchis 
 
 
166 
Health and WHO.[30] In our study, split doses of 75 mg/kg praziquantel (75 mg/kg 
divided into two doses of 50 mg/kg and 25 mg/kg) were used, which is recommended 
for individual treatment and is the most effective regimen.[22] We reported only 
moderate cure rates after praziquantel treatment, which contrasts with previous 
studies reporting 96% and 100%.[31-33]  
Single 200 mg or 400 mg oral doses of tribendimidine achieved higher cure rates and 
egg reduction rates than a double dose of praziquantel, although the difference was not 
significant. Tribendimidine is an amidantel derivative, first discovered and developed in 
China.[34] Preclinical and clinical studies to meet the international standard accepted by 
the US Food and Drug Administration (FDA) and European regulatory agencies are 
underway, with the ultimate goal of gaining approval for treatment of soil-transmitted 
helminthiases outside of China and inclusion in the WHO's essential medicines list. 
Tribendimidine has a broad spectrum of activity against intestinal nematodes (eg, A 
lumbricoides, Enterobius vermicularis, and the hookworms).[35] Single-dose oral 
tribendimidine is effective against A lumbricoides and hookworm, and shows promising 
activity against Strongyloides stercoralis and Taenia spp.[36] Our study confirms the good 
efficacy of tribendimidine for treatment of hookworm infections. 
By contrast with recent laboratory findings,[13,15] mefloquine and artesunate, and 
mefloquine–artesunate showed no effect in the treatment of O viverrini infections. In a 
proof-of-concept study of efficacy and safety of these drugs against another trematode, 
Schistosoma haematobium, in Côte d'Ivoire, similarly low cure rates were reported for 
mefloquine (21%) and artesunate (25%); however, slightly higher egg reduction rates 
for mefloquine (74%) and artesunate (85%) were seen. Furthermore, promising results 
were shown with mefloquine–artesunate (cure rate 61%, egg reduction rate >95%).[37] 
We differentiated O viverrini infections and other common foodborne trematodes by use 
of the formalin-ether concentration technique (Table 10.3, Table 10.4). Results from this 
technique confirmed the high efficacy of tribendimidine against O viverrini infection. 
Notably, the formalin-ether concentration technique showed higher cure rates of 
praziquantel and tribendimidine than did the Kato-Katz method, which could be 
explained by its lower sensitivity than the Kato-Katz thick smears. Our findings are 
consistent with those of Lovis and colleagues, [38] who showed a lower sensitivity of the 
formalin-ether concentration technique (49.4%) than of one Kato-Katz thick smear 
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(62.3%). Conversely, the low sensitivity of this technique contrasts with results from a 
study done in the south of Laos,[39] which had 96.8% sensitivity for the diagnosis of O 
viverrini infections. 
The amount of stool used in the formalin-ether concentration technique is not of 
primary importance. However, Sayasone and colleagues [39] used purged stool samples 
as the reference gold-standard to calculate the validity of the formalin-ether 
concentration technique. Two previous studies done in Laos,[38,39] both using the same 
diagnostic methods to differentiate O viverrini from O viverrini-like parasites, showed 
that O viverrini often coexists with other foodborne trematodes, including minute 
intestinal flukes (e.g, Haplorchis taichui). In our study very few co-infections with 
minute intestinal flukes were detected.   
Children treated with artesunate, or tribendimidine showed only mild adverse events, 
similar to those reported in previous studies.[20,36] Surprisingly, patients treated with 
mefloquine–artesunate in our study were more likely to experience adverse events than 
were schoolchildren treated with these drugs for S haematobium infection in Côte 
d'Ivoire, where only mild and transient adverse events were observed, with abdominal 
pain most common.[37] We cannot explain why mefloquine and mefloquine–artesunate 
were not tolerated in our study population, but O viverrini infection and other host 
factors might play a part. 
 
10.6 Conclusions 
Tribendimidine shows promising activity against O viverrini infection. The nematocidal 
and opisthorchicidal properties of this drug are very intriguing as there is huge 
geographical overlap of these parasites, and preventive chemotherapy is the mainstay 
of control. Once preclinical studies have been completed, and if the drug is registered 
outside China, large scale clinical studies should be done in O viverrini endemic settings. 
Additionally, a proof-of-concept trial with tribendimidine should be done in patients 
infected with Clonorchis sinensis, a closely related liver fluke. Furthermore, by contrast 
with in-vivo studies, antimalarial drugs seem to be ineffective for the treatment of O 
viverrini infections. Nonetheless, the use of antimalarials in areas in which malaria and 
liver fluke co-infections are common might have marginal benefits because these drugs 
slightly reduce O viverrini egg counts, as our study has shown. Moreover, studies of 
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tribendimidine–praziquantel combinations in hamsters infected with O viverrini, similar 
to those done in rats infected with C sinensis, [40] might be of interest, because 
combination chemotherapy is a useful strategy to delay the emergence of drug 
resistance. 
 
Systematic review 
We searched PubMed using the terms “Opisthorchis viverrini” OR “opisthorchiasis” 
AND “clinical trial” OR “cure rate” OR “egg reduction rate” OR “efficacy” AND 
“mefloquine” OR “tribendimidine” OR “artesunate”. No previous studies, which 
assessed the efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, 
and tribendimidine in patients with O viverrini infection were identified. 
Interpretation 
Our study provides the first evidence that tribendimidine, given at the recommended 
doses for treatment of soil-transmitted helminth infections (ie, 200 mg or 400 mg), 
seems to be an efficacious treatment for O viverrini infection. Mefloquine, artesunate, 
and mefloquine–artesunate cannot be recommended against O viverrini infections 
because of the low efficacies reported. Adverse events were most common in 
patients who were treated either with mefloquine or a mefloquine–artesunate 
combination. 
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11. General discussion and conclusions 
11.1 Overview  
The paucity of information on severe morbidity of intestinal parasitic infections and 
scarcity of efficacies of their treatment in Lao PDR were motivation for the research 
conducted in this Ph.D. and govered the design of the different studies. In particular, I 
was interested by morbidity associated with potentially severe infections with 
S. mekongi and O. viverri, and while working discovered several cases of C. philippinensis. 
In addition, the need to critically assess the efficacy of widely used anti-helminthic 
drugs became evident. In this Ph.D. thesis particular attention is paid to S. mekongi, O. 
viverrini and hookworm. The aim of my research contribution was to determine the 
morbidity associated with food- and waterborne trematodiasis (S. mekongi, O. viverrini, 
mixed infections of S. mekongi and O. viverrini), soil-transmitted helminths (hookworm), 
and the intestinal nematode C. philippinensis in the most affected communities and 
patients in hospitals (Chapter 4-8) in Lao PDR. Additionally, we investigated the efficacy 
of the current drug of choice against soil-transmitted helminths, namely Albendazole 
(ABZ), versus Mebendazole (MBZ) in schoolchildren with a high prevalence of 
hookworms (Chapter 9). Finally, we assessed the safety and efficacy of mefloquine, 
artesunate, the combination mefloquine-artesunate and tribendimidine compared to 
standard treatment, praziquantel (PZQ) against O. viverrini (Chapter 10).  
 
11.2 Document severe morbidity of parasitic infection: C. philippinensis and 
S. mekongi 
Outbreaks and mortality of intestinal capillariasis of C. philippinensis occur mainly in 
Asia (Lu et al., 2006; Odermatt et al., 2010; Saichua et al., 2008). The parasite is often 
misdiagnosed, as eggs resemble those of T. trichiura. If not adequately treated, the 
infection may cause severe morbidity, which may even lead to death (Cross 1992; 
Odermatt et al., 2010; Saichua et al., 2008). No cases had previously been documented 
in Lao PDR. We identified described the first three cases here and thus provide new 
evidence on this parasites which is circulating in Lao PDR. Hence, there is a risk for 
outbreaks in humans (Chapter 4). 
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Our patients were admitted several times in different hospitals in critical conditions. Most 
of our cases were first misdiagnosed as Trichuris infection before the definite diagnosis was 
made. Stool examination of our patients revealed eggs of C. philippinensis and harboured 
more than two parasite species, including Giardia lamblia, Entamoeba histolytica, 
Strongyloides stercoralis, O. viverrini, and hookworm. Patients with long-standing history of 
diarrhoea may be suffering from C. philippinensis. This disease is difficult to differentiate 
from other causes for chronic diarrhea. We observed that repeated stool examination and 
well-trained laboratory personnel considerably improved sensitivity in identifying eggs 
and larvae of C. philippinensis (Chapter 4). Even so, excretion of C. philippinensis eggs with 
the stool may vary over time and make diagnosis unreliable. In addition to stool 
examination, endoscopic examination in combination with biopsy and/or intestinal 
aspiration might be a useful tool for diagnosis in case of absence of eggs in the stool 
(Sangchan et al., 2007; Tesana et al., 1983). All compounds of “zole” namely ABZ (400 mg) 
and MBZ (200 mg) are effective against C. philippinensis (Cross and Basaca-Sevilla, 1987; 
Singson et al., 1975). Our study showed that a single dose of 400 mg ABZ should be the 
drug of choice for treatment of C. philippinensis and that a long regimen is required for 
preventing the recurrence of this parasite (Chapter 4).  
Transmission of waterborne S. mekongi is confined to the lower Mekong Basin. In Lao PDR, 
it includes the districts of Khong and Munlapamok in Champasack province, southern Lao 
PDR. S. mekongi was initially identified as a separate species from S. japonicum in the 
1980s. A considerable number of severe cases were described from Laos in the initial years 
(Muth et al., 2010). Surprisingly, little is known with regard to the mortality due to 
haematemesis or other complications of S. mekongi. In the 1970s, severe manifestations of 
S. mekongi infection were mainly described from Lao immigrants in France (Muth et al., 
2010). In Lao PDR, community- and hospital-based control efforts relying on praziquantel 
treatment were implemented for more than 20 years (Muth et al., 2010). By 1999, it was 
believed that S. mekongi is under control and a substantial reduction in infection rates was 
noted, predominantly in Cambodia (Muth et al., 2010; Urbani et al., 2002). No new severe 
cases have been reported and documented in the Lao health services since the 1980s until 
our study was conducted in 2006 (Hotez and Ehrenberg, 2010; Muth et al., 2010).  
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In our community helminth surveys, severe cases of S. mekongi were detected. The patients 
came forward as the survey teams were present in the villages on islands in the Khong 
district. Cases were traced yearly and their status evaluated. The severe clinical picture of S. 
mekongi seems to be re-emerging, since in our community helminth survey on Khong 
Island in 2006-2008 (Chapter 5) as we found six cases with very advanced stages of 
schistosomiasis. In a subsequent follow-up study, we found additional 3 severe cases 
between 2008 and 2010. Two cases died in 2008 due to rupture of the oesophageal varices. 
In addition to adult patients, children as young as 5 to 7 years old were diagnosed with 
these severe S. mekongi complications. In our recent surveys in three villages in Khong 
district showed that prevalence of S. mekongi and O. viverrini was 87.8% and 98.9%, 
respectively in schoolchildren (Sayasone et al, 2010), and 57% and 87%, respectively in 
adults (Chapter 5). Therefore, our case series on severe schistosomiasis provide further 
evidence that transmission of S. mekongi is ongoing in the endemic settings of Lao PDR and 
leads to re-emerging severe cases as documented by youngest severe cases. No case had 
been reported in Cambodia until the year 2000. However, an observation similar to the one 
in Laos has been made recently in Cambodia with a number of cases of S. mekongi 
appearing where MDA was conducted (Hotez and Ehrenberg, 2010; WHO 2009). However, 
sporadic cases were reported from travellers returning to their home country (Carmody et 
al., 2008; Houston et al., 2004). 
The two case series on C. philippinensis and S. mekongi identified in communities and 
hospital attempted to understand where in Laos transmission was ongoing, and how 
patients evolve under anthelminthic treatments. Like comparable studies, the case series 
reports were not representative samples from the general population. Nonetheless, their 
evidence help bridge the gap between epidemiological studies on prevalence and current 
concrete hospital practices. We suggest including the diagnosis of C. philippinensis in the 
curriculum of laboratory personals. Also, specific training on diagnostic algorithms may 
increase awareness in the Lao health care providers on the severity of diseases associated 
with the two infections, and may enhance the accurate diagnosis and early treatment of 
S. mekongi and C. philippinensis. Early diagnosis, adequate treatment and correct case 
management will prevent severe consequences and death. Public health promotion 
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regarding hygiene and sanitation practices and avoidance of contact with infested water 
bodies needs to be reinforced. 
 
11.3 Assessment of burden of parasitic infections and resolution of morbidity 
after treatment 
A first set of hepatobiliary and splenic morbidity data (Chapter 6) pertaining to S. mekongi 
infection and co-infection with O. viverrini was obtained from a 2-year follow-up, 
community-based study launched in March 2006 in three villages in Khong district, 
Champasack province. The two flukes are co-endemic in southern districts of Lao PDR. 
Both parasites inflict liver morbidity and both can be treated by praziquantel (Keiser and 
Utzinger, 2007b). Regular treatment is recommended as the main public health 
intervention for both parasites (Keiser and Utzinger, 2009; Keiser and Utzinger, 2010). 
Yearly examination in the present study included the assessment of infection status by 
stool examination using Kato-Katz thick smear technique (Katz et al., 1972) and liver 
morbidity assessment by ultrasonographical examination (Chapter 6) as put forth by the 
WHO guideline on schistosomiasis related morbidity assessment (Niamey Working Group, 
2000). The follow-up midpoint (2007) and endpoint studies (2008) assessed the infection 
status and the resolution dynamics of liver morbidity after a single oral dose of 
praziquantel treatment (40 mg/kg BW) in individuals infected with S. mekongi at the 
baseline. 
To our knowledge, our studies (Chapter 6) consitute the first assessment of morbidity due 
to S. mekongi and co-morbidity with O. viverrini and its resolution dynamics after treatment 
since MDA was launched in the community. At baseline (2006), all the subjects were egg-
positive for S. mekongi and 98.7% were infected with O. viverrini. Liver pathology was 
observed in a high prevalence of 37.1% of individuals infected with S. mekongi. No subject 
demonstrated signs of ascites and peripheral signs of decompensation. However, other 
symptoms, such as hepatomegaly (77.5%) and splenomegaly (82.2%) were observed At 
mid point (11 months after treatment), we found marked improvements of hepatosplenic 
morbidity and calcification around the portal tree had regressed, particularly among 
subjects with less advanced pathology at baseline. Nonetheless, advanced severe fibrosis 
11. General discussion and conclusions 
 
 
178 
(Pattern E-F) may not quickly resolve following PZQ treatment. Two cases developed 
ascites and died due to rupture of oesophageal varices (Chapter 6). The endpoint (23 
months after treatment) results showed slightly increased prevalence of S. mekongi 
(54.3%) and O. viverrini (74.2%). However, liver pathology remained unchanged compared 
to the midpoint evaluation. Overall, hepatosplenic lesions detected by US showed 
statistically significant improvement after treatment (p<0.01). However, in individuals 
with advanced periductal fibrosis the condition remained unchanged or reversed. Re-
infection was detected at 11 month after treatment. 
The second set of data were focusing on hepatobiliary morbidity with particular emphasis 
on cholangiocarcinoma (CCA) suspected lesions associated with O. viverrini infection 
comprised of two in-depth studies (hospital and community-based studies) conduceted in 
2011 (Chapter 7-8). Field experience in Thailand has determined that infection of O. 
viverrini led to a wide range of hepatobiliary disease, including severe manifestations such 
as obstructive jaundice and ascending cholangitis (Mairiang and Mairiang, 2003; Mairiang 
et al., 2006; Mairiang et al., 2011; Sripa et al., 2007). Chronic infections due to O. viverrini 
are also known to provoke CCA, a malignant and highly lethal bile duct cancer (Shin et al., 
2010; Sripa et al., 2007; Sripa and Pairojkul, 2008). One of the provinces in northeast 
Thailand was logged as the first elevated CCA incidence rate in the world (Sripa et al., 
2010). The incidence of CCA in Laos in unknown although infection rates with O. viverrini 
are rampant. 
Our community-based US survey in Saravan Province (Chapter 7), southern Lao PDR 
confirmed that patients infected with O. viverrini suffered from a substantial amount of 
hepatobiliar anormalities suspected lesions. A similar situation in O. viverrini- endemic 
areas was found in Thailand (Mairiang et al., 2006; Mairiang et al., 1992; Mairiang et al., 
2011). Of 431 individuals screened with US, 5 patients (1.2%) had lesions suggesting CCA. 
The five suspected CCA cases were investigated by complete blood tests, serum bile marker 
tests including tumour antigen (i.e., carbohydrate antigen [CA] 19-9); cytokines (i.e., IL-6), 
proteases (i.e., plasminogen activator inhibitor) for detecting CCA cases (Sripa et al., 2009). 
However, the readings of tumor antigens varied from normal to slightly increased. Serum 
markers might not be able to detect such CCA cases in our population. We did not have any 
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rationale to explain why these makers were not increased in our suspected CCA population 
but it may imply clinical stage of CCA. Our study pointed out constraints in diagnosing CCA 
cases using this approach. None of our cases had been confirmed with histopathological 
results (with biopsy) and neither with CT scan, nor could ERCP be performed. High blood 
creatinine level was a contraindication for imaging diagnosis, namely ERCP, MRCP and CT 
scan. These imaging techniques include the use of iodinated radiocontrast through 
intravenous injection, which can lead to renal failure in patient with high blood creatinine. 
Our hospital-based study in six referral hospitals found that there were 274 cases 
according to our criteria for diagnosis of suspected CCA (Chapter 8). Most records were 
kept in the hospital’s repository for an average of 3.3 years. The 274 cases included records 
from 2006 to 2010. Most of these CCA suspected patients were admitted at the hospitals 
with the signs and symptoms characteristic for very advanced stages and referred from the 
provincial hospitals. A number of suspected CCA cases presented at the admission with 
jaundice and/or fever, and/or right upper quadrant pain as found in previous studies 
(Bhuddhisawasdi, 1996; Mairiang and Mairiang, 2003; Uttaravichien, 1999). All suspected 
cases admitted at the hospitals had undergone their first abdominal ultrasound, and only 
CT was available (Chapter 11). ERCP has been offered at Mahosot hospital, Vientiane 
capital, Lao PDR from 2011 onwards (Dr. Bouachanh Rasachack, pers. communication). 
In Lao PDR, neither cancer registration, nor case management for CCA is available. Health 
facilities do not have the capacity to diagnose CCA and surgical and supportive treatment 
capacity are lacking. Hence, the incidence of CCA is unknown. However, given the high 
infection rates with O. viverrini which are similar (Chai et al., 2005; Rim et al., 2003; 
Sayasone et al., 2007) or beyond the rates in neighbouring Thailand, the incidence of CCA 
may be comparable to that found in north-eastern Thailand or even higher. The incidence 
of CCA and O. viverrini in Thailand has been calculated at 188 cases per 100 000 person-
years from 1990-2001 (Sripa et al., 2007). With 1.2%, the prevalence of suspected CCA 
cases in our survey was exceedingly high. The situation in Saravan is believed to be highly 
critical. Despite a lack of definitive diagnosis for this lethal disease, our result on suspected 
CCA cases is in line with a recent finding on hepatobiliary morbidity due to O. viverrini, 
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screened by US (of ~ 800 subjects, 8 suspected CCA cases) (Dr. Bouasy Hongvanthong, 
pers. communication,). They call for further work on this bile duct cancer. 
Recently, work on a new national cancer control programme has started in Lao PDR (Dr. 
Phetsamone, pers. communication). There is a good prospect that liver cancer including  
O. viverrini-induced CCA will be included in the national programme, allowing for 
establishing supportive treatment and control strategies. The resulting information will be 
crucial to develop intervention strategies, in particular the role of a cancer centre focusing 
on state-of-the-art diagnosis and treatment including surgery and palliative care for CCA 
patients. Cancer registration will lead to the better understanding of the epidemiology of 
CCA in Lao PDR (Parkin et al., 1993). It will also be essential to follow-up the prevalence of 
O. viverrini infection through large scale surveys.  
We are conscious that our investigations have constraints. The limitations of the hospital-
based study arise from the different diagnostic possibilities at the different health service 
levels and the shortage of diagnostic imaging (MRI and ERCP). Limitations of the 
community-based study include the relatively small number of study participants who met 
our selection criteria (Chapter 7). Furthermore, the health status of patients was not 
conducive to undergo CT and ERCP examination. Thus, for all suspected CCA cases we were 
unable to execute a final diagnosis or confirmation of CCA. Despite these shortcomings, our 
community- and hospital-based studies provide the first documents on the magnitude of 
morbidity associated with O. viverrini infection in Laos. Both studies underscore that 
chronic O. viverrini infection induces various hepatobiliary and -splenic abnormalities, and 
conclude that further clarifying research is urgently needed.  
The high prevalence of morbidity and infections with both trematodes at the end point 
survey indicated limitations of MDA. As chemotherapy does not prevent re-infection and 
therefore on its own does not constitute sustainable control of helminths, a package 
intervention is required for long–term control of schistosomiasis and opisthorchiasis. The 
same probably also applies to the other neglected tropical diseases, notably STHs. A set of 
interventions including IEC to discourage the consumption of raw fish, to prevent direct 
contact with infected water bodies, and to promote hygiene and sanitation practices, 
targeting the young generation, improved sanitation and water supply and geospatial 
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approaches must be the cornerstones of schistosomiasis, opisthorchiasis, and STH and 
other target disease control (Utzinger et al., 2009; Sripa et al., 2010; Knopp et al., 2011b).  
Since 2008 the Lao Ministry of Health with technical support from WHO has resumed the 
province-wide deworming programme in six selected provinces, of southern Lao PDR 
where S. mekongi and O. viverrini are endemic with prevalences higher than 25% (Dr. 
Keoka Taisaiyavong, pers. communication,). Additionally, a pilot package of intervention 
including improved hygiene and sanitation, access to clean water in combination with MDA 
and IEC might be a solution to interrupt the transmission and achieve sustainable control 
of food and waterborne trematode infections. A project has been set up in 2010 on Khong 
Island in collaboration with several partnerships including the National Institute of Public 
Health, Ministry of Health, Ministry of Health, the Swiss TPH and the International 
Development Research Centre to investigate this strategy and to assess its effectiveness 
(Somphou Sayasone, personal communication). Our studies further document and confirm 
the high magnitude of morbidity due to S. mekongi and O. viverrini. Large-scale community-
based ultrasound studies with the possibility of advanced diagnostic procedures are 
warranted to investigate the true burden due to S. mekongi and O. viverrini-endemic 
settings. Our studies call for urgent concerted fluke control. 
 
11.4 Assessment of efficacy of present anthelmintic drugs and potential 
candidates 
Hookworm takes the first rank in terms of the global burden attributable to STHs (Utzinger 
et al., 2009). It shows increased severity in those who are affected with human 
immunodeficiency virus (HIV) and tuberculosis (Bethony et al., 2006; Keiser and Utzinger, 
2009). A single dose of ABZ or MBZ is employed for school- or community-based morbidity 
control of STHs in highly endemic areas. It is also administered to vulnerable populations 
(schoolchildren and reproductive women) through regular school deworming and mass 
drug administration programmes in Lao PDR (Jex et al., 2011). Resistance to anthelminthic 
drugs in animals has been described for decades. Nevertheless, the mechanism is unclear 
(Geerts and Gryseels, 2006; Wolstenholme et al., 2004). Single doses of ABZ and MBZ have 
been considered critical as drug resistance might develop (Albonico et al., 2004). In 
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addition, low efficacies of MBZ against hookworm infections were reported from Mali, 
Tanzania, and Vietnam (Albonico et al., 2003; De et al., 1977; Flohr et al., 2007). ABZ 
resulted in low cure rates against hookworm infections in a review and in Ghana (Horton, 
2000; Humphries et al., 2011b). Consequently, there is a hot debate in respect to the low 
efficacy of benzimidazole against hookworm infections in humans (Humphries et al., 
2011a; Montresor et al., 2011). No information on the efficacy of these drugs was collected 
in Lao PDR before the study conducted in the framework of the present Ph.D. 
We investigated the efficacy of a single oral dose of ABZ or MBZ against hookworm in an 
endemic area of STHs in Laos (Chapter 9). In our trial, CRs and ERRs of ABZ proved 
superior over MBZ (P=0.01). However, both anthelminthics ABZ and MBZ, showed 
disappointing cure rates of 30.0 % and 17.6 %, respectively against hookworm in our 
study. According to a recent meta-analysis, the respective cure rates of ABZ and MBZ were 
72% and 15% (Keiser and Utzinger, 2008). CR of ABZ (36%) found in our study was 2 
times lower compared to a meta-analysis and a recent study carried out in China (CR of 
ABZ was 69% in treatment of hookworm) (Steinmann et al., 2011). 
The low cure rates of ABZ in our study might be attributable to the differences in strain 
between hookworm species, namely N. americanus and A. duodenale. Both species are 
common worldwide (Brooker et al., 2004) but in Southeast Asia, species identification has 
never been done (Jex et al., 2011). A zoonotic helminth, A. ceylanicum is also known to 
infect human in this region (Jirraanankul et al., 2011; Traub et al., 2008). Consequently, our 
study participants could have been infected with any of these parasites. Secondly the 
study’s sample size is relatively small due to day to day variation of hookworm egg counts. 
Thirdly a few incidental effects such as failure of some children to swallow the pill 
correctly, might theorically have happened and contributed to low efficacy of ABZ. 
However, we cannot rule out that drug resistance indeed exists as the drugs have been 
used for decades. Therefore, drug efficacy - particularly of single-dose administration - 
should be monitored carefully and integrated into further chemotherapy campaigns. 
In view of the low CR obtained with ABZ and MBZ against hookworm infections in Laos 
(Chapter 9), there is a pressing need to conduct large scale trials that provide new data 
regarding the efficacy of commonly used anthelminthics against hookworm infections in 
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different settings, so that the most efficacious drugs can be used in control programmes 
and emerging resistance can be detected at an early stage. Therefore, further studies 
should take into account the sample size in order to deal with variability of egg shedding, 
and the circulating parasite species. The issue is of particular concern as these drugs are 
widely used for mass drug administration, not only for STHs, but also for lymphatic 
filariasis control (WHO, 2002). Another issue is the diagnostic test employed. In the 
absence of a gold standard, the Kato-Katz thick smear technique is the most widely used 
parasitological diagnostic test for hookworm, recommended by WHO (WHO, 1991).  
Kato-Katz is a direct stool examination technique and inexpensive tool, widely deployed in 
the large scale epidemiological survey for diagnosis of helminths. However, Kato-Katz has 
limitations in detecting hookworm egg. Low sensitivity was observed, in particular of light 
infections. The novel FLOTAC technique might offer an alternative. It is a qualitative and 
quantitative stool examination technique with a high sensitivity to detect hookworm eggs 
(Utzinger et al., 2008). In addition to its high sensitivity in detecting human hookworm 
infections, FLOTAC allows detecting multi-species parasite infections with superior 
sensitivity over the traditional Kato-Katz thick smear and ether-based concentration 
techniques (Keiser et al., 2010a; Knopp et al., 2011a). It is important to note that O. viverrini 
eggs in the stool samples were diagnosed by the Kato-Katz thick smear technique and FECT 
(Formalyl ether concentration technique). The data of FECT, which is a good method to 
differentiate between O. viverrini and other intestinal trematodes (i.e, minute intestinal 
flukes), suggested that Kato-Katz technique (3 stool samples examined with duplicate Kato-
Katz slides) showed higher sensitivity than FECT (Chapter 10). These findings might be 
contradictory to previous studies employing the same procedures (Sayasone et al., 2009). 
No explanation can currently be offered to elucidate the discrepancy. PCR might be an 
alternative gold standard for O. viverrini diagnosis. Nonetheless, also this technique has 
some limitations: it is time-consuming, and needs well-trained staff as well as expensive 
equipment. Hence it is currently not feasible to apply it in the field studying resource-
constrained settings. There is thus a need for further innovation and standardization of 
diagnostic tools (Bergquist et al., 2009). 
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A broad spectrum anthelminthic developed by Chinese scientists, tribendimidine, might be 
a new candidate for hookworm treatment and control (Ren et al., 1987). In the absence of 
vaccine, elimination of hookworm might be possible by means of improving socioeconomic 
conditions, strengthening of hygiene and sanitation and targeted treatment (drug 
treatment of infected individuals only) as a successful public health program in the 
southern USA and a trend from morbidity control toward transmission control in Zanzibar 
show (Brown, 1976; Knopp et al., 2011b; Utzinger et al., 2008). The same activities and 
mechanisms are invoked as the explanation of a marked reduction of the hookworm 
prevalence in Southeast Asia (de Silva et al., 2003). 
In addition to the primary outcome, we have generated supportive evidence that ABZ and 
MBZ, even at single oral doses, have opisthorchicidal properties against O. viverrini. 
Although cure rates were relatively low in our study population, promising egg reduction 
rates were observed, corroborating previous studies (Jaroonvesama et al.,1981; Pungpark 
et al., 1984). Similar cure rates and ERRs were observed for other parasites (i.e., Ascaris 
lumbricoides and Trichuris trichura) as reported in meta-analysis (Keiser and Utzinger, 
2008). Both drugs resulted in high CRs and ERRs against A. lumbricoides and were less 
effective against T. trichura. Other studies also reported comparable outcomes (Olsen et al., 
20009; Steinmann et al., 2011). However, due to the selection bias, i.e. only persons with 
hookworm infection were recruited into the study, conclusions can be drawn.  
A host of parasitic infections are of public health concern worldwide and their areas of 
endemicity often geographically overlap in tropical and sub tropical countries, in particular 
Southeast Asia (Steinmann et al., 2008a; Steinmann et al., 2010). Today, very few 
anthelminthic agents have been approved for large scale administration to human. The 
pharmaceutical industry lacks incentives to develop new anthelmintic drugs for use in 
humans (Utzinger and Keiser, 2004). Attempts have been made to piggy back on existing 
drugs, where clinical information is already available, and which thus need not undergo the 
long and expensive process of drug development (Nawaka and Hudson, 2006). Following 
this strategy, the antimalarials artemether and artesunate, mefloquine and the Chinese 
anthelminthic tribendimidine were tested for activity against O. viverrini in a hamster 
model (Keiser et al., 2006; Keiser and Utzinger, 2007a; Keiser et al., 2008). However, the 
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efficacy of none of these compounds had been investigated in O. viverrini infected patients. 
Following a similar line of investigation, the experience related to the antimalarial drugs 
mefloquine and artesunate was used to investigate activity against Schistosoma 
haematobium in infected schoolchildren, and in a recent proof of concept study on 
treatment of chronic fascioliasis (Keiser et al., 2010b; Keiser et al., 2011). 
The Chinese anthelminthic tribendimidine has been approved in 2004 for human use in 
China (Xiao et al., 2005). Tribendimidine is a derivative of amidantel and has been 
developed by the National Institute of Parasitic Disease in Shanghai, China, since the 1980s 
(Ren et al. 1987). Currently, efforts are ongoing to register tribendimidine for the 
treatment of soil-transmitted helminthiases with international authorities such as WHO 
and major regulatory agencies including FDA and EMEA. The artemisinins are the basic 
components of modern malaria treatment (White, 2008). Mefloquine is an orally 
administered antimalarial drug developed by the Walter Reed Army Institute of Research 
in 1988 and used both for prophylaxis and treatment against malaria (Palmer et al., 1993).  
Tribendimidine treatment resulted in promisingly high cure rate (CR) and egg reduction 
rate (ERR) against O. viverrini in our exploratory trial. This drug might thus be an 
alternative for liver fluke treatment (Sripa B et al., 2011). Hence, large scale studies are 
warranted to confirm its efficacy and safety. It might be worth to study a chemotherapy 
combination, because this might delay the development of drug resistance (Olliaro and 
Tailor, 2004). A phase three four-arm study might be designed, comparing standard 
treatment, praziquantel (treatment of choice) with tribendimidine, ABZ and MBZ (Dr. 
Somphou Sayasone, pers communication). 
In chapter 10, on the basis of an intention-to–treat analysis, a 400 mg single dose of 
tribendimidine achieved better cure (70.4%) and egg reduction rates (99.3%) against 
O. viverrini than a double dose of praziquantel (CR=56.0%, ERRs=98.4%). However, this 
finding was not statistically significant since only a small number (n=125) of children was 
included in our exploratory study (p=0.29). Both intention-to-treat and per-protocol 
analysis indicated tribendimidine cured hookworm infections at a promising rate 
(CR=65%, P=0.004) (Chapeter 10) and even much higher compared to ABZ treatment 
against hookworm in the light of our previous trial (Chapter 9). In our proof of concept 
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study, mefloquine and artesunate resulted in low CR of O. viverrini. However, promising 
results of ERRs were seen in children taking mefloquine-artesunate. 
Adverse events were observed in all treatment arms, mostly of mild to moderate intensity. 
Single dose tribendimidine is generally well tolerated in the present study and had proven 
to be safe at a dose of 200-400 mg in settings where multiple intestinal helminth species 
are co-endemic (Steinmann et al., 2008b). Surprisingly, serious adverse events were 
recorded after mefloquine treatment, and in the combination treatment of mefloquine-
artesunate. Dizziness, nausea, vertigo, vomiting and headache were the most common 
adverse events observed in patients taking mefloquine and a combination of mefloquine 
and artesunate. 
 
11.5 Conclusions 
In the previous discussion sections main conclusions were given in each section. In the 
following the main conclusions are given again. 
The series of severe cases demonstrate that adequate diagnosis andcase management of 
infections with C. philippinensis are required in Laos. The severe S. mekongi cases warrant 
particular attention to re-emergence of S. mekongi in the community of Khong and adjacent 
districts. Furthermore, regular deworming programmes particularly among school-and 
pre-school aged children in S. mekongi and O. viverrini endemic communities should be 
implemented to reduce severe hepatosplenic pathogenesis and prevent chronic 
consequences in adulthood. 
O. viverrini, S. mekongi are common parasitic infections of major public health significance 
in rural areas of Lao PDR. Our study, using US and stool examination, provides an insight 
into the problems related to morbidity due to S. mekongi and O. viverrini and co-infections. 
These parasites induce a wide range of hepato-biliary and -splenic pathogenesis in the 
affected communities in southern Lao PDR. Furthermore, our studies document that severe 
morbidity and in particular CCA is associated to high degree with O. viverrini infection. It is 
of particular concern in endemic settings as well as across the country. Appropriate cancer 
care facilities (including treatment by surgery, chemotherapy, radiotherapy and palliative 
care) and cancer registration are necessary in order to assess the prevalence of CCA and 
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ethical difficulties on case management. Our evidence on morbidity due to both parasites 
could be used as a basis for a rational design and implementation of control strategies.  
The efficacy of different anthelminthic drugs has to be regularly assessed in order to guide 
policy recommendations and take timely action should resistance develop. Today, ABZ and 
MBZ have low efficacy if applied in MDA campaigns. Further investigation using sensitive 
diagnostic approaches are required for the detection of helminths. Large-scale trials 
investigating the efficacy and safety of tribendimidine should be a priority as this drug 
showed nematocidal and opisthorchicidal properties in our study. It is very intriguing to 
focus on this drug as there is huge geographical overlap of these parasites and preventive 
chemotherapy is the mainstay of control. 
Preventive chemotherapy and primary prevention including public health promotion  like 
health education, safe water supply, hygiene and sanitation as well as integrated 
approaches to enhance synergies between programmes are needed. A system of 
monitoring and surveillance is required. Regular training of doctors, health care provider, 
nurses and laboratory staff is necessary in order to timely diagnose infections, dispense 
appropriate treatment, and properly manage severe cases both at community and central 
hospital level.  
 
11.6 Further research needs 
1.-It is particularly important to implement large scale community-based ultrasound 
survey s with the aim of enabling comparisons between regions 
2.-Concerted action on health promotion needs to be re-inforced for the prevention of 
complications due to helminth infections. 
3.-Development of accurate diagnostic tools and approaches for the assessment of helminth 
infections, particularly light residual infections after treatment are needed. 
4.-Large scale assessments of safety and efficacy of tribendimidine for the treatment of 
O. viverrini and helminth co-infections, are logic next steps given the promising results 
obtained in this study. 
5.-A phase three four-arm study might be designed, comparing standard treatment, 
praziquantel (treatment of choice) with tribendimidine, ABZ and MBZ. 
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6.-Evaluation of safety and efficacy of combination chemotherapy (i.e., praziquantel- 
tribendimidine against O. viverrini) as a useful strategy to delay the emergence of drug 
resistance as in malaria treatment (i.e., artemisinin- based therapy) 
7.-A clinical trial assessing efficacy and safety of TBD against Clonorchis sinensis is 
warranted. 
8.-Studies of tribendimidine-praziquantel combinations in hamsters infected with O 
viverrini might be of interest. 
 
11.7 Recommendations 
1.-Develop a surveillance system and monitoring of severe case and proper case 
management  
2.- Recent control efforts are insufficient and need to be consolidated including regular 
MDA, case detection and improved sanitation and health services 
3.-Strengthen human resource capacities on dealing with diagnosis and treatment of CCA, 
for instance education of health professionals, lab personal and surgeon on liver surgery 
and radiology  
4.-Design and establishing a cancer registry including CCA as well as other cancers 
5.-Assessment of the efficacy of current drug used for mass drug campaigns (i.e, ABZ, MBZ 
and PZQ) 
6.-Develop CCA cancer registration as well as other organ-related cancers with a protocol 
for diagnostic algorithms and cancer treatment (palliative care, surgery and so on) with an 
aim of estimating the CCA burden in Lao PDR 
7.-Administer regular MDA programmes with a set of interventions (health education, 
engineering development, sanitation and hygiene) for control of liver fluke in other O. 
viverrini-endemic provinces  
8.-Systemic monitoring of drug efficacy and early detection of drug resistance on current 
helminth control programmes 
9.-Enforcement of long-term sustainable control programmes on improved infrastructure, 
health education, changing behaviours, sanitation, and safe water supply. 
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